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I 
Summary 
A distinctive feature of many cell types, such as endothelial cells (ECs), is 
abundant population of small plasma membrane invaginations termed 
caveolae. These structures represent a distinct membrane microenvironment 
that are involved in regulating multiple signalling pathways. Several diseases in 
human, such as heart failure, degenerative muscular illness, and vascular 
diseases, might result due to the disruption of caveolar integrity. The main 
caveolar structural membrane protein is cavin-1 and it has been shown to play 
a major role in caveolae assembly as shown by caveolae destabilisation due to 
cavin-1 deletion. However, the exact cellular process that regulate the 
functionality of cavin-1 has not been fully elucidated. One of the signalling 
pathways that have been found localised and distributed within caveolae is the 
JAK/STAT signalling, which is downregulated via the suppressor of cytokine 
signalling-3 (SOCS3). Studies based on proteomic screening and biochemical 
analysis have revealed an interaction between cavin-1 and SOCS3. As such, 
we hypothesised that SOCS3/cavin-1 interaction is an important controlling 
element in caveolae stability and/or the pro-inflammatory signalling pathway 
mediated by IL-6 in the endothelial cells. In support of this hypothesis, cavin-1 
protein levels were significantly reduced in SOCS3−/− murine embryonic 
fibroblasts (MEFs) and human endothelial angiosarcoma (AS-M.5) cells 
compared with their WT counterparts in the absence of any changes in cavin-1 
mRNA. This was associated with a reduced stability of the cavin-1 protein in 
SOCS3−/− AS-M.5 cells (t1/2=3 hr) versus WT AS-M.5 cells (t1/2>8 hr), 
significantly reduced levels of caveolin-1 and a parallel decrease in the number 
of caveolae detectable in SOCS3−/− MEFs and AS-M.5 cells by transmission 
electron microscopy. Confocal imaging experiments also revealed that cavin-1 
was required for SOCS3 localisation to the plasma membrane and effective 
SOCS3-mediated inhibition of IL-6 signalling. Our data suggest a novel role for 
SOCS3 in regulating caveolae assembly while cavin-1, acting as a scaffold-
protein, might aid SOCS3-dependent regulation of JAK/STAT signalling. This 
is the first indication of a novel role for SOCS3 in caveola homeostasis and 
suggests that loss of caveolae represents a novel mechanism by which chronic 
activation of pro-inflammatory JAK/STAT signalling could be triggered in 
disease. Together, these data demonstrate an important interaction between 
cavin-1 and SOCS3 responsible for reciprocal regulation of their respective 
functions. 
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1 
1 Introduction 
1.1 Plasma membrane organisation and function 
1.1.1 Lipid rafts 
The fluid mosaic model of Singer and Nicolson [1] is the most accepted 
representation of the cell membrane organisation and dynamics. According to 
this model, the lipid bilayer is a neutral two-dimensional fluid construct that 
allows free diffusion of membrane constituents [2]. Later, a series of 
experimental findings revealed that partial restriction of most proteins within the 
plasma membrane over the nanometre scale, and the hypothesis of membrane 
microdomain ‘lipid rafts’ was formulated. 
Lipid rafts include a variety of nanoscale, transient, relatively ordered 
assemblies with distinct compositions and properties [3]. They are defined as 
small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-
enriched domains that compartmentalise cellular processes [4]. Specific 
protein-lipid and protein-protein interactions are proposed to enlarge and 
stabilise functional membrane rafts complexes [5-7]. Furthermore, disrupting 
lipid raft integrity is associated with the pathogenesis of cardiovascular 
diseases, such as cardiac hypertrophy and atherosclerosis [8], and chronic 
inflammatory diseases, such as systemic lupus erythematosus and rheumatoid 
arthritis [9]. Therefore, pharmacological modulation of membrane rafts and 
perturbing their interactions with signalling molecules may hold potential 
therapeutic significance in devising new treatments or many human diseases. 
The plasma membrane includes two types of microdomain: planar lipid rafts 
and a subset of rafts known as caveolae. Flotillin-rich planar lipid rafts are flat 
non-invaginated microdomains that lack distinguishing morphological features 
[10]. Caveolin-rich caveolae, on the other hand, are spherical or ﬂask-shaped 
invaginations of the plasma membrane and represent a subset of membrane 
lipid rafts with specific functions conferred by the presence of caveolin proteins 
[11] (Section 1.2). Lipid rafts and caveolae share the similar lipid composition. 
Nevertheless, caveolae do not seem to occur in all cells compared to lipid rafts 
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although both rafts and caveolae can co-exist in a given cell type [11]. Flotillin-
1 and flotillin-2 have been generally considered as marker proteins of planar 
lipid rafts. They are thought to function as scaffolding proteins within lipid 
microdomains by promoting the co-assembly of activated and specific 
glycosylphosphatidylinositol GPI-anchored proteins in plasma membrane 
microdomains to allow interaction with specific signalling molecules, such as 
the high-affinity IgE receptor (FcεRI), epidermal growth factor receptor (EGFR), 
and Ephrin-B1 receptors [12, 13].  
1.1.1.1 Development of the raft model of the cell membrane  
The common biochemical methods for studying the membrane lipid rafts 
include: 1) isolation of detergent-resistant membrane fractions (DRMs) by 
antibiotics (e.g. Nystatin) or pore-forming agents (e.g. Saponin)  and 2) 
cholesterol depletion by methyl-β-cyclodextrin [13]. Recently, the existence of 
dynamic cholesterol-dependent nano-clusters in the cell membrane has been 
demonstrated by advanced super-resolution microscopy techniques such as 
photoactivated localisation microscopy (PALM), stimulated emission depletion 
(STED) fluorescence microscopy and stochastic optical reconstruction 
microscopy (STORM) [14]. Although an enormous amount of direct and indirect 
evidence indicates the lipid rafts presence in cell membranes, the concept of 
lipid rafts is still evolving and a matter of debate. Thus, research in the field has 
grown in the past decade as hundreds of papers were published annually to 
discuss the lipid raft hypothesis (for an authoritative review of caveolae and lipid 
raft structures and functions, see ref.[15]). 
1.1.1.2 Signalling through Lipid Rafts 
Accumulating evidence suggests that lipid rafts play an important role in 
receptor-mediated signal transduction, providing a distinct platform for the 
functioning of receptors and intracellular molecules [16]. Such data were 
obtained via several helpful methodological approaches despite their potential 
pitfalls. For example, simple non-ionic detergent extraction is considered a 
useful means for the detection of floating lipid rafts although the detection 
process can be affected by the changes in extraction and detergents conditions 
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as well as the existence of non-floating rafts which might be connected to the 
cytoskeleton [17-19]. Another common approach which is used to identify 
putative raft association is the antibody patching and immunofluorescence 
microscopy [20]. However, quantification of rafts by using this method may be 
difficult due to cell-cell variability [19]. In addition, more advanced techniques 
that require technical expertise and specialised equipment include 
immunoelectron microscopy, photonic microscopy and fluorescence resonance 
energy transfer [21-23]. Importantly, chemical cross-linking enables adequate 
identification of native raft protein complexes although the selection of 
appropriate reagents and conditions may be semi-empirical [24]. Collectively, 
these techniques led to the proposal that rafts are indeed dynamic in nature 
rather than static in situ and that specific signals might affect the distribution of 
membrane proteins in raft domains [25].  
From an historical perspective, these microscopic cholesterol-enriched lipid 
rafts were initially implicated in various innate and adaptive immune responses. 
Specifically, Immunoglobulin E (IgE)-mediated signal transduction was the first 
signalling pathway that highlighted the association of lipid rafts during parasitic 
and allergic immune responses [26]. Since then, key immune receptors such 
as T-cell antigen receptor and B-cell antigen receptor were found in membrane 
rafts following receptor activation [27, 28]. In neuronal cells, lipid rafts are 
associated with the three components of the ciliary neurotrophic factor (CNTF) 
receptor complex, namely the CNTF-R itself and its signal transducers the 
leukaemia inhibitory factor (LIF) receptor and the interleukin-6 (IL-6) signal 
transducer glycoprotein (gp130) [29]. In addition to their involvement in immune 
and neuronal signalling, lipid rafts are also critical for haemostasis and 
thrombosis. Lipid rafts are required for fibrin clot retraction and platelet 
aggregation via the collagen receptor GPVI, the ADP receptor P2Y12, the Fcγ 
receptor FcγRIIa, and the thromboxane A2 receptor [30]. Furthermore, lipid 
rafts-dependent signalling has also been reported in other receptors that have 
intrinsic tyrosine kinase activity (e.g., insulin receptor, EGFR, and Kit receptor 
tyrosine kinase) [30, 31]. Additionally, signal transduction of certain G-protein-
coupled receptors (GPCR) depends on the interaction with lipid rafts. For 
example, dopamine D1 receptors were found to preferentially regulate the 
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activity of specific adenylyl cyclase isoforms (AC 3, 5, and 6) in a lipid rafts-
dependant manner [32].  
1.2 Caveolae 
The earliest research on caveolae was conducted by Yamada and Palade in 
the 1950s [33, 34]. Ultrastructural investigations of the plasma membrane by 
transmission electron microscopy revealed the presence of distinct ‘cave-like’ 
intracellular organelles. Caveolae were first identified in the continuous 
endothelium of the heart and then in the gall bladder epithelium. These 
structures exhibit the following characteristic features: 1) Flask-shaped 
membrane invaginations that are typically associated with the plasma 
membrane and occasionally seen with narrow neck or a diaphragm; 2) Typical 
sizes are 50-100 nm without an apparent electron-dense region found in larger 
“coated” vesicles-i.e., clathrin-coated pits [35, 36]. Morphologically identiﬁable 
caveolae have since been found in a variety of cell types. They are particularly 
abundant in smooth muscle cells, endothelial cells and adipocytes where they 
comprise up to 35% of the cell surface [37]. In contrast, they are reportedly 
absent in most neural tissues [38], lymphocytes, red blood cells, and platelets 
[39]. 
The discovery of the protein composition of caveolae marked a significant 
breakthrough in understanding the nature and importance of these organelles 
[40]. Caveolae are comprised of two classes of proteins, the integral membrane 
caveolins (caveolin 1-3) and caveola-associated cavins, (cavin 1-4) [41]. 
Mutation of caveolar proteins in mammals is associated with a broad range of 
diseases, such as lipodystrophy, muscular dystrophy, cardiovascular diseases 
and cancers [42-46]. 
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Figure 1–1: The morphology and composition of caveolae.  
(A) An endothelial cell showing the flask-like invaginations by electron 
microscopy. (B) Caveolin filaments are shown on the caveolae surface as 
viewed by rapid-freeze deep-etch electron microscope in the cytoplasm 
of a human fibroblast cell. Individual caveolae are depicted in the lower 
panel (C) An individual caveolae with caveolar proteins and lipid species. 
Additionally, DRMs (lipid rafts) are shown with flotillin-1 protein. Adapted 
from Shibata et al. [39] and Pilch et al. [47].  
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1.2.1 Caveolins 
Caveolins (CAV) are a family of three (caveolins-1-3) small ~18-22kDa proteins 
characterized by marked homology to each other despite their dissimilarity to 
other typical proteins. They include membrane integral proteins that resemble 
hairpins having cytoplasmic NH-2 and COOH-termini [48]. The four major 
domains of caveolins are the: scaffolding domain (CSD), N-terminal domain 
(NTD), C-terminal domain (CTD), and intramembrane domain (IMD) [49-51] 
(Figure 1–2). The family of caveolin genes consists of three caveolins (1, 2, and 
3). While many cell types express CAV-1 and CAV-2 (such as the endothelial 
cells, fibroblasts and adipocytes), CAV-3 is exclusively expressed in skeletal, 
cardiac, and smooth muscles [52, 53]. Both CAV-1 and CAV-3 are closely 
related to each other based on protein sequence homology; they are  85% 
similar and 65% identical [54]. Further, there is a close proximity between CAV-
1 and CAV-2 on the chromosome 7 (q31.1), while CAV-3 is found on 
chromosome (3p25) [55]. Additionally, CAV-2 complexes that subsequently 
form caveolae are assembled depending on the expression and oligomerisation 
of CAV 1/3. Actually, this property is exclusive for CAV-2 rather than CAV 1/3. 
As such, CAV-2 fails to leave the Golgi complex and undergoes rapid 
degradation in the absence of CAV-1 [56]. In addition, phosphorylation of CAV-
1 and CAV-2 can occur on multiple residues, while all caveolins are 
palmitoylated on three cysteine residues [57-60] (Figure 1–2 and Figure 1–3). 
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Figure 1–2: The different subdomains of caveolin proteins. 
Phosphorylation sites and the palmitoylated cysteine residues are shown 
in red and yellow text, respectively. Adapted from Sverdlov et al. [61] 
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Figure 1–3: The basic structures and posttranslational modifications 
of CAV-1 and CAV-3.  
Both proteins have four domains: The N-terminal domain (orange) with 
several ubiquitination sites as well as exclusive phosphorylation sites on 
CAV-1, scaffolding domain (blue) which forms alpha helices, 
intramembrane domain (fuchsia) which moves out of the membrane at a 
palmitoylation site, and C-terminal domain (green). Adapted from Busija 
et al. [48] 
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1.2.1.1 Caveolin-1 
CAV-1 is a 22kDa protein comprised of 178 amino acids. Alternatively-spliced 
CAV-1 transcripts encode two distinct isoforms: CAV-1 alpha (CAV-1α) and 
CAV-1 beta (CAV-1β; 32-178), in which the first 31 amino acids are absent [62, 
63]. Such isoforms have specific differences in their impact on the structure and 
depth of caveolae and how they affect the functions of cytokine receptors [62, 
64-66]. For example, studies have demonstrated that deep caveolae are 
associated with CAV-1α, while CAV-1β has the ability to inhibit the signals of 
cytokines [64-66].  
Human CAV-1 molecule contains nine tyrosine residues, three of which are 
located only in CAV-1α. Such residues might act as potential substrates for Src 
[67]. Studies have shown that CAV-1α is selectively phosphorylated in cells 
expressing viral Src (v-Src) and the basic phosphorylation site of cellular Src 
(c-Src) is Tyr-14 [68]. CAV-1 phosphorylation by Src family kinases would 
possibly have an impact on caveolar functions through distinct morphological 
changes, such as aggregation, flattening, and fusion of caveolae [68]. Gottlieb-
Abraham et al. [69] found that Src-mediated CAV-1 phosphorylation at Tyr-14 
resulted in modulation of focal adhesion dynamics via accumulation of Src 
kinases in focal adhesions. 
Within the full-length protein (Figure 1–2), the CAV-1 NTD (residues 1–81) is 
responsible for the assembly of complexes that build caveolae by the integrated 
oligomerization domain [70]. Additionally, the interaction of CAV-1 with the CSD 
(residues 82-101) may be involved in the downregulation of many signalling 
molecules although the presence of specific binding sites to such domains 
remains unclear [71, 72]. The IMD (residues 102-134) is composed of two α-
helices separated by a unique three residue linker region containing a proline 
(P110) that induces a ~50° angle between the helical regions [73, 74]. This 
pattern gives CAV-1 the hairpin topology, with the C- and N- termini directed 
towards the cellular cytoplasm [73, 75, 76]. Caveolin-1 oligomer/oligomer 
interactions require CTD (residues 135–178) that also contains three sites of 
cysteine palmitoylation (C133, C143 and C156) mediating membrane 
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attachment. Nonetheless, palmitoylation of caveolin is not necessary to target 
this protein to caveolae [77]. 
1.2.1.2 Caveolin-2 
Two distinct isoforms of caveolin-2 (CAV-2α and CAV-2β) have been identified. 
The full-length protein is encoded by CAV-2 alpha (CAV-2α), while the beta 
isoform lacks the N-terminus. In addition to the transcript variants which encode 
CAV-2 isoforms, using alternate in-frame initiation codons would encode CAV-
2 isoforms, particularly the β isoforms, that are preferentially located in lipid 
droplets [78]. Nonetheless, Fujimoto et al. [78] reported variations in the 
subcellular distribution of both isoforms although the detailed knowledge 
pertinent to them is still insufficient.  
The assembly of CAV-2 can be established in the form of homo-dimers or 
hetero-oligomers with CAV-1 [79, 80].  The expression of CAV-1 is necessary 
for CAV-2 expression, trafficking, and targeting of caveolae. For instance, In 
CAV-1 knock-out mice, the expression of CAV-2 is not sufficient to form 
caveolae and CAV-2 remains trapped in the Golgi. However, caveolae 
formation is not affected in CAV-2-deficient mice despite the reported reduction 
in CAV-1 expression (by 50%) observed in pulmonary abnormalities, including 
hypercellularity of lung parenchyma, thickening of alveolar septa and 
abundance of the endothelial cells expressing vascular endothelial growth 
factor receptors [80, 81]. Seemingly, it is unclear that CAV-2 could exert its 
functions independent of caveolae and CAV-1 on the cellular and tissue levels 
[80]. However, some reports have shown that CAV-2 has some roles in 
enhancing caveolae formation [82], inhibit pulmonary fibrosis caused by 
medications [83], downregulation of cellular proliferation [84, 85], insulin 
signalling, stimulate blood vessel formation in the tumours [86], and prevent 
gastrointestinal cellular injury or hyperpermeability [87]. Thus, CAV-2 appears 
to be involved in CAV-1 functionality to a specific extent, while the independent 
action of CAV-2 needs to be better elucidated.  
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1.2.1.3 Caveolin-3 
CAV-3 forms most of the caveolae present in muscle cells [88]. In addition to 
their predominance in the skeletal and cardiac muscle cells, there is an 
evidence of their presence in smooth muscle cells [89]. Unlike CAV-1 and CAV-
2, there are no isoforms of CAV-3. The biochemical characterisation of 
immortalised murine CAV-3-/- myoblasts suggested novel roles for CAV-3 
during myoblastic development at the step of myoblast fusion into myotubes 
and in the formation of transverse tubules during the differentiation of muscle 
cells [90-92]. In mature muscle fibres, CAV-3 has a remarkable post-maturation 
role as it is found in the sarcolemma, affecting muscular metabolic processes, 
such as glucose uptake and energy metabolism [93], activation of signalling 
pathways that mediate the cardiac hypertrophic response [94], and muscular 
contractility [95]. Talukder et al. [96] revealed that there was a significant 
change in muscular insulin signalling that was associated with changes in CAV-
3 expression. Mutations in CAV-3 have been associated with abnormal 
elevations of the levels of serum creatine kinase and they were found in several 
muscular diseases, such as Duchenne muscular dystrophy (DMD), rippling 
muscle disease (RMD), and limb-girdle muscular dystrophy (LGMD) [92, 97-
99].  
Experimental animal models that lack CAV-3 exhibit skeletal muscle 
abnormalities, including muscular dystrophy and cardiac muscle abnormalities, 
such as progressive cardiomyopathy, hypertrophy, dilation, and reduction of 
fractional shortening [92, 94]. It has been reported that CAV-3 null mice display 
impaired insulin resistance and lipid metabolism [100, 101]. In spite of such 
perceived roles of CAV-3, the exact pathophysiological mechanisms implicated 
in disease progression are not fully elucidated. Overall, CAV-3 plays an 
important role in muscle tissue as indicated by a variety of muscle disease that 
could develop as a result of CAV-3 gene mutations. Challenging aspects 
related to the identification of potential modifying factors or genetic mutations 
need to be revealed.  
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1.2.2 Cavins 
Although CAV-1 is a vital protein necessary for caveolae formation, it may not 
be sufficient for their formation [102]. A distinct class of caveolae-associated 
proteins called cavins (Cavin-1 and -4) was subsequently identified that have 
significant roles in the biological functions, formation and localisation of 
caveolae. Cavin1 was formerly known as “polymerase I and transcript release 
factor” (PTRF) [103], cavin-2 as serum deprivation protein response (SDPR) 
[104], cavin3 as SDPR-related gene product that binds to C kinase [105], and 
cavin4 as muscle-restricted coiled-coil protein (MURC) [106]. Kovtun et al. [107] 
performed a combined sequence of all cavin proteins in mouse and zebrafish 
Cavin4, revealing two strongly-predicted positively-charged α helical regions 
called HR1 and HR2 with a high degree of sequence conservation (HR1 is more 
consistently similar among cavin proteins than HR2) (Figure 1–4). HR1 and 
HR2 domains are flanked by negatively-charged, acidic, disordered and poorly 
conserved regions termed DR1-3. A coiled-coil domain exists in the HR1 
domain as confirmed by crystallography analysis and it is involved in the 
interactions between different cavin proteins [108]. In addition, a leucine zipper-
like motif (LZD), which helps in protein-protein interaction, is located in the HR1 
of cavin1-3 and HR2 of cavin-1. Furthermore, all cavin proteins have distinct 
domains, rich in proline (P), glutamic acid (E), serine (S) and threonine (T), 
termed PEST motifs [109]. Despite their apparent role in proteolytic degradation 
through the µ-calpain and 26S proteasome system that might lead to the 
shortening of the half-life of cavins, the exact function of the PEST domains in 
the cavin proteins has not been defined [110, 111]. A membrane association 
domain (which mediates the attachment to the membrane) is a basic domain 
located at the C terminus of cavins [112]. Cavin proteins map to different human 
chromosomes, unlike CAV-1 and CAV-2. Thus cavin-1 is located on 
chromosome 17 (q21.2), cavin-2 in on chromosome 2 (q32.3), cavin-3 in 
chromosome 11 (p15.4) and cavin-4 in on chromosome 9 (q31.1) [112].  
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Figure 1–4: Cavin family proteins 
(A) Structure of different cavin proteins in human. (B) The combined 
sequence revealed two positively-charged helical regions (HR1 and HR2) 
which are separated by non-conserved regions named DR1-3. N, Nuclear 
localization signals, LZD; Leucine zipper-like motif; HR, Helical regions; 
and DR, Disordered region. Adapted from Nassar and Parat [108] 
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A putative nuclear localisation signal was originally linked to Cavin-1. Indeed, 
this is consistent with the former identification of cavin-1 as an RNA-polymerase 
I regulator as it plays an important role in the process of loop formation which 
is required for activation of ribosome transcription [113]. However, there is a 
growing body of evidence that showed an important role of cavin-1 outside the 
nucleus [114]. Post-translational modification of cavins, results in a 10-15kDa 
higher migration than expected from their primary structure during fractionation 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Such modifications include multiple aspects of an unclear functional 
significance. The abundance of PEST motifs in the DR domains of cavins 
affects their proteolysis and might modulate cavin localisation, given the 
removal of the C-terminus DR3 results in association with microtubules [115] 
and the involvement of DRs in cavin oligomerisation [107]. Ubiquitylation has 
been also reported in cavins consistent with the identification of SUMOylation 
and ubiquitylation sites [116] and the acceleration of proteasome-dependent 
proteolysis of non-caveolar cavin-2 [117]. Phosphorylation is another commonly 
reported modification of cavins. As with caveolins, all cavin proteins have one 
or more phosphorylation sites, with dozens of reported sites within the DRs 
[107, 114]. Studies have shown that cavins might undergo rapid 
phosphorylation following stimulation of adipocytes, indicating a possible 
linkage between their regulation and the signalling pathways [118-120]. 
However, the effect of such extensive phosphorylation on the functions of 
cavins has not been discerned [114]. 
Cavin 1-3 are found in the body with the same distribution as CAV-1 [102, 121]. 
In addition, Cavin-1 is present also in skeletal muscle while cavin-3 is found in 
liver and brain. cavin-4 is exclusively located in the skeletal muscles [106]. 
Cavin-1 genetic deletion causes a remarkable loss of CAV-1-3 proteins in 
approximately 80-90% of tissue [121]. Such genetic loss results also in 
reduction of cavin-2 and -3 levels, but to a less extent, with no effect on cavin-
4 expression. Overall, the expression of CAV-1 and cavin-1 is essential for 
caveolae formation, while the stability and function of caveolae are preserved 
by cavin-2 and cavin-3. Co-immunoprecipitation data have shown that 
members of the cavin family interact in a multimeric complex in the cytosol and 
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plasma membrane fractions yet a clear connection of such interaction to 
caveolins has not been uncovered [106]. 
In general, cavin proteins in human and mice show strong homology, with the 
strongest homology in cavin-1 (93%), while cavin-2, -3, and -4 share 
homologies of 83%, 78%, and 89%, respectively. Within the murine species, 
cavin-4 shows a homology of 29% to cavin-1, 24% to cavin-2, and 20% to cavin-
3, while it shows a similarity of 49%, 42%, and 39% to cavin-1, cavin-2, and 
cavin-3, respectively [106]. Compared to caveolins, cavin proteins are larger, 
with cavin-1 comprising 390 amino acids, cavin-2 425 amino acids, cavin-3 261 
amino acids in, and 364 amino acids in cavin-4 (Figure 1–4) [112].  
Immunogold labelling technique showed that the expression patterns of cavin 
proteins are generally demonstrated in a uniform manner around the caveolar 
bulb [122]. As per single-molecule fluorescence microscopy findings, cavin 
monomers are composed of 50 molecules with specific patterns of interaction 
between all cavin family members in a given caveolae [123]. Changes in the 
membrane tension (membrane stretch) can cause disassembly of the cavin 
coat into distinct subcomplexes containing cavin-1 and cavin-2 or cavin-1 and 
cavin-3 [123].  
1.2.2.1 Cavin-1 
Cavin-1 was first identified by a yeast two-hybrid screening assay [124]. Cavin-
1 was named as polymerase I and transcript release factor (PTRF) because it 
enables the dissociation of RNA polymerase I transcripts and the tertiary 
structures [125]. Given that the transcription termination factor (TTF)-l is 
involved in the transcription process of ribosomal mRNA (mediated by 
polymerase I), the PTRF-related investigations were conducted using the TTF-
l as a bait in the yeast two hybrid screen. PTRF was then reclassified following 
its identification in specific enriched fractions with distinct localisation patterns 
in caveolae as shown by immunogold labelling [125]. Bastiani et al. [106] 
reported that cavin-1 is 66% homologous to cavin-2 and 59% homologous to 
Cavin3 and Cavin4. In terms of tissue distribution, cavin-1 expression has been 
reported in the heart, lungs, and adipose tissue [121]. The role of cavin-1 is 
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clearly demonstrated by the failure of caveolae formation in the lung epithelium, 
smooth muscles of the intestine, and cardiac muscle cells along with metabolic 
and adipocyte dysfunction when cavin-1 gene is deleted in mice [121, 126].  
Notably, cavin-1 depletion is associated with a significant reduction in protein 
expression of all cavins and caveolins [102, 106]. Even though Liu et al. [121] 
found that cavin-1 deficiency triggered an upregulation of expression levels for 
caveolin isoforms. In addition, it has been shown that the consequences of 
cavin-1 mutations or gene knockout are reduced adipose tissue, muscular 
dystrophy, cardiodystrophy, hypertriglyceridemia, hyperinsulinemia, and 
glucose intolerance [121, 126, 127]. Indeed, these patterns were typically 
reported CAV-1/CAV-3 double knockout mice [128]. This is consistent with the 
fact that the tissue distribution of combined CAV-1/CAV-3 mimics that of cavin-
1.  
Akin to caveolin proteins, the pathophysiological consequences of cavin-1 
deficiency in animal models have been replicated in rare human genetic 
disorders [129]. For example, genetic screening on more than 2,700 muscular 
dystrophy specimens showed that five patients with Berardinelli-Seip congenital 
lipodystrophy (BSCL), characterized by a marked reduction of the adipose 
tissue along with severe dyslipidaemia and insulin resistance, were deficient in 
CAV-3 in the absence of any CAV-3 mutations [127]. However, cavin-1 protein 
in all BSCL patients had remarkable frame-shift mutations that yielded severely 
truncated proteins. Furthermore, such BSCL patients suffered also from a 
generalised muscular dystrophy [127].  
In addition, cavin-1 has been involved in lipodystrophy. Several studies have 
shown that cavin-1 had potentially a major role in the pathogenesis of the near 
total loss of adipose tissue and multiple myopathic abnormalities in patients with 
congenital generalized lipodystrophy subtype 4 [43, 44, 130]. Therefore, the 
outcomes of these studies confirm that cavin-1 produces similar pathological 
pictures in human and mice.  
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The location of cavin-1 at the 17q21.2 region on the human genome have been 
linked with multiple human diseases. For instance, Barrett et al. [131] revealed 
that cavin-1 was widely reported in patients with type I diabetes, whereas 
another study conducted by Ikram et al. [132] showed a possible correlation 
between the variants at 17q21.2 and the intracranial volume. This would 
eventually lead to inability to attain maximal brain size. However, there is a lack 
of confirmed evidence regarding a possible role of cavin-1 in these conditions. 
It worthy to note that the BRCA1 gene (breast cancer gene 1), the well-known 
tumour suppressor gene, is located at the 17q21.31 locus [133]. Interestingly, 
there has been a controversy regarding the cancer-related effects of cavin-1. 
Some studies have proved that cavin-1 is a tumour suppressor in multiple 
studies, including colorectal [134], prostate [135], breast [45], and lung cancer 
[136]. In contrast, a recent study proved that cavin-1 promotes the proliferation 
of glioma cells, thus acting as a tumour promoter [137]. This is because cavin-
1 was enriched in glioblastoma subtypes and its increased expression with 
advanced tumour grades indicated a possible correlation with poor prognosis 
[137]. In sum, it seems that cavin-1 has a dual role in cancer.  
1.2.2.2 Cavin-1 as a regulator of caveolae 
The apparent role of cavin-1 proteins in the regulation of caveolae was first 
identified by the fact that reduced cavin-1 levels were associated with a 
reduction of CAV-1 protein recruitment into lipid raft fractions, while an increase 
of CAV-1 incorporation in lipid rafts was observed in human kidney embryonic 
kidney (HEK) HEK293-caveolin-1-cavin overexpressing cells [121]. Given the 
important linkage between caveolae and the actin cytoskeleton which is of an 
important implication for cellular response to mechanical stress [138], such 
linkage may be accomplished by cavin-1 since it has been reported that a 
truncation mutant of this protein localised to a cytoskeletal-like structure rather 
than the plasma membrane [139]. In contrast, Verma et al. [140] showed that 
CAV-1 was localised to long branched tubules derived from the plasma 
membrane (up to 50 µm) when it was expressed in certain cancer cells, while 
CAV-1 was appropriately localised to the plasma membrane when cavin-1 was 
co-expressed with CAV-1. As such, adequate proportions of cavins and 
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caveolins are required so that they could be appropriately localised to the 
plasma membrane and subsequently form caveolae.  
Indeed, in addition to decreasing the amounts of CAV-1, knockdown of cavin-1 
can also lead to a significant reduction in caveola density as demonstrated by 
electron microscopy due to an increase in the lateral motility and excessive 
lysosomal degradation of CAV-1 [102]. Moreover, genetic deletion of cavin-1 in 
mice resulted in a significant instability of all three caveolin proteins [121]. 
Besides, while cavin-1 exhibits a generally stable expression (like CAV-1), 
cavin-1 gene can be also induced by stress conditions, such as starvation [118], 
oxidative stress, and exposure to catecholamines which could ultimately lead 
to an increase in caveolae number [141].  
As mentioned above, a lipodystrophic phenotype is seen in mice in which both 
copies of the cavin-1 gene are knocked-out. This might be related to a lack of 
caveolae which impairs triacylglycerol uptake and storage in adipocytes [121]. 
In humans with cavin-1 mutations, cardiovascular and pulmonary disorders 
appear to evolve along with the lipodystrophic phenotype as these mutations 
result in either the loss of cavin-1 expression or the generation of non-functional 
C-terminally truncated cavin-1 proteins, leading to loss of caveolae in myocytes 
and fibroblasts [43, 44, 127]. However, diet-induced atherosclerosis caused a 
remarkable disruption of the positive association between CAV-1 and cavin-1 
[142]. In mice fed on a high-fat diet, the DRMs in the lung endothelial cells 
showed upregulation of CAV-1 despite reduced cavin-1 levels. As a 
consequence, caveolae were lost and caveolae-dependent signalling was 
impaired, providing one potential explanation for the association between 
cardiovascular and pulmonary disorders [142].    
It has also been shown that cavin-1 silencing and cholesterol-depleting drugs 
which disrupt caveolae can limit CAV-1 localisation to lysoendosomal 
compartments, where it is eventually degraded [143]. Such CAV-1 degradation 
is prevented by neutralisation of lysosomal pH and partially blocked by 
proteasome inhibitor MG132 suggesting that the endosomal system could 
possess a proteasomal activity that modulates CAV-1 turnover [143]. Although 
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these data reveal the necessity of cavin-1 for an adequate expression of normal 
amounts of caveolins, the exact details of such mechanism remain unclear. The 
contribution of cavin-1 has been shown in the process of CAV-1 trafficking and 
caveolae formation. Once CAV-1 moves to the Golgi after its synthesis in the 
endoplasmic reticulum (ER), it interacts with cholesterol and its mobility in the 
plasma membrane is lost. Following cholesterol-CAV-1 interaction, caveolae 
assembly is inhibited and CAV-1 degradation is accelerated [130, 143]. 
1.2.2.3 Cavin-2 
Cavin-2, formerly known as SDPR, was discovered by Gustincich and 
Schneider in the early 1990s as an mRNA that was intensively induced in 
response to serum deprivation in 3T3 fibroblasts [104]. The relationship 
between caveolae and cavin-2 was subsequently determined following its 
identification as a protein that mediates caveolae binding to the signalling 
enzyme protein kinase C (PKC) alpha [144]. In addition, it was recognised as a 
binding protein to phosphatidylserine in human platelets. This protein was re-
named as cavin-2 following detection of its localisation to the plasma membrane 
at the caveolae using confocal imaging [145].  
The sequence identity of cavin-2 with cavin-1 is 66%, 68% with cavin-3 and 
57% with cavin-4 [106]. It was found that excessive expression of cavin-2 led 
to caveolae deformity as well as tubular membrane structures as seen by 
immunofluorescence and electron microscopy [145].  
On the other hand, knockdown of cavin-2 was associated with loss of caveolae 
and a significant reduction of cavin-1 and CAV-1 expression [145]. Overall, 
these reports demonstrate an essential role of cavin-2 in the formation of 
caveolae.  
A clear relationship between cavin-2 and cholesterol has been shown when 
3T3-L1 adipocytes exposed to the cholesterol-depleting agent methyl-β-
cyclodextrin, which led to cavin-2 degradation by the proteasome. Interestingly, 
cholesterol repletion fully reversed the effect of methyl β- cyclodextrin and 
restored cavin-2 levels, which allowed reformation of the caveolae [139].  
 
 
20 
cavin-2 is highly expressed in the heart with considerable expression also 
detected in the lung and adipose tissue [146]. The role of cavin-2 in 
cardioprotection is still debated although it has been suggested that cavin-2 
might act as a negative regulator of Akt and extracellular signal–regulated 
kinase (ERK1/2) signalling. This is because inadequate cavin-2 expression in 
the heart results in hypertrophy and resistance to apoptosis caused by H2O2 
stimulation and hypoxia [147]. Moreover, Higuchi et al. [148] reported that 
cavin-2 may be considered an important mediator in the progression of heart 
failure, as it modulated phosphatase and tensin homolog (PTEN)/Akt signalling 
and enhanced cardiac cell death in response to pressure overload. The authors 
suggested that this protein might be a promising therapeutic target for heart 
disease [148]. Another recent report by Boopathy et al. [149] showed a critical 
role of cavin-2 in regulation of nitric oxide production in endothelial cells through 
an adequate control of the activity and stability of nitric-oxide synthase. Indeed, 
this might reveal an important impact of cavin-2 on endothelial cell maintenance 
and function. It is noteworthy that immunofluorescence and immunoblotting 
analyses have shown that cavin-2 expression was higher with the progressive 
differentiation status of liposarcoma tumour cell lines rather than their 
proliferation, suggesting cavin-2 as a potential marker for liposarcoma 
differentiation [150]. 
In terms of disease association, the location of cavin-2 on the 2q32-q33 locus 
suggests a potential role in cancer. This might be attributable to the previous 
evidence of a genomewide linkage screen, which showed a possible correlation 
between the 2q32-q33 locus and familial serrated neoplasia (Jass syndrome), 
a rarely reported form of colorectal cancer [151]. Moreover, the cavin-2 gene 
locus is involved in the pathogenesis of the eponymous chromosome 2q32-q33 
deletion syndrome, which is characterised by marked mental retardation, 
craniofacial dysmorphism and microcephaly [152, 153]. Recently, Unozawa et 
al. [154] found that cavin-2 expression was down-regulated in oral squamous 
cell carcinoma using immunoblot analyses and the clinical data of 
immunohistochemistry revealed an increase in tumour progression in patients 
deficient in cavin-2 [154]. However, these cancer phenotypes were not 
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observed in the knockout studies in mice, which might highlight the need to 
conduct future investigations concerned with malignancies.  
1.2.2.4 Cavin-3 
Cavin-3 was first identified as a protein that interacted  with PKC delta (δ), which 
was later found to be directly associated with caveolins and localised in the 
caveolae fraction [155]. Co-immunoprecipitation experiments suggest that 
cavin-3 interacts with cavin-1 and cavin-2 [106]. Cavin-3 is expressed a variety 
of cells, including brain cells and adipocytes [106]. However, cavin-3 is more 
widely distributed in the tissue, which may suggest other physiological functions 
outside the caveolae [109, 155]. Further, cavin-3 cardiac expression is 
comparable to that of caveolins [146].  
Bastiani et al. [106] stated that the general similarity of cavin-3 to other cavins 
has been estimated to be 59% to cavin-1, 68% to cavin-2, and 51% to cavin-4. 
Five variants of cavin-3 protein can be generated as a result of alternative 
splicing of cavin-3 mRNA resulting in a considerable variation in the molecular 
weight (14 to 31-kDa) [155].  
Multiple functions of cavin-3 have been reported, including intracellular 
transport and endocytosis [155]. The importance of cavin-3 is more apparent in 
cell signalling since it can mediate AAkt, ERK1/2, and EGFR signalling 
pathways. It may act also as a coupling agent to these signals to the transport 
machinery within the cells [155, 156]. McMahon et al. [155] suggested that 
caveolae signalling could be mediated by cavin-3 by budding of distinct vesicles 
called “cavicles” by microtubules. The authors supported their findings by the 
fact that cavicle trafficking was reduced in absence of cavin-3 [155].  
Cavin-3 deficiency in lung tissue is associated with an increase in phospho-Akt 
levels and a reduction in phospho-Erk levels when compared to wild-type 
counterparts. Moreover, it has been shown that cavin-3 deficiency was 
associated with a pleiotropic phenotype, where a late cachexia with shortened 
life span occurred [156]. Heart tissue deficient in cavin-3 did not show changes 
in the expression of cavin-1 and CAV-1 and cavin-3 was found dispensable for 
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formation of endothelial caveolae [146]. Nonetheless, recent evidence has 
shown that loss of cavin-3 in mice produces a 40% reduction in the expression 
of cavin-1 in the smooth muscles of the urinary bladder and blood vessels [157]. 
Although this was also associated with a reduction in caveolae number, the 
physiological consequences were mild, with the main effect being marginal 
elevation of soluble guanylyl cyclase expression [158].  
1.2.2.5 Cavin-4 
Cavin 4, is the most recently identified member of the cavin family. Cavin-4 is 
encoded by two conserved exons and has no splice variants, yielding a single 
362 amino acids long polypeptide [106]. This protein is also named muscle-
restricted coiled-coil protein (MURC) since it is exclusively expressed in 
cardiomyocytes, skeletal myocytes, and smooth muscle cells [159]. Based on 
its sequence homology with cavin-1 as well as its caveolae localisation, MURC 
was re-named cavin-4 [106, 145]. It seems that the role of cavin-4 is modest in 
the process of caveolae formation despite its apparently important impact on 
the disrupted caveolar shape. The latter function was demonstrated by the 
observed increase in caveolae size by cavin-4 overexpression [160]. Maturation 
of cardiac muscle cells and cultured muscle cells would entail cavin-4 
upregulation. On the other hand, expression levels of cavin-4 and CAV-3 are 
impaired in cases of severe myopathy and both proteins may together 
cooperate for proper functioning of skeletal muscle tissue [106, 159].  
Cavin-4 has the ability to form complexes with CAV-3, cavin-1, and cavin-2. 
The localisation of cavin-4 to caveolae and T-tubules in cardiac muscle cells 
was reported although cavin-4 is dispensable for caveola formation [161]. The 
coiled-coil domain of cavin-4 is thought to be responsible for protein 
oligomerisation, and other proteins that contain this domain (including the 
cartilage oligomeric matrix protein, α-keratin, and vemintin) are involved in a 
number of important cellular functions, such as cell division, membrane 
extrusion, gene regulation, and drug extrusion [162, 163]. Naito et al. [161] 
showed that deletion of the coiled-coil domain impaired cavin-4 localisation in 
cardiomyocytes, caused a significant reduction in CAV-3 levels in the plasma 
membrane, and eventually led to cardiac dysfunction. 
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Overexpression of cavin-4 results in induction of fibrosis, atrial arrhythmia, 
ventricular hypertrophy, and alterations in gene expression [159]. Moreover, six 
non-synonymous cavin-4 mutations have been identified in patients with 
hypertrophic cardiomyopathy [164]. Cavin-4 overexpression in rat cardiac 
muscle cells has been induced by hypoxia, which could be a result of induction 
of cavin-4 by serum response factor [165]. Conversely, cavin-4 deficiency might 
lead to attenuation of phenylephrine-induced cardiac hypertrophy following α1-
adrenergic receptor stimulation [160]. Further, cavin-4 knockdown prevented 
myocardial ischemia-reperfusion injury via reduction of oxidative damage and 
is thought to be associated with reactive oxygen species (ROS)-p38 mitogen-
activated protein kinase (MAPK) signalling pathway [166]. In addition to cardiac 
pathology, cavin-4 might be involved in modulating the progression of 
abdominal aortic aneurysm through activation of matrix metalloproteinase-9 
(MMP-9) and JNK [167]. Actually, the aforementioned studies indicate that 
cavin-4 might be a novel therapeutic target for ischemic heart disease as well 
as abdominal aortic aneurysm progression. Finally, cavin-4 was found to be 
disrupted along with CAV-3 in human suffering from rippling muscle disease 
[60]. Collectively, future studies should importantly consider targeting cavin-4 
to investigate its potential therapeutic benefits for inhibiting the exacerbation of 
cardiac, vascular, and muscular disease.  
 
1.2.3 Caveolae biogenesis 
Caveolae biogenesis is a stepwise process that involves trafficking of proteins 
and vesicles from the endoplasmic reticulum (ER) to the plasma membrane 
[48]. The Caveolins are synthetized in the rough ER and co-translationally 
inserted in the ER membrane. After the insertion, CAV monomers aggregate to 
give rise to 8S-Cav oligomers (150-200kDa). 8S- CAV oligomers translocate to 
ER exit sites (ERES) from where they traffic to the Golgi apparatus through coat 
protein 2 (COPII) vesicle-dependent transport (reviewed in [48]). At the cis-
media Golgi, 8S- CAV oligomers further oligomerize into more complex 
structures that contain roughly 160 CAV monomers and are referred to as 70S-
Cav oligomers. Simultaneously, CAV molecules associate to cholesterol-rich 
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membranes, perhaps via the CRAC (cholesterol recognition amino acid 
consensus) domain(reviewed in [48]). At this point the cholesterol associated 
70S-CAV oligomers exit the Golgi network in phosphate adapter protein 1 and 
2 (FAPP1-2) and phosphatidylinositol-4- phosphate (PI4P) dependent transport 
and head to the PM (Figure 1–5) [48]. When 70S-CAV-cholesterol vesicles 
approach the PM, members of the cavin protein family are recruited. The exact 
mechanism of Cavin recruitment at 70S-CAV-cholesterol vesicles sites remains 
unclear, but some hypotheses have been made. 1) low affinity interaction of 
cavins with phosphatidylserine and CAV-1 simultaneously, is the trigger for 
recruitment or 2) changes in the PM curvature could already trigger the 
recruitment of cavins without further molecular interactions [112]. Once at the 
PM, CAV oligomers and cavin oligomers interact to form hetero-oligomeric 
complexes [73].  
The interaction of CAV, cavins and cholesterol generate the membrane 
curvature necessary to form caveolae [48]. Caveolins and cavins together 
produce the membrane invagination by forming an extended tubular structure 
along the PM. In addition, EHD2 is another protein that may be involved in 
producing the fully-invaginated caveolae as well as controlling their stabilisation 
and association to cell surfaces [168, 169]. Furthermore, Hansen et al. [170] 
have reported that pacsin 2, that contains a membrane curvature-associated F-
BAR domain, has also an important role in sculpting caveolae. The end result 
is a mature caveola, composed of three layers: a cholesterol-enriched 
membrane (negatively charged), a 70S-CAV oligomers coat, and a layered 
60S-Cavin complex that runs outside the 70S-CAV oligomers coat (Figure 1–
5) [48]. 
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Figure 1–5: Caveolae biogenesis. 
CAV-1 and CAV-2 enters the endoplasmic reticulum, where they are 
oligomerised into 8S-CAV oligomers. After their exit through the 
endoplasmic reticulum exit sites, these oligomers are transported to the 
Golgi apparatus, where the 70S-CAV complexes are formed by the help 
of cholesterol crystallisation. The complexes are then transported to the 
plasma membrane. At or near this site, the oligomers are palmitoylated by 
palmitoyl acyltransferases and the trimerised cavins are aggregated on 
the 70S-Cav membrane, where they assist in the membrane curvature to 
eventually form mature caveolae. Adapted from Busija et al. [48] 
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1.2.4 Functions of caveolae 
A growing body of evidence suggested that the lack of caveolae impairs multiple 
functions of endothelial cells, adipocytes, and myocytes [112, 129]. This is 
because caveolae are involved in a variety of functions, including lipid 
homeostasis, endocytosis, mechanoprotection and signal transduction 
cascades [112]. The best evidence of caveolar functions comes from 
phenotypes of mice and patients lacking genes relevant to caveolae formation.  
1.2.4.1 Mechanoprotection 
In general, the morphology of caveolae buffer against rapid changes in 
membrane tension [59]. This property was first shown by Dulhunty and 
Franzini-Armstrong [171] when they suggested that caveolae could function as 
“safety valves” by flattening during increased membrane tension as a result of 
mechanical stretch as observed in the stretched frog muscles. In such 
circumstances, caveolae flatten due to detachment of the associated coats of 
cavin-1 from the membrane, leading to an increase in the surface area [129]. 
This would, in turn, prevent rupture of cell membrane and subsequent cell lysis. 
In addition to skeletal muscle tissue, caveolae have a mechanoprotective role 
in endothelial tissue and cardiac muscle cells, providing protection against 
hypo-osmotic swelling and increased mechanical force [172-174]. It has been 
shown that caveolae are essential elements for signalling cascades induced by 
mechanical stress on the PM, such as Akt phosphorylation and Ca2+ fluxes 
[175, 176]. 
Another mechanoprotective role of caveolae is apparent following membrane 
damage, during which caveolae modulate membrane repair through the 
formation of clusters at the site of damage [177]. Corrotte et al. [178] showed 
that caveolae repair membrane damage that can be induced by the pore-
forming toxin streptolysin O. They emphasized also the role of CAV-1 in the 
resistance against membrane damage caused by mechanical insults and toxins 
[178]. The importance of caveolae can be best demonstrated in the reported 
phenotypes of muscular and pulmonary dysfunction in human and mice that 
have been associated with loss of caveolae [99, 127, 179-181]. Overall, this 
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model of caveolar functions reveals a potential paradox. While lateral forces 
implied on the PM causing a mechanical stress would lead to disassembly of 
caveolae, these forces might result in disruption of the membrane, where 
caveolae can act by removing the membrane lesion. As such, the complex 
mechanoprotective role of caveolae needs to be further clarified, including the 
actual stimuli that trigger caveolar budding, the molecular components involved 
in stimuli detection, and finally the signalling pathways induced by mechanical 
stress.  
1.2.4.2 Endocytosis  
Several research studies have been conducted to investigate the role of 
caveolae in endocytosis. For example, it has been shown that SV40 virus and 
cholera toxin could be endocytosed by caveolae (Figure 1–6) [182-184]. 
However, linking caveolae to endocytosis has been controversial. Recent 
studies revealed that overexpression of CAV-1-green fluorescent protein (GFP) 
resulted in its degradation in the late endosomal compartments, and this 
supports the possibility of involvement of classical endocytosis processes in 
cargoes uptake rather than via caveolae [185]. In addition, the investigations 
based on quantitative analysis and microscopy demonstrated a minimal 
contribution of caveolae in the endocytic flux that might reach to only 5% of the 
total caveolar population at high lipid induced levels [186]. Although the results 
of recent studies did suggest a possible role of caveolae in the regulation of 
clathrin-independent endocytic processes [52], the cellular functions of caveolar 
endocytosis remain incompletely defined [129]. 
Similarly, the impact of dynamin on caveolar budding is still doubtful. While 
reports have shown the localisation of dynamin at the neck of caveolae [187, 
188], it seems that it is not essentially involved in caveolar endocytosis of 
damaged membrane [178]. Conversely, caveolar dynamics are controlled by 
the ATPase EHD2 during uptake of the affected membrane via co-localisation 
with caveolae [178].    
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Figure 1–6: Caveola-Mediated Endocytosis.  
An electron micrograph of a CV-1 monkey kidney cell showing Simian 
virus binding to gangliosides in the plasma membrane and entry via 
caveolae. Scale bar = 100 nm. Adapted from Marsh and Helenius [189]. 
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1.2.4.3 Transcytosis 
A specialised form of endocytosis has been shown in the endothelial cells, 
namely transcytosis, which involves the transport of lipids and proteins through 
the apical surface of vascular endothelial cells. Multiple reports proposed that 
caveolae could mediate transcytosis and transport of albumin, insulin, and low-
density lipoproteins [190-192]. Caveolae-based transcytosis might take place 
via fusion-fission model that facilitate vesicular transport and/or the formation 
of temporary trans-endothelial pores [193, 194]. However, these data were in 
contrast with studies based on CAV-1-deficient mice, showing that 
transvascular protein transport has been accomplished in such animals [195, 
196]. Therefore, there are still outstanding questions about whether caveolae 
are required for vesicular transcytosis in endothelial cells, if not, another set of 
cellular machinery for this process has to be addressed [129]. 
1.2.4.4 Lipid homeostasis 
In general, the most frequently-reported phenotypes in caveolae-deficient mice 
are loss of subcutaneous fat, lipodystrophy, and dysfunctions of adipocytes [44, 
197]. The functions of CAV-1 in lipid trafficking were first reported in 
Caenorhabditis elegans [198, 199]. CAV-1 has the ability to bind to fatty acids 
and cholesterol and it may have an important function in cholesterol trafficking 
[200]. Studies have shown that glycosphingolipids trafficking was altered and  
glycosphingolipids were accumulated in lysosomes present in CAV-1−/− cells 
[186, 201]. In addition, the expression of lipid biosynthetic enzymes is 
decreased with loss of CAV-1, leading to a significant reduction of specific lipids 
such as the glycosphingolipid GM3 and phosphatidylcholine [202]. Such 
evidence corroborates the importance of caveolae in the regulation of lipid 
composition in the plasma membrane. Moreover, alteration of lipid composition 
would have deleterious effects on the membrane nanoclusters, which contain 
distinct sets of proteins specialised for signal transduction. Therefore, this may 
represent an indirect mechanism by which caveolae disruption could alter 
signal transduction through disorganisation of particular lipids at the plasma 
membrane rather than through a direct interaction with membrane proteins 
[203].   
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1.2.4.5 Caveolae-localised signalling 
Reports have shown that caveolae are involved in cellular response to a diverse 
set of mechanical and chemical stimuli [204]. Caveolae have the ability to act 
as molecular switches for several cellular processes, in which they may be 
responsible for activation, inhibition, and modulation of multiple functions 
according to the self-interactions between signalling molecules. Such 
molecules include endothelial nitric oxide synthase (eNOS), insulin receptors, 
MAPK, and EGFR [205-209]. Ariotti et al. [202] have shown that agonist-
stimulated MAPK activation might become unaffected by cholesterol depletion 
in CAV-1−/− MEFs, which could be mediated by a switch to K-RAS signalling. 
CAV-2 has been also shown to be an inhibitor of TGF-β signalling and 
antiproliferative action in lung endothelial cells and, on the other hand, this 
function is switched to a pro-proliferative effect in the presence of TGF-β [210]. 
The involvement of caveolae in cell signalling became clear following the 
discovery of caveolin gene family. For example, it has been reported that a 
single knockout of caveolin genes would have no effect on the vitality and 
fertility in mice, while cardiomyopathy and inflammation would be the 
consequences of double deletion of CAV-1 and CAV-3 [128]. These 
observations sparked considerable interest in understanding the pathological 
implications of dysfunctional caveolae with impairments in cell signalling.  
Involvement of caveolae in signal transduction came from studies conducted 
on CAV-1, focusing on capability of such protein to bind and sequestrate a 
number of signalling adapters and the role of such binding in the essential 
regulation of downstream pathways. It has been shown that the CAV-1 binds to 
signalling molecules through its CSD domain and these molecules might be 
activated or inactivated within the caveolae.  
The scaffolding property of CAV-1 led to the development of the “caveolae 
signalling hypothesis” [72, 211] which proposed a potential interaction between 
the 20-amino acid segment in CSD and a particular caveolin binding motif on 
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specific protein targets as a mechanism for caveola-mediated regulation of 
signal transduction. Actually, binding to CSD can cause inhibition of G-proteins, 
eNOS, EGFR, and H-Ras [208, 212, 213]. Nonetheless, such hypothesis has 
been refuted via a structure-based study of Collins et al. [214], whereby the 
most of conserved caveolin-binding motifs in signalling molecules are buried 
and inaccessible to the CSD domain.  
Another observation which raised the interest regarding the role of caveolae in 
signal transduction is that caveolins might have the ability to modulate signalling 
regardless of their structural actions exerted during caveolae formation [215]. 
Within the endothelial cell models, it has been found that a variety of signal 
transduction receptors, such as GPCR and receptor tyrosine kinase (RTK), are 
either localised in caveolae or in a continuous interaction with caveolins [216]. 
There is also an evidence of caveolar contribution during GPCR internalisation. 
For instance, Escriche et al. [217] used cholera toxin to label the ganglioside 
GM1 in smooth muscle cell lines to study the involvement of caveolae in A1 
adenosine receptor internalisation. The authors found that caveolae and CAV-
1 contributed significantly during the receptor-mediated endocytic process. 
Indeed, caveolae might be an important therapeutic target for repairing the 
damaged endothelial tissue [204] relying on the critical roles of adenosine in 
inflammation and ischemia as well as the expression of adenosine receptors in 
endothelial cells [218]. In addition, RTKs represent a large family of molecules 
and their deregulation is involved in several diseases. Studies revealed that 
members of RTK family including angiopoietin, vascular endothelial growth 
factor (VEGF), and Platelet-derived growth factor (PDGF), have an essential 
role during angiogenesis and endothelial caveolin-1 specifically regulates 
VEGF-induced angiogenesis suggesting that localisation of VEGF to caveolae 
microdomains  is crucial for VEGF-mediated signalling [219]. Overall, although 
the idea that supports the role of caveolar proteins in intracellular signalling has 
been confirmed elsewhere in the literature, many signalling-related aspects of 
caveolae are still unclear. It is imperative to reveal the effect of multiple caveolar 
isoforms on signalling in a given cell type. Given the post-translational 
modifications of caveolins [220], the putative impact of modified caveolins on 
cell signalling should be investigated.  
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1.2.5 Potential caveolae-targeting therapeutics 
Caveolae provide a distinct environment where multiple receptor signalling 
components are sequestered, clustered and compartmentalized for efﬁcient 
signal transduction. As such, considerable attention has been focused on the 
biology of lipid rafts generally and caveolae specifically as important sites of cell 
signalling. Indeed, a pivotal role of caveolae in the regulation of vascular 
contractility through binding to eNOS has been well-characterised [221]. In 
essence, eNOS was found to be inactive while it is linked to the scaffolding 
domain of CAV-1. Such linkage is disrupted when Ca2+ concentration is 
increased in the cytosol due to activation of calmodulin. As a result, nitric oxide 
is increasingly generated with a subsequent vasodilatation. This could be 
supported by blocking the interaction between CAV-1 and eNOS by a cell-
permeable peptide that contains the CAV-1 scaffolding domain, namely 
cavnoxin, leading to sustained production of nitric oxide and a marker reduction 
in the blood pressure of wild-type but not eNOS knockout mice [221].  
Indeed, caveolae can occupy up to 40% of the area of the plasma membrane 
in mammalian cell types such as adipocytes and muscle cells [185]. Moreover, 
the PM also contains a vital class of proteins that play central roles in cellular 
processes such as regulation of signal transduction, trafficking as well as the 
recently discovered scaffolding and shaping of the PM itself [14, 39]. Because 
of these diverse roles, the PM proteome accounts for 50% of the mass across 
biological membranes [222] and current estimates suggest that 15-39% of the 
genes in most sequenced genomes encode membrane proteins [223].  
The study of PM proteins holds a great potential to yield many therapeutic 
targets across disease types. Mutations or improper folding of these proteins 
are implicated in a wide range of human diseases such as heart disease, 
obesity, cancer, cystic fibrosis, depression and many others. Currently, 
approximately 60% of commercially produced drugs target membrane proteins, 
mainly GPCRs [224, 225]. Thus, characterisation of PM proteins and their 
functions are critical for providing the molecular framework for understanding 
signalling and the effects of stimulation with various signal molecules [226]. 
Defining membrane proteomes is crucial to understanding the role of 
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membranes in the fundamental biological processes and for finding new targets 
for action in drug development. 
1.3 Cytokine Signalling 
Cytokines are a complex of soluble extracellularly-secreted proteins that act as 
regulators of most aspects of the immune function, such as inflammation, as 
well as multiple facets of physiological processes, such as the wound healing 
[227, 228]. The main actions of cytokines generally include paracrine, 
autocrine, juxtacrine, and endocrine cellular communications which are exerted 
in a synergistic and pleiotropic manner. Notably, the expression of cytokines is 
transient and may last for hours to days to induce anti- or pro-inflammatory 
responses. Such action is essentially specific to cells in order to activate the 
effects of particular leukocytic compartments [229]. While the effects of 
cytokines are primarily targeted for the clearance of infection, other negative 
sequelae might emerge, such as lethargy, fever, allergy, sleepiness, and loss 
of appetite. Furthermore, multiple chronic inflammatory conditions, such as 
cardiovascular disease (Figure 1–7) and chronic rheumatoid arthritis, can be 
associated with persistent cytokine production [230, 231].  
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Figure 1–7: The role of cytokines during atherosclerosis 
development.  
The expression of adhesion molecules on the activated endothelial cells 
recruits the circulating monocytes, which would differentiate into 
macrophages in the arterial wall. Such macrophages express scavenger 
receptors to take up modified low-density lipoproteins (LDL). A fibrous cap 
is formed due to an increase in the lipid content that released from the 
dead foam cells. In addition, an atherosclerotic plaque forms due to 
persistent formation of foam cells along with profound inflammatory 
responses. Several anti-inflammatory (purple) and pro-inflammatory 
(blue) cytokines are involved in plaque development. IL, interleukin; IFN, 
interferon; MCP, monocyte chemoattractant protein; and TGF, 
transforming growth factor. Adapted from Moss and Ramji [232]. 
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There are over 50 cytokines and many exist in families that share receptor 
components and signal transduction pathways [229]. Cytokines include 
interleukins (IL), interferons (IFN), tumour necrosis factors (TNF), transforming 
growth factors (TGF), and colony stimulating factors (CSF). Additionally, 
researchers have identified about 70 potential candidates by using sequence 
comparisons [233]. The structure of the target receptors, that include 
hematopoietin/type 1, interferon/type 2, IL1/toll-like receptor, and TNF is 
considered an important determinant of the affecting cytokine. For instance, the 
effects of IL-6 can be exerted on the haematopoietin/type 1 receptors, where 
glycoprotein (gp)-130 is the commonest signalling unit [234]. 
The biological effects of cytokines involve dimerisation of cell receptors into 
assemblies [235, 236]. In the canonical model of cytokine signalling, this would 
in turn result in activation of Janus Kinases (JAKs) and non-receptor tyrosine 
kinase (TYK2) [237]. At this stage, both TYK2 and JAKs are constitutively 
bound to cell receptors. JAKs then cause phosphorylation and activation of 
signal transducer and activator of transcription (STAT) proteins, which 
subsequently mediate gene expression modulation and eventually the fate of 
the cell [238-240]. Additionally, some cytokines may have a role in the activation 
of the ERK1,2 and Akt signalling and other signalling pathways [241, 242]. 
In general, pleiotropy and redundancy represent the main features of cytokines, 
in which their degenerate nature is responsible for such properties [243]. 
Pleiotropy is defined as the ability of a given cytokine to induce a variety of 
responses. The impact of a single cytokine might be exerted on more than one 
receptor complex leading to activation of specific JAK/STAT signalling 
pathways and subsequently a number of functional responses [244]. In 
addition, the capacity of a group of cytokines to induce their actions in 
overlapping activities is another remarkable feature of cytokines, that is their 
redundancy. Indeed, multiple cytokines might share the receptor subunits to 
form certain cytokine complexes which, due to the presence of four JAKs and 
seven STAT proteins, would activate a set of JAK/STAT combinations [245, 
246]. Despite utilising a limited number of signalling proteins in these 
combinations, cytokines still have the capacity to perform a variety of activities 
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and they can be involved in highly complicated immune functional responses 
[247]. Nonetheless, the current understanding is still incomplete regarding 
multifarious determinants of cytokine receptor signalling that integrate into a 
broad range of biological actions and it seems that researchers in this field have 
to elucidate more details about the ways by which such specificity could be 
attained, considering the redundant and pleiotropic nature of cytokines.   
It is noteworthy that most recent knowledge emphasises complex relationship 
between a given activated signalling molecule and the resultant biological 
activity. For example, although STAT3 could be activated by both the IL-6 and 
IL-10, the exact roles of such cytokines are typically contrasted, in which the 
former induces a pro-inflammatory and the latter elicits an anti-inflammatory 
response [248, 249]. Moreover, another clear example is that there are more 
than 16 subtypes in the type I IFN system that could share a corresponding 
receptor complex, inducing a set of distinct biological activities [250, 251]. Given 
the importance of lipid rafts-mediated cytokines receptors signalling that has 
been demonstrated by several lines of evidence [252-254], knowledge about 
the effects of caveolin expression or function on the JAK/STAT signalling 
pathways is still insufficient. In the following sections, I explain the JAK/STAT 
signalling pathway and its potential interaction with cavin-1.  
1.3.1 The JAK/STAT pathway and its regulation  
Four proteins constitute the JAK family, namely JAK1, JAK2, JAK3, and TYK2 
[255]. On the other hand, the STAT family in mammals is composed of seven 
proteins, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 [256]. 
All STATs are highly homologous in multiple regions, such as the SRC 
homology 2 (SH2) domain, which is involved in the process of STAT activation 
and dimerisation [257]. The JAK/STAT pathway is utilised by multiple cytokines, 
hormones and growth factors. Following cytokine receptor activation by its 
ligand, the kinase function is activated and this would be accompanied with 
auto-phosphorylation as well as cross-phosphorylation of a distinct JAK 
molecule that is bound to the heterodimer domain of the cytokine receptor [258]. 
In addition, the intracellular tail of the receptor (tyrosine residues) is 
phosphorylated, creating suitable docking sites and allowing binding of the 
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cytoplasmic STATs to these regions through the SH2 domain (Figure 1–8). 
After their phosphorylation, conformational changes would occur in the STATs 
leading to their separation from the receptor followed by dimerisation (or binding 
of two homologous STATs). STATs are then translocated to the nucleus, where 
they promote the expression of their specific genes [238]. Given the high 
functional specificity of the resultant complexes of different JAK/STAT proteins 
in various aspects of the immune response as revealed by the genetic knockout 
studies [259, 260], it is thought that such specificity can be attributed to the 
activation patterns of individual cytokines and, to some extent, specific 
regulation of gene expression [261].      
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Figure 1–8: A schematic representation of the JAK/STAT pathway. 
Cytokine-induced JAK activation leads to phosphorylation of STATs with 
subsequent dimerisation and translocation to the nucleus. Adapted from 
O'Shea et al. [262].  
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The JAK/STAT pathway is tightly regulated by distinct mechanisms at several 
steps. The mechanisms of the post-translational regulation include the protein 
inhibitor of activated STAT (PIAS), protein tyrosine phosphatases (PTPs), and 
suppressor of cytokine signalling (SOCS) proteins. In addition, other levels of 
regulations might involve the typical cross-talks between the various JAK/STAT 
pathways as well as other cell signalling pathways [263].  
Multiple PTPs have been implicated in the regulation of JAKs, such as SH2-
containing PTP (SHP)-1, SHP-2, T-cell PTP, and PTP1B [264]. An additional 
role of SHP-2 in case of IL-6 has been emphasised as it is required for ERK1/2 
and PI3K pathways [265, 266]. Furthermore, studies have shown that SHP1 
might be responsible for dephosphorylation of JAK1 and JAK2 [267, 268], while 
JAK2 and TYK2 can act as potential substrates of PTP1B [269]. In addition, 
JAK1 and JAK3 are dephosphorylated by T-cell PTP [270]. Indeed, PTPs have 
important physiological and pathophysiological consequences [271]. 
The role of PIAS is targeted for the regulation of several transcription factors, 
including STATs [272]. The family of PIAS proteins includes PIAS1, PIAS3, 
PIASX, and PISAY. The interaction of PIAS proteins with STAT members have 
been identified in the mammalian cultured cells, in which PIAS1 interacts with 
STAT1 in macrophages [273], PIAS3 with STAT3, and PIASX with STAT4 [272, 
274, 275]. Moreover, PIASY-STAT1 interaction has been reported [276]. It has 
been shown that STAT regulation via PIAS proteins is cytokine-dependent and 
this interaction is not demonstrated in the unstimulated cells. This can be 
supported by the interaction of PIAS1 with the dimeric, rather than the 
monomeric, form of STAT1 [277]. All PIAS family members have the ability to 
inhibit STAT-induced gene activation through inhibition of their DNA binding or 
recruitment of histone deacetylases [278].  
1.3.2 Suppressor of cytokine signalling proteins 
1.3.2.1 Structure and functions of SOCS 
CIS was the first identified member of the SOCS family in 1995 [279]. This was 
followed by an evidence of the inhibitory effects of SOCS1 on STAT1 signalling 
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[280, 281] along with the prediction of existence of other homologous SOCS 
proteins. Currently, there are eight identified members, SOCS1-7 and CIS. 
Each member of the SOCS family contains a central SH2 domain, which is 
flanked by a short C-terminal domain (the SOCS box) and a variable N-terminal 
domain (Figure 1–9a) [282].  
Some of the inhibitory effects of the SOCS are performed by ubiquitination and 
proteasome-induced degradation. The SOCS box binds to a complex that 
contains elongin B and C and cullin-5 [283, 284]. Having a central SH2 domain, 
SOCS proteins can function as substrate adapters for phosphorylated JAKs, 
phosphorylated STATs, and phosphorylated receptors (Figure 1–9b). 
Therefore, the SH2 domains would mediate the degradation of kinase-activated 
proteins [284].  
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Figure 1–9: The structural domains of the SOCS family proteins and 
their perceived interaction in cellular signalling. 
(A) Different structural domains of SOCS 1-7 and CIS; (B) The functional 
interaction of the SOCS domains. The SH2 domain binds to specific 
phosphorylated tyrosine residues located on its substrates, mostly JAK 
proteins, while the SOCS box facilitates ubiquitination of target proteins 
through the interaction with Elongin B (EB), Elongin C (EC), Cullin5, 
RING-box-2 (Rbx2), and an E2 ubiquitin-conjugating enzyme. The kinase 
inhibitory region (KIR) is located in some SOCS proteins and it might act 
as a pseudosubstrate to inhibit the kinase activity of bounded proteins. 
Adapted from Galic et al. [285] and Akhtar and Benveniste [286]  
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Nonetheless, it has been reported that both SOCS1 and SOCS3 exhibit 
inhibitory activity even in the absence of their SOCS box domains [287]. These 
SOCS box domains can be also bound to the E3 ubiquitin ligase in a lower level 
than that of other SOCS proteins [284]. In particular, SOCS1 and SOCS3 can 
bind directly to the JAKs causing inhibition of their catalytic activity. While the 
inhibition of tyrosine phosphorylated JAKs by SOCS1 depends on the direct 
binding to its SH2 domains, the inhibition of JAKs by SOCS3 requires the 
interaction, or binding, between SOCS3 and the activated receptor [280, 281, 
288, 289]. 
Experimental studies revealed an important role of SOCS proteins on the 
physiological and pathological levels. For example, early lethality occurs within 
3 weeks in mice deficient for the SOCS1 molecule as a result of severe 
generalised inflammation and excessive interferon signalling [290]. Further, 
SOCS2 knockout led to the development of gigantism in mice, possibly due to 
hyper-responsiveness to growth hormone [291]. Finally, defective placental 
formation was the most apparent reason of perinatal death that has been 
reported resulting from homozygous deletion of the SOCS3 gene [292, 293].  
1.3.2.2 Regulation of cytokine signalling by the SOCS proteins   
SOCS represent one of the major regulatory mechanisms of cytokine signalling 
[294]. They can generally act as negative feedback circuits, where each SOCS 
molecule is transcriptionally induced by its corresponding, or target, STAT 
protein. It is necessary to note that the SOCS proteins are scarcely detectable 
in unstimulated cells, while cytokines induce rapid expression of SOCS genes.  
Given the essential control exerted by the SOCS on JAK activity in terms of 
intensity and duration, SOCSs have the potential to regulate both the 
quantitative and qualitative patterns of cytokine signalling. For example, the 
transcriptional signature of IL-6 is transitioned from a STAT3-mediated to a 
STAT1-mediated process in the absence of SOCS3, demonstrating the 
qualitative side of cytokine signalling [295, 296]. As a consequence, studies 
have shown that SOCS proteins have remarkable effects on immune cell 
function, which is supported by the inflammation-induced death in in mice 
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lacking SOCS1 protein as well as the role of the latter protein in T cell 
development and pro-allergic T cell responses [294, 297, 298].  
In addition, the roles of SOCS2 and SOCS3 has been emphasised in 
macrophage differentiation [299], which is related to the control of SOCS3 
ubiquitination and turnover by SOCS2 [300]. Moreover, SOCS3 plays a key role 
in the regulation of macrophage functions as demonstrated by the IL-6-
mediated suppression of LPS-induced TNF-α production in SOCS3-/- 
macrophages [301]. 
1.4 SOCS3 
The induction of SOCS3 proteins is mediated by several cytokines, such as 
those affecting the gp130 receptors (IL-6), IL-2, IL-3, IL-4, IL-10, type I and type 
II IFNs, and leptin. Moreover, agonists of the toll-like receptors, including 
lipopolysaccharide (LPS) and CpG-DNA, cyclic AMP-mobilising hormones, 
prolactin, and growth hormone might also mediate SOCS3 induction [294, 302-
304]. At this step, SOCS3 proteins have an important role in the regulation of 
the magnitude, quality, and the different kinetics of JAK/STAT signalling. A key 
factor is the binding of the SH2 domain of SOCS3 proteins to particular 
phosphorylated tyrosine (PTyr) residues on their targets (Figure 1–10). Given 
the primary action of SHP2 in the activation of the ERK1/2 pathway which might 
also drive the Gab1-dependent phosphatidylinositol-3-kinase (PI3K)-Akt 
signalling [305] and, on the other hand, the ability of SOCS3 to bind to the SHP2 
binding site on gp130, it is expected for the SOCS3 proteins to inhibit ERK1/2 
and PI3K activation through a direct competing mechanism on the SHP binding 
site. However, this competition has not been demonstrated since Lehmann et 
al. [306] found that both SOCS3 and SHP2 can act independently to inhibit IL-
6 signalling.  
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Figure 1–10: Inhibition of IL-6 signalling via SOCS3.  
Following activation of gp130-bound JAKs via IL-6 interaction, gp130 
tyrosine residues are phosphorylated and act as docking sites for STAT 
proteins (predominantly STAT3). Following their phosphorylation, STATs 
dimerise and translocate to the nucleus to induce gene expression. Then 
SOCS3 proteins are encoded by one of the induced genes to interact with 
the phosphorylated gp130. Such interaction is exerted via two distinct 
mechanisms: 1) inhibition of the receptor-bound JAKs via the KIR domain 
and 2) integration in an E3 ubiquitin complex that mediates the 
proteasomal degradation of target proteins. Adapted from Williams et al. 
[307]. 
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1.4.1 SOCS3 structure 
In general, three domains have been identified in SOCS3 proteins: the N-
terminal domain (which includes the kinase inhibitory region “KIR”, containing 
residues from 1 to 29), the SH2 domain (residues from 30 to 185), and the 
SOCS box domain (residues from 186 to 225, Figure 1–11A).  
 
Figure 1–11: Structural organisation of the SOCS3 domains  
(A), structural homology modelling of the ECS-E3 ubiquitin ligase complex 
in a graphical illustration (B) and a schematic diagram (C). Adapted from 
Piessevaux et al. [308] and Williams and Palmer [309]. 
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1.4.1.1 The KIR domain 
It has been shown that both SOCS1 and SOCS3 have a pseudosubstrate 
domain, namely the KIR, at the N-terminal domain (a 12-residue motif) which is 
able to interact with the receptor-associated JAKs via their JH1 domain (Figure 
1–11). This interaction is thought to have an inhibitory effect on substrate 
phosphorylation [310]. Since the first eight residues of KIR are not structured 
and the remaining residues represent the first part of the α-helix [311, 312], KIR 
has been reclassified as residues 21-32, with the 33-44 residues forming the 
extended SH2 domain (ESS) [313]. 
Studies have shown that the KIR might act as a pseudosubstrate for JAK1 and 
JAK2 causing inhibition of their activity [314]. This might be attributable to the 
similarity of sequence between KIR and the activation loop that is located on all 
JAKs. While unphosphorylated, such loop blocks substrate/ATP binding 
through acting as a potential pseudosubstrate. Therefore, the process of 
binding of the SH2 domain of SOCS3 to the phosphorylated activation loop 
would entail a significant inhibition of its action. Nonetheless, Babon et al. [315] 
postulated that SOCS3 might act as a non-competitive inhibitor of JAKs by 
binding to a specific glycine-glutamine-methionine (GQM) motif in distinct JAK 
proteins rather than the competitive inhibition of the activation loop. More details 
about SOCS3-GQM interaction would be discussed in section 1.4.3. 
1.4.1.2 The SH2 domain 
The activity of SH2 domains is linked to their ability to bind to the 
phosphotyrosine residues on some proteins, such as the pY1007 residue on 
JAK2 [310] and pY757 on the gp130 co-receptor. In fact, the affinity of binding 
of the gp130 co-receptor to the SH2 domain of SOCS3 is more than 1000-fold 
greater than the binding to pY1007 on JAK2 [316, 317]. Moreover, other SH2-
binding cytokine receptors include leptin [318], granulocyte colony-stimulating 
factor receptor [319], erythropoietin receptor [317, 319] , growth hormone 
receptor [320], insulin receptor [321], and IL-12Rβ2 [322]. The high affinity of 
the SH2 domain for binding with such distinct cytokine receptors might be the 
major player in the specificity of SOCS3 in the process of signalling 
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suppression. It is important to note that the predominant targets of SOCS3 for 
signalling inhibition are IL-6, IL-11, ciliary neurotrophic factor, granulocyte-
colony stimulating factor, and leptin as per results based on genetic knockout 
studies in mice.  
The crystal structure of the SOCS3/JAK2/gp130 complex revealed whether 
SOCS3 can bind to gp130 and JAK in a sequential or simultaneous manner 
[323]. In fact, SOCS3 is able to bind to both the cytokine receptor and JAK2 at 
the same time and it can also exert its action targeting the specific JAK/gp130 
complexes. Such structure showed that the gp130 receptor was bound to the 
SH2 domain via its phosphotyrosine binding pocket. On the other hand, the 
JAK2 kinase was bound to the other side of the SH2 domain as well as the KIR 
and the ESS helix in a phospho-independent fashion. The ability of SOCS3 to 
exclusively inhibit a distinct set of cytokines that signal via JAK1, JAK2, and 
TYK2 might be explained by the SOCS3 requirements to simultaneously bind 
to the receptor-JAK complex [324]. 
Another remarkable feature of the SH2 domain is that it contains an 
unstructured loop of 35 residues in which its sequence mimics that of the Pro-
Glu-Ser-Thr-rich (PEST) motif [311, 325]. It is thought that the PEST motif 
mediates the proteasome degradation of proteins. In fact, the role of the PEST 
motif in SOCS3 degradation is as the half-life of SOCS was increased without 
altering SOCS3 functionality when the PEST motif was deleted [324]. 
1.4.1.3 The SOCS box domain 
The SOCS box domain was initially-identified as a characteristic motif in the C-
terminal domain of SOCS3 proteins, but it is now known to be shared by more 
than 80 other proteins in humans [326]. In general, two interaction sites have 
been identified in the SOCS box: the Cul5-box and the BC-box. The former is 
known for its ability to bind to cullin 5, the scaffold proteins, while the latter is 
responsible for elongin B and C recruitment [281, 327]. Elongin B and C as well 
as SOCS3, cullin 5 and the Rbx2 Really Interesting New Gene (RING) protein 
form the E3 ubiquitin ligase complex [284], for subsequent proteasomal 
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degradation. More details about the elongin-cullin-SOCS (ECS)-E3 ubiquitin 
ligase complex can be found in section 1.4.4.  
1.4.2 SOCS3 expression and regulation 
Both the mRNA and protein expression of SOCS3 are tightly regulated. 
Transcription of SOCS3 is rapidly induced by several type I and type II 
cytokines. Induction of SOCS3 expression by IL-6 is dependent on the 
specificity protein 3 [328], while LPS induces SOCS3 expression via the c-Jun 
N-terminal kinase (JNK) and MAPK-ERK1/2 pathways [329]. In addition, TNFα-
induced expression occurs by activation of the MAP kinase kinase 
(MKK)/MAPK pathway [330], whereas Epac-1 (exchange protein directly 
activated by cAMP 1) is utilised to induce expression of SOCS3 by cyclic 
adenosine monophosphate (cAMP) [304]. IL-1, IL-9, IL-10, and leptin are 
considered other contributors in inducing SOCS3 expression [331-334]. On 
other hand, proto-oncoprotein growth factor independence-1B and hepatocyte 
nuclear factor-1β might suppress SOCS3 transcription [335, 336], while TGF-β 
inhibits SOCS3 induction [337].  
Proteasomal and non-proteasomal degradation pathways are involved in 
controlling SOCS3 proteins. This could be demonstrated in several in vitro 
studies via modification or knockout of the SOCS box, PEST motif, or mutation 
of ubiquitination site Lys6 to Gln [283, 311, 338] although their significance in 
vivo has not been fully discerned. Experimental evidence in cell lines have 
shown that the increased expression of SOCS2 proteins might contribute to 
enhanced SOCS3 degradation [300, 339]. It has been suggested that the 
formation of an E3 ubiquitin ligase comprised of SOCS2, SOCS3, and elongin 
B/C might promote SOCS3 ubiquitination and thereby mediate SOCS3 
degradation. In contrast, SOCS3 regulation has been shown to be independent 
of SOCS2 in SOCS2-deficient primary mice cell lines, suggesting some 
redundancy in this process [340].  
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1.4.3 SOCS3 as an inhibitory protein through KIR-JAK2 
interaction 
Babon et al. [315] have shown that the ability of SOCS3 to selectively bind to 
JAK1 and JAK2 as well as TYK2 rather than JAK3 may be attributable to the 
lack of hydrophobic amino acid sequences (GQM sequences) in the latter. In 
general, the GQM sequence is located at the JH1 kinase domain at its α-helical 
region that is exclusively present in the JAK proteins [341]. More specifically, 
the location of GQM sequence at positions 1071-1073 on JAK2 enables the 
binding of SOCS3 protein through the KIR, SH2, and ESS (Figure 1–11). 
Although the structural changes of JAK2 implied by binding of the GQM 
sequence to SOCS3 might be minimal [323], the inhibitory functions of SOCS3 
are lost when mutations take place in specific key residues (Phe25Ala) at the 
KIR domain of SOCS3, indicating the importance of such domain [323]. Further, 
it has been suggested that SOCS3 might inhibit JAK2 by prevention of cognate 
substrate binding and thereby can be a JAK2 pseudosubstrate [315]. Additional 
confirmatory evidence of KIR importance is demonstrated by a ten-fold increase 
in the half maximal inhibitory concentration (IC50) of the inhibitory effect of 
SOCS3 exerted on JAK2 when the first 3 residues in the KIR are deleted. 
Additionally, studies of the crystalline construct of the SOCS3-JAK2-gp130 
complex demonstrated that Arg21, which flanks the KIR, might act as a true 
pseudosubstrate residue as it interacts with the substrate binding domain of 
JAK2 [323]. Indeed, SOCS3 phosphorylation would occur upon mutation of the 
first 3 residues in the KIR [323]. 
1.4.4 SOCS3 and E3 Ubiquitin Ligase activity  
The SOCS box domain in all SOCS family members is able to form a complex 
called ECS-E3 ubiquitin ligase complex, which would target its substrates for 
subsequent ubiquitylation and proteasome-mediated degradation (Figure 1–
11). E3 ligase is one of three sequential enzymes that catalyse the conjugation 
of ubiquitin to lysine residues of the target proteins [342]. The Leu210ProGlyPro 
domain of the SOCS box of SOCS3 has the ability to directly bind the cullin 5 
protein [343]. In addition, SOCS3-cullin5 binding could be attained indirectly via 
the interaction between SOCS3 and elongin B/C heterodimer which is bound to 
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the N-terminal domain of cullin 5. Cullin 5 is bound also to the Rbx2 protein via 
its RING domain in the C-terminus, leading to facilitation of the interaction with 
the E2 conjugation protein (Figure 1–11B) [324, 344].  
Nonetheless, the short half-life and slow on-rate properties of SOCS3 caused 
a significant reduction of its affinity for the E3 scaffold proteins (ten-fold lower 
when compared to other SOCS members) [284, 307]. Such low affinity might 
be related to the variations in the binding sequences, where LeuProGlyPro 
binds to SOCS3 while LeuProLeuPro binds to other SOCS proteins except 
SOCS1 [284]. Hence, SOCS proteins can be divided into two subclasses 
according to their affinity to cullin 5 binding. While SOCS1 and SOCS3 act in a 
dual pattern, other SOCS proteins can only exert their inhibitory actions through 
ubiquitin-dependent pathways [284]. Nonetheless, in light of the reported E3 
ligase functionality with SOCS1 and SOCS3 proteins, E3 actions should be 
investigated for other SOCS proteins [284]. The knowledge concerning 
SOCS1/3 substrates which are regulated by ubiquitin is incomplete. The 
immunological defects that have been reported in mice deficient in the SOCS 
box of SOCS1 or SOCS3 might raise the interest in understanding the 
regulatory roles of both SOCS family members in such proteasome-dependent 
processes [345, 346].  
The dual inhibitory mechanisms of SOCS3 proteins is supported by the central 
SH2 domain that allows binding of SOCS proteins to the phosphorylated targets 
(Figure 1–11B). It is worthy to note that the formation of an E3 ligase complex, 
which is of a large size, might sterically hinder the binding of SOCS3 proteins 
to their targets. It seems that the availability or the abundance of E3 ligase is 
the essential determinant of assembly and functionality [307]. However, the 
inhibition or ubiquitylation of SOCS3 substrates might be performed in a 
sequential manner, which means that, in certain events, it is not possible to 
perform these roles independently [307].  
Currently, several targets of the elongin-cullin-SOCS (ECS)-E3 ubiquitin ligase 
complex have been identified. These include JAK1 [347], Siglec7 [348], and G-
CSFR [349]. In the case of G-CSFR, SOCS3 exerts a direct inhibitory effect, 
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via binding to the pY729 motif of the receptor and inhibiting receptor-bound JAK 
via the KIR domain, as well as indirectly inhibiting signalling through forming a 
ligase complex to ubiquitinate Lys632 of the G-CSFR leading to signal 
attenuation and sorting of lysosomal proteins [350].  
Experimental studies on mouse myeloid progenitor cells have revealed a SOCS 
box-dependent inhibition of colony formation via the G-CSF [351]. Furthermore, 
a significant reduction of SOCS3 mRNA and protein expression as well as an 
enhanced activation ratio of STAT5/STAT3 in response to G-CSF were 
observed in mice with a truncated form of G-CSFR lacking the SOCS3 
recruitment site (Tyr729) [352]. In addition to G-CSFR, the proteolytic role of 
the ECS-E3 ubiquitin ligase complex has been demonstrated on the insulin 
receptor substrate (IRS)-1/2 [353].  
1.4.5 Identifying cavin-1 as an interactor SOCS-3  
Protein ubiquitylation is a post-translational modification that regulates cell 
signalling. It might be associated with several outcomes, such as endocytosis, 
DNA repair, endocytosis and protein degradation. E3 ligases are considered a 
vital element of the ubiquitin proteasome system (UPS) that outline the 
specificity of substrate via the covalent binding to ubiquitin. Although there are 
more than 600 E3 ligases that have been identified, several aspects relevant to 
their characterisation are still not completely elucidated, particularly those 
pertinent to the specific protein substrates [354]. Target identification by using 
novel methods, models, and tools might represent a major approach for 
enhancing the understanding of various aspects of UPS function as well as 
improving knowledge about a variety of disease processes in which it is 
involved [354]. 
Currently, ubiquitylation and proteasomal degradation in a SOCS3 SOCS box-
dependent manner have been observed in a limited number of SOCS3 
substrates (Table 1–1). Nonetheless, such observations are based on cellular 
overexpression models, and this ultimately entails validation via cell-free-
ubiquitylation studies that utilise purified components [307]. The identified 
SOCS3 substrates perform unique functions in the cells, and these substrates 
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shared two properties which are: (1) their interaction with the SH2 domain of 
SOCS3 occurs in a Tyr phosphorylation-dependent manner, and (2) the 
process of substrate ubiquitylation requires an intact SOCS box [307, 309].  
 
Table 1–1: Known SOCS3 substrates  
An updated list of the identified SOCS3 substrates that can be 
ubiquitylated and proteasomally-degraded. Adapted from Williams and 
Munro [307]. 
 
Novel physiological functions of SOCS3 are likely to be revealed by the 
discovery of additional substrates of the SOCS3 E3 ubiquitin ligase. This will 
provide adequate knowledge about the down regulation of the inflammatory 
response as well as the protein degradation pathways relying on ubiquitin. This 
would possibly lead to further identification of novel therapeutic targets which 
might be applicable to cytokine-driven conditions such as atherosclerosis, 
arthritis, viral or bacterial infection, or cancer [307, 324]. However, false-positive 
outcomes could be attained as a result of some limitations in the currently-
utilised methodologies. In addition, protein-protein interaction can be employed 
for validation purposes. This might include co-immunoprecipitation, 
fluorescence resonance energy transfer, protein-microarray, peptide array, and 
glutathione-S-transferase-pull-down assays [354].  
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Williams et al. [309] used an unbiased identification approach to experimentally 
identify the proteins that might be targeted by SOCS3 for ubiquitylation. To this 
end, (His)6+biotin-tagged Ub (HB-Ub)-expressing WT and SOCS3−/− mouse 
embryonic fibroblasts (MEFs) were produced via retrovirus-mediated gene 
transfer. These cell lines were tested by immunoblotting for stably expressing 
equivalent levels of a tandem-affinity-tagged ubiquitin transgene as previously 
described by Meierhofer et al. [355]. This enabled a tandem afﬁnity puriﬁcation 
of ubiquitin, maintaining the ubiquitylation status by the denaturing conditions 
and reducing the possibility of co-purification of proteins that are bound to 
ubiquitin. Using a targeted analysis of the purified ubiquitin comprised of stable 
isotopic labelling of amino acids in cell culture (SILAC) and liquid 
chromatography (LC), multiple ubiquitylated proteins have been identified by 
Williams and Palmer [309] in wild type MEFs but not their SOCS3−/− 
counterparts, indicating that these proteins could be newly identified potential 
targets for the ECSSOCS3 complex. Notably, the detection of FAK1, which was 
formerly described as a substrate for SOCS3-dependent ubiquitylation, 
provided supportive evidence for the validity of this approach [309].  
Experimental procedures and data analyses: 
Intracellular cAMP was elevated along with forskolin (50 μM) as an adenylyl 
cyclase activator to induce SOCS3 (Figure 1–12) [356]. To enhance the 
possibility of identifying SOCS3-dependent ubiquitylating proteins, a 
combination composed of sodium orthovanadate and H2O2 was used to inhibit 
protein tyrosine phosphatases and to maximise binding to the SH2 domain of 
SOCS3. In addition, the proteasome inhibitor MG132 was used to preserve the 
cellular ubiquitinome. An Orbitrap Velos fourier transform mass spectrometer 
(FTMS) was utilised to analyse the tandem afﬁnity-puriﬁed ubiquitinomes from 
the WT and SOCS3-deficient MEFs. Data processing was performed using the 
MaxQuant quantitative proteomics software package [356].   
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Figure 1–12: WT and SOCS3-/- MEFs proteomics screen. 
A comparison between tandem-affinity purified, SILAC-labelled 
ubiquitinomes isolated from WT MEFs and SOCS3-/- MEFs. After SOCS3 
induction via forskolin (50 µM) and MG132 for 2 hrs (blue box). Adapted 
from Williams et al. [356]. 
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Results revealed a significant elevation of cavin-1 protein in WT MEFs (5 unique 
peptides, count ratio of 6, and log2(H/L) = 1.37), indicating the ubiquitylation of 
cavin-1 specifically via a SOCS3-dependent pathway. It could be also 
suggested that such interaction was independent on tyrosine phosphorylation. 
However, the exact regulatory mechanism of that implied by SOCS3 on cavin-
1 ubiquitylation and its functional consequences have not been fully identified. 
As such, further investigations are warranted to reveal the mechanism of such 
interaction, referring to cavin-1 expression, caveolar stability and effective 
inhibition of JAK/STAT signalling.  
1.5 Hypothesis 
Caveolae represent a distinct membrane microenvironment that are involved in 
regulating multiple signalling pathways. Several diseases in human, such as 
heart failure, degenerative muscular illness, and vascular diseases, might result 
due to the disruption of caveolar integrity. The main caveolar structural 
membrane protein is cavin-1 and it has been shown to play a major role in 
caveolae assembly as shown by caveolae destabilisation due to cavin-1 
deletion. However, the exact cellular process that regulate the functionality of 
cavin-1 has not been fully elucidated. One of the signalling pathways that have 
been found localised and distributed within caveolae is the JAK/STAT 
signalling, which is downregulated via the suppressor of cytokine signalling-3 
(SOCS3). Studies based on proteomic screening and biochemical analysis 
have revealed an interaction between cavin-1 and SOCS3. As such, we 
hypothesised that SOCS3/cavin-1 interaction is an important controlling 
element in caveolae stability and/or the pro-inflammatory signalling pathway 
mediated by IL-6 in the endothelial cells.   
1.6 Aims 
1. To generate human vascular endothelial cell lines lacking SOCS3 via 
CRISPR/Cas9-mediated gene knockout which will form the basis for 
further examination of the working hypothesis. 
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2. To characterise the cavin-1/SOCS3 interaction and to assess the 
stability of cavin-1 at the basal level or following SOCS-3 induction by 
intracellular cAMP elevation in WT and SOCS3-/- cells. 
3. To assess whether cavin-1 controls SOCS3 recruitment to caveolae.  
4. To examine the impact of SOCS3 deletion on cavin-1 stability, cavin-1 
expression and plasma membrane levels of caveloae in human vascular 
endothelial cells. 
5. To investigate regulation of cytokine signalling pathways due to altered 
caveolae stability in SOCS3-deficient cells.  
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2 Materials and Methods  
2.1 Materials 
Table 2–1 List of general materials and reagents 
Supplier Description Cat. No. 
Agar Scientific 
 Ltd UK 
Sodium cacodylate AGR1104 
Osmium tetroxide AGR1015 
Agilent Technologies, UK XL1-Blue Competent Cells 200249 
Bio-Rad Laboratories Ltd, UK 
Precision Plus Protein® 
Kaleidoscope® Standards 161-0375 
Precision Plus Protein Kaleidoscope 
Standards 161-0375 
Biolog Life Sciences 8-pCPT-2'-O-Me-cAMP-AM C 051 
Carestream Health, UK Medical X-ray Blue/MXBE Film 7710783 
GE Healthcare Life Sciences, UK Amersham® Protran® 0.2 μm pore Nitrocellulose Membrane 10600001 
Invitrogen Ltd, Paisley, UK SuperScript™ II Reverse Transcriptase  18064022 
Melford Laboratories Dithiothreitol M1505 
Merck Biosciences, UK 
Forskolin 344270 
MG-132 474790 
Millipore H-89 dihydrochloride 371963 
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Perkin-Elmer Life Sciences, UK 
Enhanced chemiluminescence (ECL) 
reagents NEL 104 
Wizard® Plus SV minipreps A1330 
6 x Blue/Orange Loading Dye G1881 
1kb DNA ladder G5711 
100bp DNA ladder G2101 
Premier International Foods “Marvel” milk powder  
Qiagen, UK 
Polyfect Transfection reagent 301105 
SuperFect transfection reagent 301305 
Roche Applied Science, UK Complete, EDTA-free protease inhibitor cocktail tablets 11836170001 
Sigma-Aldrich, UK 
Paraformaldehyde 158127 
Emetine E2375 
Tween – 20 P5927 
30% (w/v) acrylamide/0.8% (w/v) bis-
acrylamide A3699 
Soybean trypsin inhibitor T9003 
Benzamidine 12072 
Bovine serum albumin A7030 
 
 
59 
Sigma-Aldrich, UK 
N, N, N’,N’-
tetramethylethylenediamine (TEMED) T9281 
Phenylmethylsulphonyl fluoride 
(PMSF) P7626 
Donkey serum D9663 
Ponceau S dye P3504 
Gluteraldehyde (25% aqua Pure, EM 
Grade) G5882 
Triton® X-100 T8787 
SMITH SCIENTIFIC 13mm glass coverslips NPS13/2222 
Thermo Fisher Scientific  
Solaris Mouse qPCR Gene Expression 
Assay (PTRF) 
AX-040777-
00-0200 
Solaris Mouse qPCR Gene Expression 
Assay (Gapdh) 
AX-040917-
00-0100 
ProLong® Gold antifade reagent with 
DAPI P36935 
ThermoScientific Thermanox coverslips 150067 
 
Table 2–2 Reagents and materials used in cell culture applications 
Supplier Description Cat. No. 
Fischer Scientific Opti-MEM® Reduced Serum Media 11058021 
Lonza EGM-2 Endothlial Medium CC-3162 
Sarstedt Tissue culture cell scraper 25cm 83.183 
Sigma-Aldrich, UK 
Greiner CELLSTAR® white flat 
bottom 96 well plate 655083 
Dulbecco's Modified Eagle's Medium D6046 
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Sigma-Aldrich, UK 
Foetal bovine serum F9665 
L-glutamine G7513 
Penicillin-Streptomycin solution P0781 
Endotoxin-free phosphate buffered 
saline (PBS) 14140-094 
1x Trypsin-EDTA solution T3924 
Sterile filtered cell culture water W3500 
Puromycin P8833 
Medium 199 M7528 
VWR International Ltd, UK 
Corning® 6 well flat bottomed cell 
culture plate 734-1599 
Corning® 60mm cell culture dish 734-1699 
Corning® 100mm cell culture dish 734-1815 
 
Cell lines 
Wild-type (SOCS3+/+) murine 
embryonic fibroblasts (MEFs)  
Generously provided by Prof. Akihiko 
Yoshimura (Kyushu University, Japan) 
[353] 
SOCS3-/- MEFs 
Wild-type (cavin-1+/+) MEFs 
Generously provided by Prof. Paul F. 
Pilch (Boston University, USA) [102] 
Cavin-1-/- MEFs 
Human endothelial angiosarcoma 
(AS-M.5) 
Generously provided by Dr Vera 
Krump-Konvalinkova V (Johannes 
Gutenberg University, Germany) [357] 
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Table 2–3 Plasmid constructs 
Construct Name Vectors Donor/Supplier 
cavin-1 pEGFP-N1 (Clontech) 
a kind gift from Prof. Paul Pilch 
(Boston University, USA) [102] 
SOCS3 pEGFP-N1 (Clontech) In-house 
ΔPEST SOCS3 pEGFP-N1 (Clontech) 
In-house 
(ΔPEST SOCS3 was generously 
provided by Dr Jeff Babon, Walter 
and Eliza Hall Institute of Medical 
Research, Australia) (Nicholson, 
Willson [288] 
Human SOCS3 
CRISPR/Cas9 KO 
CRISPR/Cas9 KO 
Plasmid  
 
Santa Cruz Biotechnology 
human SOCS3 
HDR  
Cre Vector 
 Santa Cruz Biotechnology 
cavin-1  pmCherry-N1 (Clontech) 
a kind gift from Dr Ben Nichols 
(MRC Laboratory of Molecular 
Biology, Cambridge, UK) [145] 
 
Table 2–4 Primary antibodies used for western blotting 
Target Protein 
Predicted 
molecular 
weight of the 
protein 
Host 
species 
Suppliers/ 
Cat. No. 
Working Dilution/ 
Diluent* 
SOCS3 24.7 kDa Rabbit In house 
1:000 
 (5% (w/v) dried 
milk) 
SOCS3 24.7 kDa Rabbit Abcam #ab16030 
1:1000 
(5% (w/v) dried 
milk) 
SOCS3 24.7 kDa Goat 
Santa Cruz 
Biotechnology 
#sc-7009 
1:500 
(5% (w/v) dried 
milk) 
α-phospho 
CREB 
(Ser133) 
43 kDa Mouse New England Biolabs #9196 
1:1000 
(5% (w/v) BSA) 
Phospho-
STAT3 
(Tyr705) 
79 kDa-86 
kDa Rabbit 
Cell Signaling 
#9131 
1:1000 
(5% (w/v) BSA) 
STAT3 79 kDa-86 kDa Mouse 
Cell Signaling 
#9132 
1:1000 
(5% (w/v) dried 
milk) 
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GAPDH 36 kDa Mouse Abcam #ab8245 
1:20,000 
(5% (w/v) dried 
milk) 
Cavin-1 50 kDa Rabbit Abcam #ab48824 
1:1000 
(5% (w/v) dried 
milk) 
Caveolin-1 22 kDa Rabbit BD Biosciences #610059 
1:1000 
(5% (w/v) dried 
milk) 
Nurr1/Nur77  
Nurr1: 66 kDa 
Nur77: 64 kDa  
 
Rabbit 
Santa Cruz 
Biotechnology 
# sc-990 
1:2000 
(5% (w/v) dried 
milk) 
GFP 27 kDa Sheep In house 
1:2000 
(5% (w/v) dried 
milk) 
β-Actin 45 kDa Rabbit New England Biolabs #4970S 
1:1000 
(5% (w/v) dried 
milk) 
 
Table 2–5 Secondary detection agents for western blotting 
Linked 
molecule Epitope Species 
Suppliers/ 
Cat. No. 
Working Dilution/ 
Diluent* 
HRP Mouse IgG Goat Sigma-Aldrich A4416 
1:1000 
(5% (w/v) dried milk) 
HRP Rabbit IgG Goat Sigma-Aldrich A9169 
1:1000 
(5% (w/v) dried milk) 
HRP Goat IgG Rabbit Sigma-Aldrich A5420 
1:2000 
(5% (w/v) dried milk) 
 *Diluent solution: TBS-Tween (50mM Tris pH 7.5, 150mM NaCl, 0.05% (v/v) 
Tween-20)  
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2.2 Methods 
2.2.1 Cell culture 
All cell types were cultured at 37°C in a humidified atmosphere regulated at 5% 
(v/v) CO2.  
2.2.1.1 Cell culture growth media for MEFs 
The cell culture medium for murine embryonic fibroblasts (MEFs) was 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) 
inactivated foetal bovine serum (FBS), 100U/ml penicillin, 100µM streptomycin, 
and 1mM L-glutamine. The cell monolayers were grown in Corning® 150cm² 
flasks until ~80% confluence. Passaging (sub-culturing) of MEF monolayers 
was performed by removal of the cell culture medium, followed by rinsing with 
4 ml tissue culture grade PBS. Cells were incubated in 2 ml pre-warmed sterile 
trypsin (0.05% (v/v) in diaminothanetetra-acetic acid, disodium salt [EDTA]) for 
2-3 minutes at room temperature to detach the cells from the flask. The trypsin 
was then neutralised with 8 ml fresh medium. Cells were finally resuspended 
via gentle pipetting before transferring to 10-12ml of fresh media. Cells were 
split 1 in 20 into fresh T150cm flasks at each passage. 
2.2.1.2 Culture of endothelial AS-M.5 cell lines 
Human endothelial angiosarcoma (AS-M.5) cells were maintained as 
monolayers in endothelial growth medium (EGM, Lonza) consisting of 
endothelial basal medium supplemented with 2% (v/v) foetal bovine serum 
(FBS), 0.04% (v/v) hydrocortisone, 0.4% (v/v) human fibroblast growth factor-B 
(hFGF-B), 0.1 % (v/v) vascular endothelial growth factor (VEGF), 0.1% (v/v) 
insulin-like growth factor-l (IGF-l), 0.1% (v/v) ascorbic acid, 0.1% (v/v) human 
epidermal growth factor (hEGF), 0.1% (v/v) gentamicin sulphate and 
amphotericin-B (GA-1000) and 0.1% (v/v) heparin, as recommended by the 
supplier (Lonza). Cells were cultured in Corning® 150cm² flasks and sub-
cultured by washing the cells twice with tissue culture grade PBS and adding 
2ml of sterile endothelial grade trypsin-EDTA solution (5 U/ml porcine trypsin, 
1.8 % (w/v) EDTA) to each flask. Cells were left for a few minutes at 37°C to 
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allow detachment from the flask surface. Once adherent cells detached, fresh 
EGM was added to neutralise the action of the trypsin. The cell mixture was 
transferred to a Falcon centrifuge tube and spun down at 1200 x g for 5 minutes. 
The cell pellet was then resuspended in fresh medium and seeded into plates 
or dishes at an appropriate level according to the experiment performed. Cells 
were split 1 in 20 into fresh T150cm flasks at each passage.  
2.2.1.3 Preparation of protein lysates from cultured cells 
Confluent cells cultured on appropriately sized dishes were placed on ice and 
washed twice with ice-cold 1 x PBS to remove any residual media components. 
Cell lysates were obtained by harvesting the cells with 100μl ice-cold 
radioimmuno-precipitation assay (RIPA) buffer (50 mM sodium HEPES [pH 
7.5], 150 mM sodium chloride, 5 mM EDTA, 10 mM sodium fluoride, 10 mM 
sodium phosphate, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 
0.1% (w/v) sodium dodecyl sulphate (SDS), 0.1 mM phenylmethylsulphonyl 
fluoride, 10 μg/ml soybean trypsin inhibitor, 10 μg/ml benzamidine, and EDTA-
free complete protease inhibitor mix). 
The cells were scraped off using a cell lifter and transferred into pre-cooled 1.5 
ml microcentrifuge tubes. To facilitate cell lysis and protein solubilisation, the 
extracts were incubated for one hour at 4°C with rotation. Cell extracts were 
then centrifuged (15 minutes at 21000 x g, 4°C) to remove detergent-insoluble 
cellular fractions. The supernatants were subsequently collected and frozen in 
aliquots for storage at -20oC.  
2.2.2 Protein concentration determination 
The protein concentration in cell lysates was determined using a bicinchoninic 
acid assay (BCA). This colorimetric  assay [358] is based on measuring  purple 
Cu+1 generated by proteins in the sample. The intensity of the purple complex 
is directly proportional to the amount of protein present in the solution and it can 
be estimated by comparison to a protein standard, such as bovine serum 
albumin (BSA) (0.0-2.0 mg/ml). Protein lysates were diluted 1 in 5 in the same 
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lysis buffer (2μl sample + 8μl buffer). Both standards and samples were added 
to a clear 96-well plate in duplicate (total volume 10 μl/well). 
The BCA working solution was prepared in a 20ml universal at a ratio of 1:50 
dilution of copper sulphate (4% (v/v) to BCA reagent (1% (w/v) 4,4 dicarboxy-
2,2 biquinoline, disodium salt, 2% (w/v) sodium carbonate anhydrous, 
0.16%(w/v) sodium potassium tartate, 0.4% (w/v) sodium hydroxide, 0.95% 
(w/v) sodium bicarbonate, pH 11.25). 200µl were then added to each well 
before incubating at 37˚C for 10 minutes. Spectrophotometric analysis was 
performed using a POLARstar OPTIMA (BMG LabTech) microplate reader. The 
plate was read at 495nm and the mean absorbance for each sample duplicate. 
Measuring the absorbance of the BSA standards allowed plotting a best fit 
straight line from which the concentrations of the protein samples were 
quantified. Protein concentrations were determined using POLARstar OPTIMA 
MARS data analysis package v.1.20 and GraphPad Prism v.4. 
2.2.3 SDS-Polyacrylamide Gel Electophoresis 
Following protein determination by BCA assay, detergent-soluble whole cells 
lysates were equalised for protein content (15-30 μg/sample) and volume. 
Samples were prepared for SDS-PAGE to total volume of 30μl by addition of 
equal volume of SDS-loading buffer (50 mM Tris pH 6.8, 10% (v/v) glycerol, 
12% (w/v) SDS, 1 mM dithiothreitol (DTT), 0.02 % (w/v) bromophenol blue). 
Using the BioRad Mini-PROTEAN® cell system, proteins were resolved via 
SDS-PAGE on 1.5 mm thick vertical slab gels containing between 10-12% (w/v) 
poly-acrylamide gels. Size estimation of immunoreactive protein bands was 
consequently determined by running a Bio-Rad Rainbow marker alongside the 
samples. Electrophoresis was performed in 1% (w/v) SDS running buffer (0.1% 
(w/v) SDS, 192 mM glycine, 25 mM Tris, pH 8.3) at a constant voltage of 150 V 
for approximately 1.5 hours until the blue dye had reached the bottom of the 
resolving gel and good separation of the molecular weight markers had been 
obtained. 
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Table 2–6 Resolving gel components 
Component 10% 12% Volume required 
dH20 3.4ml 2.74ml 
Buffer 1 
(1.5M Tris, pH 8.8, 0.4% (w/v) SDS) 2.5ml 2.5ml 
50% (v/v) glycerol 0.65ml 0.65ml 
Ammonium persulphate  
(APS, 0.3mg/ml) 32µl 32µl 
TEMED 8µl 8µl 
30% (w/v) acrylamide/0.8 (w/v) bis-acrylamide 3.3ml 3.96ml 
 
Table 2–7 Stacking gel components 
Component Volume required 
dH20 3.4ml 
Buffer 2 
(0.5M Tris-HCl, pH 6.8, 0.4% (w/v) SDS) 1.34ml 
Ammonium persulphate  
(APS, 0.3mg/ml) 54µl 
TEMED 7µl 
30% (w/v) acrylamide/ 0.8 (w/v) bis-acrylamide 0.63ml 
 
2.2.4 Immunoblotting for proteins 
2.2.4.1 Electrophoretic transfer of fractionated proteins onto 
nitrocellulose  
Following gel electrophoresis , the gels were removed from the glass casing 
and placed on top of an equal-sized sheet of nitrocellulose membrane (0.2 μm 
pore size). Transfer cassettes were assembled with sponges, filter paper 
(Whatman 3MM blotting paper), SDS gel and nitrocellulose membrane, all pre-
wetted in transfer buffer (24.7 mM Tris, 0.19 M glycine in 20% (v/v) methanol). 
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The proteins were electrophoretically transferred to the nitrocellulose 
membrane using the Mini PROTEAN® Tetra Cell (Bio-Rad) transfer system at 
a constant current of 400 mA for 45 minutes. Ponceau stain (0.1% [w/v] 
Ponceau S acid red diazo dye in 1% [v/v] acetic acid) was used to confirm the 
transfer of protein from the gel to the membrane. 
2.2.4.2 Blocking of membranes and probing with primary antibodies 
To reduce non-specific antibody binding the membrane was incubated with 5% 
(w/v) skimmed milk powder in TBST (10 mM Tris-HCl PH 7.5, 150 mM NaCl, 
0.05% (v/v) Tween 20) for 1hr at room temperature. Following blocking, the 
appropriate primary antibody (Table 2–1) diluted in 5% (w/v) milk-TBST or 5% 
(w/v) BSA-TBST for phospho-specific antibodies was applied to the blot and 
incubated, with shaking, overnight at 4°C. 
2.2.4.3 Secondary antibodies and chemiluminescence western blot 
detection 
Following incubation with primary antibody, membranes were washed three 
times for 10 min in TBS/T at room temperature with rotation on a shaker 
(150rpm). Membranes were subsequently incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at RT 
in 5% (w/v) dried milk powder in TBS/T, followed by three washes for 10 min in 
TBS/T to remove unbound antibodies. Equal volumes of enhanced 
chemiluminesence (ECL) reagent 1 and 2 (Perkin-Elmer Life Sciences, UK) 
were mixed and membranes were immersed in the combined ECL substrate for 
1 min. After removal of the  detection reagents , membranes were placed 
between plastic film in  autoradiography cassette with Kodak film, and 
developed using a X-OMAT 2000 processor (Kodak). 
2.2.4.4 Stripping of nitrocellulose membranes 
Stripping buffer (0.15M NaCl, 0.1M Glycine, pH 2.6) was prepared to remove 
primary and secondary antibodies bound to a western blot membrane. 
Membranes were incubated in stripping buffer for 30 mins at room temperature 
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with shaking. The membranes were then washed in TBS/T (3 x 5 min) and 
blocked in 5% (w/v) dried milk before incubation with another primary antibody. 
2.2.4.5 Densitometric quantification of protein bands 
Immunoreactive proteins on the developed film were scanned on HP Scanjet 
G3110 scanner using Adobe Photoshop software. The optical density of the 
immune-detected protein was measured using Totallab v2.0 imaging software 
(Phoretix). 
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2.2.5 Cell Transfection 
MEFs were seeded and allowed to grow to 50-60% confluency on 6 cm2 dishes. 
Transient transfection of DNA constructs was then carried out using PolyFect 
transfection reagent (Qiagen, 301105) according to manufacturer’s 
instructions. Briefly, 4 μg of plasmid DNA was mixed with 150 μl Opti-MEM (Life 
Technologies) followed by addition of 40μl PolyFect transfection reagent and 
mixed thoroughly via gentle pipetting. The DNA/PolyFect mixture was 
incubated for 10 minutes at room temperature to allow formation of transfection 
complexes. In the meantime, 3 ml fresh DMEM growth medium was added to 
the 6 cm2 dish. The DNA/PolyFect solution was then mixed with 1 ml DMEM 
growth medium prior to being added drop-wise to the target cells. Cells were 
incubated in a humidified incubator (5% CO2, 37°C) for 24 hrs to allow transfer 
of DNA into cells. Transfection efficiency of DNA constructs was assessed 
using the Axiovert 40 CFL (Zeiss Microscopy,) fluorescent microscope and 
Zeiss Vision AxioVision Viewer 4.0 software. Cells were subsequently split onto 
6 well plates and treated as described in the figure legends. 
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2.2.6 RNA Extraction, Purification and Quantification 
2.2.6.1 Extraction of RNA from MEFs 
RNA from MEFs was extracted using a miRNeasy mini kit (including on-column 
DNase treatment) according to manufacturer’s instructions (Qiagen, Hilden, 
Germany). Briefly, the media was removed and the cells were washed with ice-
cold PBS. Cells were then lysed directly with 700 µl QIAzol lysis reagent and 
homogenised through a sterile 23-guage needle and syringe 10 times. Cell 
homogenates were placed into pre-cooled 1.5ml eppendorf tubes and stored at 
-80ᵒC until required. 
Cell lysates were thawed on ice and mixed with 140 µL chloroform by shaking 
the tube vigorously for 15 sec. Lysates were incubated at room temperature for 
2 min, prior to centrifugation at 12,000 x g (15 min, 4°C). After centrifugation, 
the upper aqueous phase containing total RNA was carefully collected and 
transferred to a new 1.5 ml tube and mixed thoroughly with 550 µL 100% 
ethanol. Lysates were transferred to RNeasy mini spin columns and centrifuged 
at 8,000 x g for 1 min and the flow-through discarded. The columns were 
washed with 350 µL RWT buffer and two times with 500 µl RPE buffer. Each 
wash was followed by centrifugation at 8,000 x g for 1 min at room temperature. 
miRNeasy spin columns were then transferred to new 2 mL collect tubes and 
centrifuged at 14,000 x g for 2 min at room temperature to remove any buffer 
contaminants. Total RNA was then eluted by adding 30 µL of nuclease-free 
water through the spin column for 1 min at 8,000 x g. To obtain an optimal RNA 
yield, the RNA eluates were collected and re-eluted through the column.  
The RNA concentration were quantified by measuring the absorbance of the 
sample at 260nm using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, Paisley, UK) and samples stored at -80°C until required. 
2.2.6.2 cDNA synthesis by reverse transcription 
For messenger RNA (mRNA) expression analysis, cDNA was generated from 
total RNA using Super-Script™ II Reverse Transcriptase (Invitrogen) according 
to manufacturer’s instructions. 
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Per reaction, 1µg of DNase-free RNA were reverse transcribed. Each reaction 
contained 100 ng random hexamers, 2.5 mM of each deoxyribonucleotide 
triphosphates (dNTPs), 40 U RNaseOUT (Invitrogen) and 200 U Super-Script™ 
II Reverse Transcriptase. RNase-free water was used to make up the reaction 
volume to 20 μl. 
Samples were incubated as follows: 
Temperature °C Cycle time (Min) Function 
25 10 annealing of random primers 
42 50 reverse transcription 
70 15 inactivate the reverse transcriptase 
 
cDNA samples were stored at -20°C. 
2.2.6.3 Quantitative Real-Time PCR (qRT-PCR) analysis for expression 
of cavin-1 gene transcripts 
qRT-PCR) analysis was performed  using Power SYBR® Green PCR Master 
Mix (Applied Biosystems).The final volume per reaction was 10 µl, containing 1 
µl of cDNA, 1 x Power SYBR Green master mix and 0.5 mM of each primer. 
Non-template controls in which cDNA was substituted with water were included 
in each reaction.  Samples were loaded in triplicate in real-time PCR 96-well 
plates (primerdesign, UK) which was covered with optical cover and centrifuged 
at 1000 RPM for 1 minute.  
Real-time quantitative PCRs were performed on a MX3000P® QPCR system 
(Stratagene). The gene amplification began with an initial denaturation at 95°C 
for 10 minutes, 40 cycles of 95°C for 5 seconds and 60°C for 20 seconds, 
followed by a final extension at 72°C for 5 minutes. 
Glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) was used as a 
reference gene. 
Primers in Table 2–8 were used to amplify genes of interest. 
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Table 2–8 List of primer sequences used for qRT-PCR analysis in 
this study 
Gene Species forward primer reverse primer 
cavin-1 Mouse 5’-GCAAGGTCAGCGTCAAC-3’ 5'-CCGGCAGCTTGACTTCA-3’ 
GAPDH Mouse 5'-GGCTGGCATTGCTCTCAA-3’ 5'-GCTGTAGCCGTATTCATTGTC-3’ 
 
Data obtained were analysed using the comparative threshold cycle(Ct) 
method. The formula 2- ΔΔCt [359] was employed to compare the Ct value of the 
target gene to the Ct value of the control gene. Data was calculated in Microsoft 
Excel 2007 and expressed as the fold change of the gene of interest compared 
to the control condition. 
2.2.7 Ultrastructural analysis 
2.2.7.1 Preparation and Fixation of AS-M.5 cells 
WT and SOCS3-null AS-M.5 cells were seeded at a density of 1×106 cells per 
ml into 6-well plates and onto Thermanox coverslips (13 mm diameter) for 
culturing to conﬂuency. The cells were then ﬁxed in 1.5% (w/v) glutaraldehyde 
in 0.1 M sodium cacodylate buffer at 4°C for 1 h. 
2.2.7.2 Post-fixation 
Cells were washed 3 times in 0.1M sodium cacodylate buffer in 2% (w/v) 
sucrose prior to incubation with 1% (w/v) osmium tetroxide/0.1 M sodium 
cacodylate for 1 h. The cells were then washed 3 times in distilled water and 
incubated in 0.5% (w/v) uranyl acetate in the dark for 1 hour followed by 2 rinses 
in distilled water. 
2.2.7.3 Dehydration, embedding and microscopy 
Dehydration was carried out with a graded alcohol series (30–100% (v/v)), 
followed by overnight incubation in a 1:1 mix of propylene oxide/TAAB araldite 
Epon 812 resin. The propylene oxide was allowed to evaporate to leave pure 
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resin, which was changed twice before the sample was embedded flat in fresh 
resin polymerised overnight at 60 °C. Ultrathin sections were cut using a Leica 
Ultracut UCT and a Diatome diamond knife, contrast stained with aqueous 2% 
(w/v) methanolic uranyl acetate and Reynolds lead citrate, and viewed using a 
LEO 912AB TEM (Carl Zeiss) at an accelerating voltage of 120 kV. TIF images 
were captured using an Olympus Soft Imaging System and image contrast 
modiﬁed using Adobe Photoshop CS. 
2.2.8 Immunofluorescent Confocal Microscopy 
2.2.8.1 Cells preparation and fixation 
For immunofluorescent analysis of endogenous cavin-1 and transfected 
SOCS3-GFP, WT, and cavin-1−/− MEFs, cells were allowed to grow at 
appropriate density in 10 cm dishes and transiently transfected with or without 
SOCS3-GFP expression constructs using the method described previously in 
section 2.2.5. After 24 h, cells were split on ethanol-sterilised 13 mm glass 
coverslips and allowed to adhere overnight. On the following day, cells were 
washed with PBS and ﬁxed with 4% (w/v) paraformaldehyde (PFA) in PBS for 
25 min.  
2.2.8.2 Permeabilisation and staining 
After washing with PBS and quenching residual PFA with 20 mM glycine in 
PBS, cells were permeabilised with 0.1% (v/v) Triton X-100 for 10 mins, and 
non-speciﬁc binding sites blocked by a 30 min of incubation at room 
temperature in PBS containing 3% (w/v) BSA and 10% (v/v) donkey serum. 
Cells were then incubated with rabbit anti-cavin-1 antibody (Abcam ab48824, 1 
in 100 dilution) for 90 min at room temperature. 
Cells were washed with PBS containing 0.1% (v/v) Triton X-100, 1% (w/v) BSA, 
and 10% (v/v) donkey serum prior to incubation with Alexa Fluor 594-
conjugated donkey anti-rabbit IgG (Life Technologies A21207, 1 in 200 dilution) 
for 1 hour at room temperature. The cells were washed with PBS and the 
coverslips were mounted onto glass slides using ProLong® Gold anti-fade 
reagent containing nuclear stain 4’,6-diamidino-2-phenylindole (DAPI). 
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2.2.8.3 Visualisation by confocal microscopy 
Cells were visualised using a 63xoil-immersion Plan Fluor Apochromat 
objective lens, on a Ziess LSM510 laser scanning confocal microscope (Carl 
Zeiss GmbH, Oberkochen, Germany) equipped with a Zeiss LSM5 Pascal 
instrument and AOTF Laser module.  
GFP fusion proteins were excited with an argon laser at 488 whereas Alexa 
Fluor 594 were excited with a helium neon laser. Images were analysed using 
MetaMorph® imaging software to generate Pearson’s correlation coefﬁcients. 
2.2.9 Production of SOCS3 Knockout AS-M.5 via CRISPR 
2 x 105 AS-M.5 cells were seeded into 6 cm2 dishes and grown in endothelial 
growth medium (EGM) until reaching approximately 80% confluency. Cells 
were then co-transfected with human SOCS3 CRISPR/Cas9 KO and human 
SOCS3 HDR plasmids using SuperFect transfection reagent (Qiagen) 
according to the manufacturer’s protocol. Briefly, 30μL of Superfect reagent 
was mixed with 3μg of each DNA construct and made up to 300μL with cell 
growth medium. Following 10 minutes incubation at room temperature, the 
DNA-Superfect complexes were then added directly to the cells and allowed to 
incubate for 3 hours at 37°C. DNA complexes were then removed and complete 
EGM was added to dishes.  
48 hours after transfection, the cells were split into 6-well plates at 1:10-1:15 
ratio and allowed to proliferate for another 48 hrs prior to selection in medium 
supplemented with puromycin (2 μg ml−1).  Cultures were maintained for up to 
14 days and the media was replaced every 2-3 days. Following dilution and re-
plating, individual clones were identified for the successful elimination of 
SOCS3 gene production (as described in Chapter 3) and a single knockout 
clone was compared with an unselected control cell population. 
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Figure 2–1 Flowchart outlining the experimental procedures to 
generate SOCS3 KO AS-M.5 cell lines. 
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2.2.10 Statistical analysis 
Results were expressed as the mean ± standard error of the mean (SEM). 
Statistically analysis included unpaired, two-tail t-test or a one-way analysis of 
variance (ANOVA) followed by the Bonferroni multiple comparisons test when 
comparing the means of multiple treatment groups. P value <0.05 was deemed 
statistically significant. 
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3 Generation and characterisation of 
endothelial SOCS3KO cells for the further 
examination of the working hypothesis 
3.1 Perturbation of Target Gene Expression  
The basic functionality and relationships of proteins could be elucidated via 
understanding of their levels and activities in the cell. Several methods have 
been utilised to transiently and specifically perturbate target protein expression, 
including knockdown by RNA interference, chemical inhibition or 
overexpression by non-integrating vectors. For more stable perturbations, 
editing of the endogenous gene locus encoding the protein of interest can also 
be employed [360]. 
Two early forms of customised nucleases have been utilised for this purpose; 
zinc-finger nucleases (ZFNs) and Transcription activator-like effector nucleases 
(TALENs) [361]. The ZFNs system is composed of DNA-binding domains and 
zinc finger proteins (ZFPs) as well as a DNA-cleavage domain (FokI) (Figure 3-
1a). Different combinations of ZFPs can be produced to target a distinct DNA 
sequence since the ZFP region has the ability to interact with nucleotide (nt) 
triplets. The specificity of ZFNs systems is apparently demonstrated in creating 
double-stranded breaks (DSBs), FokI dimerisation, and DNA cleavage [361]. 
TALENs proteins originate from repeated domains of bacterial (prokaryotic) 
transcription activator-like effector that interact with a single nt and is bound to 
a FokI nuclease (Figure 3-1b). Pairs of TALENs are constructed to position the 
FokI nuclease domains to adjacent genomic target sites, where they induce 
DSBs that stimulate error-prone nonhomologous end-joining (NHEJ) or 
homology-directed repair (HDR) [362]. Although ZFN and TALEN platforms 
enable site-specific gene mutagenesis and editing, the need of extensive labour 
efforts and prolonged time may represent major limitations, in addition to having 
low efficiency, suboptimal precision, and poor scalability [363]. 
Recently, clustered regularly interspaced short palindromic repeat/associated 
9 (CRISPR/Cas9) (Figure 3-1c) has provided a more straightforward approach 
for genome editing and has been efficiently utilised to produce model organisms 
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in multiple species [364]. Despite its initial presentation as unknown sequences 
of unidentified biological significance, a considerable progress has been made 
in the CRISPR system suggesting it as the method of choice for genome editing 
[363]. 
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Figure 3–1 Nuclease-induced genome editing  
(a) Two monomers of zinc-finger nuclease containing three zinc fingers 
and a FokI cleavage domain in each. (b) The FokI cleavage domain is 
coupled to two TALEN monomers that entail a repeat region and C- and 
N-terminal extensions. (c) tracrRNA:crRNA recruits Cas9 to the target site 
of the DNA sequence. The complementary PAM sequence binds to 
crRNA and the DSBs are generated by Cas9 HNH and RuvC domains. 
(d) the process of DNA repair can be performed in two different pathways. 
A small number of bases can be removed and this might be associated 
with inducing a frameshift mutation via a NHEJ process. NHEJ typically 
inactivate gene function. Additionally, HDR may be followed if the donor 
template is transfected with Cas9 mRNA and the guide RNA. In this 
pathway, single base alterations could be inserted into the repaired 
strand, resulting in gene knockout. HDR: homology-directed repair; PAM: 
protospacer-adjacent motif; NHEJ: Non-homologous end joining; 
tracrRNA: trans-activating crRNA; ZF: Zinc finger (Adapted from [365, 
366]).  
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3.1.1 Advances in the development of the CRISPR/Cas9 
system  
The history of CRISPR discovery extends back to 1987, when a set of 29 nt 
repeats in Escherichia coli were found to be divided by short non-repetitive 
sequences [367]. Later, Mojica et al. [368] reported similar repeats in other 
bacterial species and in some prokaryotic Archaea. In 2002, the acronym 
“CRISPR” was created to replace the short regularly spaced repeats (SRSR) 
[369]. A conserved gene sequence that can interact with CRISPR repeats has 
been subsequently discovered and named CRISPR-associated (Cas) genes. 
Such genes encode various important proteins, such as the Cas3 gene which 
encodes a single-stranded DNA nuclease and ATP-dependent helicase , and 
Cas4 which encodes exonuclease [363]. Additionally, a large protein with 
nuclease activity has been found to be encoded by Cas9 gene as revealed by 
Bolotin et al. [370]. Furthermore, the protospacer adjacent motif (PAM), another 
component of the CRISPR system, has been discovered and contributed to 
revealing several technical details pertinent to the novel gene editing tool [370]. 
A more recent remarkable discovery is that certain complexes of Streptococcus 
thermophilus and Streptococcus pyogenes (Cas9–CRISPR (cr)RNA 
complexes) might exert an in vitro RNA-guided endonuclease action [369]. As 
a consequence, these complexes might be utilised in genome editing thereby 
expanding horizons for use of CRISPR technology in new applications. 
Of the three CRISPR systems, the CRISPR type II system has been well 
characterised. It is composed of pre-crRNA, trans-activating (tra)crRNA, and 
Cas9 proteins [363]. In Cas9, the HNH domain and RuvC-like domain are 
known for their prominent nuclease activity (Figure 3-1c). Pre-crRNA is cut into 
crRNA by a coordinating action of tracrRNA and RNaseIII. Then, an interaction 
between crRNAs and tracrRNAs occurs, helping the appropriate recognition of 
Cas9 to the specific DNA sites. The random identification of DNA sequences 
starts by the Cas9–RNA complexes and it requires a PAM motif to match its 
sequence. Once identified, the HNH nuclease domain on Cas9 cleaves the 
DNA strand at its specific cleavage site that is bound to crRNA. Additionally, 
the other DNA strand is cut by the RuvC-like domain to generate the relevant 
DSBs. Following creating the break sites, the repair mechanism is directed in 
 
 
81 
either two different ways depending on the stage of cell cycle or the existence 
of a donor template. These repair mechanisms include NHEJ or HDR. The 
NHEJ pathway entails conjoining the broken strands through multiple insertions 
or deletions (indels) leading to a frame shift and inducing premature stop 
codons in the reading sequence. On the other hand, when a donor template is 
available, distinct insertions, deletions, or mutations are generated in the HDR 
repair mechanism [363]. 
3.1.2 Experimental cell lines 
Vascular endothelium of an adult human is composed of 1–6 × 1013 endothelial 
cells lining a total surface of 4000-7000 m2 of blood and lymph vessels [371]. 
Endothelial cells play a key role in diverse physiological and pathological 
process such as inflammation, thrombosis, wound healing, angiogenesis, and 
tumour metastasis. Thus, systematic identification of the specific molecular 
features of the endothelial cells is essential for the development of new 
approaches for both the prevention and therapy of cardiovascular diseases 
[372]. 
Utilising human endothelial cells has been an essential element in experimental 
culture systems to investigate drug interactions, vascular remodelling and 
inflammation as well as blood haemostasis [373]. In the present thesis, the use 
of AS-M.5 cell line was considered. This cell line is derived from a rare 
malignancy in scalp endothelium, namely cutaneous angiosarcoma [374]. 
Immunohistochemical analyses and RT-PCR analyses have shown they 
display several characteristics of primary vascular endothelial cells: these 
include inducible expression of cell surface adhesion molecules (intercellular 
adhesion molecule-1 (ICAM-1), vascular endothelial cell adhesion molecule 1 
(VCAM-1), and E-selectin) when exposed to LPS, TNF, and IL-1β) and the 
expression of endothelium markers von Willebrand factor (vWF) and CD31 
[357]. Confirmation of the endothelial origin of this cell line was originally based 
on their increased uptake of acetylated-low density lipoprotein (acLDL), which 
is considered a defining function of endothelial cells [357, 375]. These 
characteristics are all comparable to those of primary isolated human umbilical 
endothelial cells (HUVECs) which have been widely used to study the 
 
 
82 
endothelial physiology and pathology. Unlike HUVECs that exhibit a limited 
proliferative capacity in culture [376], AS-M.5 cells can undergo more than 100 
population doublings (PDs) while remaining morphologically stable [357] and 
thus maintained many of endothelial characteristics. Additionally, AS-M.5 
culture systems are a cheaper and more tractable alternative for stable knock-
in or knockout experiments. Therefore, WT and SOCS3-null AS-M.5 cells could 
potentially be useful cell models for further examination of the specific roles of 
cavin-1/SOCS3 interaction in JAK-STAT signalling and caveolae stability in 
endothelial cells.. 
3.1.3 Aims 
In this Chapter, Generation of an immortalized human endothelial cell line that 
lacks SOCS3 protein expression is documented. This was achieved by: 
1) Obtaining commercially CRISPR/Cas9 KO Plasmids that have a suitable 
gRNA for SOCS3 gene editing. 
2) Determining the optimal Plasmid DNA: transfection reagent ratio to minimize 
cell toxicity followed by co-transfection the appropriate amount of 
CRISPR/Cas9 KO Plasmid with HDR Plasmid aiming at the highest level of 
transfection efficiency in WT AS-M.5 cell lines. 
3) Examining successful transfection of CRISPR/Cas9 KO Plasmid and HDR 
Plasmid by detection of the green fluorescent protein (GFP) and the red 
fluorescent protein (RFP) via visual confirmation using fluorescent microscopy. 
4) Selection SOCS3 KO cells with media containing puromycin antibiotic, 
followed by phenotypic analysis of SOCS3 KO in selected clones using 
fluorescent microscopy and western blotting. 
3.2 Results and discussion 
Caveolae and their major protein components, particularly cavin-1, are 
abundantly located in the endothelial cells [121]. Generation of endothelial 
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SOCS3 knockout cells is instrumental to define specific roles of cavin-1/SOCS3 
interaction and caveola abundance in endothelial cells.  
3.2.1 CRISPR/Cas9 Constructs 
SOCS-3 CRISPR/Cas9 KO Plasmid (h2) (sc-400455-KO-2) and SOCS-3 HDR 
Plasmid (h2)(sc-400455-HDR-2) were utilised (Santa Cruz Biotechnology, Inc., 
Texas, U.S). In the SOCS-3 CRISPR/Cas9 KO Plasmid (h2) product, a 3-
plasmid-containing pool is used to create a DSB in a 5' constitutive exon 
causing disruption of the genomic expression of the SOCS3 gene. DSBs could 
be made by the CRISPR plasmids via cloning of three 20 nt target sites into the 
gRNA scaffold. The pool of the SOCS3 CRISPR/Cas9 plasmids consists of 3 
sgRNA sequences developed from the Genome-Scale CRISPR Knock-Out 
library (GeCKO v1 and v2 lentiviral sgRNA libraries) as formerly described by 
Zhang Lab (Broad Institute, Massachusetts, U.S) [377, 378] where further off-
site modifications were prohibited or minimised by the selection of each specific 
target site. As such, three gRNAs (20 nt each) would target SOCS3 (Table 3–
1) and then the respective SOCS-3 CRISPR/Cas9 KO Plasmids (h2) were 
cloned, encoding the Cas9 nuclease along with an enhanced green fluorescent 
protein (EGFP) to enhance the visualisation of positive clones [379]. The 
gRNAs, which are located immediately adjacent to a PAM sequence, target a 
specific DNA sequence by Cas9. Subsequently, either the high-fidelity HDR or 
the error-prone NHEJ mechanisms are employed to repair the target sequence 
[380]. At this end, the role of the SOCS-3 HDR Plasmid (h2)(sc-400455-HDR-
2) could be apparent. Such repair template would render the edited cells 
containing a puromycin resistance gene, which could be further utilised for 
selection purposes. Figure 3–2 depicts a scheme for both plasmids used for 
transfection. 
Table 3–1 Guide RNA sequences used for constructing knockout cells.  
Data were adapted with permission from Santa Cruz Biotechnology, Inc.[381] 
  
gRNA gRNA sequence 
sgRNA1 Sense: CTTAAAGCGGGGCATCGTAC 
sgRNA2 Sense: CACAGCAAGTTTCCCGCCGC 
sgRNA3 Sense: GCTTGAGCACGCAGTCGAAG 
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Figure 3–2: Design of the CRISPR/CAS9 system for SOCS3 gene 
deletion. 
 (A) A scheme of the SOCS-3 CRISPR/Cas9 KO Plasmid (h2) which 
includes the following sites: 1) 20 nt RNA sequence that act as a guide to 
target Cas9 to a specific sequence in the genomic DNA. 2) gRNA scaffold 
which facilitates Cas9 binding to the target DNA. 3) termination signal. 4) 
chicken β-Actin hybrid (CBh) promoter which drives Cas9 expression 5) 
Nuclear localization signal 6) SpCas9 ribonuclease 7) nuclear localisation 
signal 8) 2A peptide that enables producing both GFP and Cas9 from the 
same CBh promoter 9) Green Fluorescent Protein to facilitate the 
visualisation of transfection. 10) U6 promoter: drives expression of gRNA. 
(B) A scheme of the SOCS-3 HDR Plasmid (h2) containing the following 
sites: 1) EF1a promoter which initiates expression of the Puromycin 
resistance gene. 2) Red Fluorescent Protein to enable accurate 
visualisation of transfection. 3) Puromycin resistance gene enables 
selection of cells in which DSBs have been induced by Cas9. 4) a Cre 
recombinase-recognisable Lox P (34 bp) recombination site. (C) The 
human SOCS3 gene is located on the 17q25.3 locus, which constitutes 
the long arm of the chromosome. The molecular location on chromosome 
17 from the base pair 78,356,777 to 78,360,079. Adapted from the 
Genetics Home Reference [382].  
A B 
  
C  
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3.2.2 Transfection of CRISPR/Cas9 Constructs 
In the current experimental work, liposomal transfection was initially employed 
using the PolyFect® Transfection Reagent (QIAGEN, Venlo, The Netherlands) 
but it was of a very low efficiency (data not shown). Therefore, it has been 
replaced with another commercially poly(amidoamine) (PAMAM) dendrimers-
based gene delivery system, SuperFect® Transfection Reagent (QIAGEN, 
Venlo, The Netherlands) (Figure 3–3). Seemingly, PAMAM dendrimers-
mediated transfection depends on both the charge of the complexes (where a 
net positive charge is more preferable and is inversely correlated with the 
hydrophobicity of the complexes) and dendrimer generation (higher efficiency 
is prospected with larger sized-dendrimers) [383]. 
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Figure 3–3: Fluorescence expression in AS-M.5 cells transfected 
with a CRISPR/Cas9 plasmid that expresses enhanced GFP. 
AS-M.5 cells were co-transfected with CRISPR/Cas9 KO Plasmid and 
HDR Plasmid (Santa Cruz Biotechnology, Inc.) using SuperFect® 
Transfection Reagent (QIAGEN). 24 hours post transfection, cells were 
visualized under a Zeiss Axiovert fluorescence microscope (Carl 
Zeiss, Germany). Representative bright field image of transfected cells 
and fluorescence image of the same field of cells. Scale bars: 100 µm 
  
Bright-field Fluorescent field 
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3.2.3 Puromycin selection 
AS-M.5 cells were co-transfected with CRISPR/Cas9 KO Plasmid and HDR 
Plasmid using the SuperFect® Transfection Reagent according to the 
manufacturer’s instruction. Five days post transfection, puromycin selection 
was used to select cells that had taken up the CRISPR/Cas9 KO Plasmid with 
HDR Plasmid. Titration of puromycin on the AS-M.5 cell line was previously 
performed and the optimal concentration 2 µg/ml was found sufficient to kill 
parental cells within 2 days (Kirsten Munro, University of Glasgow, personal 
communication). Selection was continued for 10 days (Figure 3–4), which 
resulted in large cell death. Dilution plating was performed for puromycin-
resistant cells using 10 cm cell culture dishes. Dilution would facilitate formation 
of separate discrete colonies with large gaps in-between for better 
characterisation.  
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Day 0 Day 5 
  
Day 7 Day 10 
  
Figure 3–4: The effect of puromycin treatment on CRISPR/Cas9-
transfected AS-M.5 cells.  
Representative phase contrast micrographs AS-M.5 cell after 5, 7, 
10 days of exposure to puromycin treatment (2µg/ml) as indicated 
(panels A-D). The number of dead cells increased significantly 
which aided the enrichment of targeted cells (puromycin-resistant 
cells). Images were taken using a Zeiss Axiovert microscope (Carl 
Zeiss, Germany), Scale bars: 100 µm. n=1. 
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3.2.4 Cell assay to confirm complete allelic knockouts 
The small-sized colonies (enough to be physically recognisable) were collected 
using trypsin-immersed cloning disks (Sigma-Aldrich). Single foci were picked 
from 10 cm dishes and seeded into separate wells of non-coated 48-well tissue 
culture plates. Following the expansion phase, characterisation of Cas9-
mediated SOCS3 genome editing was performed via western blotting. As 
shown in Figure 3–5, cells grown from one clone were treated with the adenylyl 
cyclase activator forskolin (Fsk) at a concentration of 50μM for 5 hours, in the 
presence of the proteosome inhibitor, MG132 at a concentration of 6μM. 
Polyclonal rabbit anti-SOCS3 antibodies (Abcam; Ab16030) were utilised to 
analyse SOCS3 expression. cAMP-elevation by Fsk induced endogenous 
SOCS3 expression and MG132 inhibited proteasome mediated degradation in 
the WT AS-M.5 cells whereas SOCS3 protein levels in the single-cell clone was 
null (Figure 3–5). Interestingly, Nur77, a well-characterised immediate early 
response gene whose expression is rapidly induced by cAMP elevation [384], 
was detectable in both WT and SOCS3-null AS-M.5 cells. Thus, the lack of 
response to the Fsk stimuli provided an evidence that such cells are SOCS3 
knockouts. Likewise, SOCS3 was detected (~27KDa) in the WT AS-M.5 cells 
treated with Fsk + MG132 but not in the six single cell clones which were 
expanded as potential SOCS3 knockouts (Figure 3–6). Notably, one single 
clone appeared to have a single allele (heterozygous) deletion as it exhibited 
incomplete knockout. Overall, deletion of SOCS3 via the CRISPR/Cas9 system 
was efficiently performed and occurred in six clonal cell lines in the current 
experiment. 
3.2.5 Phenotypic Differences in SOCS3–/– Endothelial Cells 
To determine whether SOCS3 deletion affected the quality of AS-M cells, the 
morphology of the endothelial clones was observed and digital images were 
taken using a microscope (Zeiss AxioVert, Germany). Phase contrast images 
showed that SOCS3-null endothelial cell clones grew in loose arrangements 
and at a slower rate when compared to the parental cells. Additionally, in 
contrast to the WT spindle-shaped AS-M.5 cells that grew in swirling patterns, 
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the endothelial clones exhibited a polygonal morphology with a growth pattern 
resembling a cobblestone (Figure 3–7).  
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A 
 
B 
SOCS3+/+ SOCS3–/– 
   
 
 
Figure 3–5 CRISPR/Cas9 mediated disruption of SOCS3 locus 
generated complete gene knockouts. 
(A) Detergent-soluble whole cell lysates from WT and SOCS3-null AS-M.5 
human angiosarcoma-derived ECs treated with either vehicle or Fsk (50 
µM) plus MG132(6 µM) for 5 hr were equalised for protein content for 
SDS-PAGE for immunoblotting with the indicated antibodies. N=3. 
(B) Representative phase-contrast micrographs showing the morphology of 
WT AS-M.5 cells and one clonal cell lines lacking SOCS3 protein. 
Images were taken using a Nikon Eclipse Ti-S inverted microscope 
(Nikon, Tokyo, Japan). Scale bar, 200 µm. 
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Figure 3–6 Immunoblot screening of CRISPR/Cas9-mediated 
SOCS3 gene knockout in AS-M.5 cells 
WT human angiosarcoma-derived ECs and clonal cell lines were 
treated with Fsk (50 µM) in the presence of MG132 (6µM) for 5 hr. 
Detergent-soluble whole cell lysates were equalised for protein content 
and then resolved by SDS-PAGE for immunoblotting with the indicated 
antibodies. Data shown are representative of three separate 
experiments. 
 
 
 
93 
 CRISPR CLONE 
   
 
  
 
  
Figure 3–7 Phase contrast photomicrographs of the parental AS-M.5 
human angiosarcoma-derived ECs and clonal cell lines in culture. 
WT AS-M.5 and the immortalized CRISPR/Cas9-mediated SOCS3 
knockout cell monolayers exhibit the typical cobblestone cell morphology 
that is characteristic of endothelial cells. While AS-M.5 cells were spindle-
shaped, clonal cell lines exhibited a polygonal-shape. Brightfield cell 
images were visualized under a Nikon Eclipse Ti-S inverted microscope 
(Nikon, Tokyo, Japan) equipped with a Nikon Digital Sight DS-Fi2 camera. 
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3.3 Conclusion 
In the present study, CRISPR/Cas9 gene editing was utilised to knockout 
SOCS3 gene expression. Three gRNAs were used to successfully generate six 
clonal cell lines with a complete absence of SOCS3 protein expression as 
detected by the Western blot analysis compared to unedited controls. SOCS3 
knockout cell lines could be created within a 7-week-period that extends from 
the day of transfection to cryopreservation of clonal production cell lines.  
SOCS3 has a significant regulatory role in inflammatory-mediated pathways. 
Functional studies of SOCS3 are critical to elucidate the pathological 
mechanisms underlying complex human diseases, such as insulin resistance, 
cardiovascular diseases, rheumatoid arthritis and specific cancers [324]. Other 
SOCS3-related diseases include anaemia [385], viral infection [386], and 
psoriasis, where psoriasis-like inflammation is induced by SOCS3 deletion 
[387]. Focusing on the heart, the interaction between SOCS3 proteins and 
gp130-JAK1 complexes yields a remarkable regulatory role of three major 
downstream pathways, including the Ras/MEK/ERK, JAK/STAT, and PI3K/ 
AKT [388, 389]. These multifaceted aspects of SOCS3 in different diseases 
highlight the importance of conducting future relevant studies to reveal the 
potential pathophysiological and therapeutic implications. Transitional research 
relies on mutant cell lines with a specific knocked-out protein to investigate the 
sequelae of allelic dysfunctionality in a given experimental study. The microbial 
CRISPR/Cas9 systems offered unprecedented ways of genomic manipulation 
induce gene knockouts in diploid cells and hence the biological significance of 
generating SOCS3-deficient endothelial cell lines as novel tools for the current 
experimental project and beyond. To the best of our knowledge, this study is 
the first to create endothelial SOCS3-deficient clonal cell lines using 
CRISPR/Cas9.  
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4 Characterisation of cavin-1/SOCS3 
interaction 
4.1  Introduction 
SOCS3 proteins have a vital role in regulating specific cytokine-mediated 
signalling and thus can be regarded as key players in various processes in the 
hematopoietic and immune systems, such as negative regulation of 
granulopoiesis, regulation of a number of cytokine receptors, and other 
regulatory roles in T cell development and functions [315, 390]. The inhibitory 
actions of SOCS3 are exerted on the catalytic activity of JAKs which have been 
implicated in initiating cytokine signalling [323]. Such actions are attributable to 
the central SH2 domain which binds to distinct phosphorylated tyrosine 
residues on target proteins [307]. Following the recognition of these residues 
by SH2 domains, downstream signalling pathways are regulated either via 
enhancing a distinct enzymatic activity or undergoing SH2-mediated protein-
protein interactions (Section 1.4.3 and 1.4.4). As such, the interest in 
investigating phosphotyrosine-dependent SOCS3 substrates has been 
substantially-increased. The characteristics of the identified substrates so far 
include a specific Tyr phosphorylation-dependent interaction with the SOCS3 
SH2 domain as well as the presence of an intact SOCS box required for 
ubiquitylation of the bound targets [307]. Subsequently, proteasome-mediated 
degradation of some targets, such as FAK1, would follow substrate 
ubiquitylation [307]. However, the exact regulatory mechanisms of SOCS3 
functions by other cellular proteins and the knowledge about ubiquitylated 
SOCS3 substrates remain unclear.  
Comparison of tandem affinity purified ubiquitinomes have shown that SOCS3-
expressing fibroblasts have a significant enhancement of cavin-1 ubiquitylation 
when compared to SOCS3-null cells [356]. Cavin-1 protein contributes to 
caveolae coupling to the microtubule network to inhibit caveolin-1 degradation 
and thus prevent caveolar disassembly [121]. A direct interaction between 
SOCS3 and two specific regions on cavin-1 independent of tyrosine 
phosphorylation has been demonstrated in studies employing co-
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immunoprecipitations and overlapping peptide array overlays [356]. Since 
elevated JAK/STAT signalling is involved in the pathophysiology of chronic 
inflammatory disorders, it is plausible that the SOCS3 might have a therapeutic 
role as an E3 ligase [307]. A novel therapeutic potential may emerge through 
the adequate identification of cAMP/Epac1-regulated ECSSOCS−3 E3 ubiquitin 
ligase targets and investigation of their impact on the cell.  
4.1.1 Aims 
This chapter aims to demonstrate whether SOCS3 could play a role in cavin-1 
and caveolin-1 regulation through assessment of their endogenous protein 
expression in wild type and SOCS3-null AS-M.5 cells and MEFs. This was 
further examined at the gene expression of cavin-1 in MEFs. In addition, the 
impact of cAMP-mediated elevation of SOCS3 expression was investigated to 
elucidate the effects of changes in endogenous SOCS3 expression on cavin-1. 
4.2 The effect of SOCS3 on cavin-1 stability in 
fibroblasts and endothelial cells  
The most significant non-lysosomal proteolytic pathway in the cell is mediated 
by the regulatory protein ubiquitin. In this pathway, protein degradation takes 
place via sequential catalytic reactions by three enzymes: ubiquitin activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). 
Subsequently, the 26S proteasome hydrolyses the target protein. Indeed, E3 
ligases are highly specific to their substrates and the control of such proteolytic 
pathway relies basically on the ubiquitin-substrate interaction [391]. The latter 
is not only important in protein turnover control in physiological and pathological 
conditions but also may contribute in the endeavour of developing novel 
therapeutic approaches (Section 1.4.1 and 1.4.4). 
Studies concerned with investigating the protein-protein interaction are 
designed not only to reveal the specific binders, but also to measure the 
resultant dynamic changes that might follow any disruptions. Gene knockout 
may be induced temporarily via siRNA or shRNA or more preferably through a 
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CRISPR/Cas9 KO control which would yield a permanent and stable negative 
control [392].  
The potential regulatory effects of SOCS3 on endogenous cavin-1 levels were 
assessed by investigating the impact of homozygous SOCS3 gene deletion on 
cavin-1 expression in AS-M.5 cells. Results have shown that cavin-1 
expression was significantly reduced in SOCS3−/− AS-M.5 cells when compared 
to WT cells as revealed by immunoblotting of whole-cell extracts. This was also 
associated with a decrease in CAV-1 protein expression levels, which has been 
similarly reported by other studies in normal and pathological conditions [121] 
(Figure 4–1). Furthermore, SOCS3−/− MEFs showed a significant reduction of 
cavin-1 levels as compared to WT MEFs (Figure 4–2). Thus, loss of SOCS3 in 
two distinct cellular systems (embryonic fibroblasts and endothelial cells) using 
two different methods (homologous recombination and CRISPR/Cas9 gene 
editing) results in reduced cavin-1 expression. 
Other regulatory mechanisms, including splicing and post-translational 
modifications, might exist and they may increase proteome complexity. In the 
present thesis, the observed reduction of cavin-1 levels in SOCS3−/− cells might 
be caused by post-translational modifications of the existing proteins rather 
than a de-novo synthesis of proteins, providing a novel mechanism of SOCS3 
protein involvement. To test whether the observed reduction in cavin-1 protein 
was accompanied by a corresponding decrease in mRNA levels, cavin-1 mRNA 
levels in WT and SOCS3-null MEFs, total RNA was extracted and quantitative 
real time-PCR measurements of cavin-1 mRNA abundance were performed as 
described previously (Section 2.2.6.1). There was a significant increase in the 
abundance of cavin-1 gene transcripts in SOCS3−/− cells versus WT MEFs 
(Figure 4–2). These results suggest that the steady state of cavin-1 proteins in 
SOCS3-deficient cells cannot be explained by a parallel reduction in the relative 
abundance of cavin-1 mRNA and suggests instead that the presence of SOCS3 
may enhance cavin-1 stability in WT MEFs. 
Cycloheximide is usually used in the kinetic experiments to inhibit protein 
synthesis. However, emetine was alternatively utilised in the present thesis as 
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it does not activate stress-activated MAP kinases such as p38 [393]. Emetine 
acts by preventing the enzymatic translocation of peptidyl-tRNA from the 
acceptor site to the donor site [394]. To quantify cavin-1 protein turnover in WT 
and SOCS3 deficient AS-M.5 cells, changes in the expression of cavin-1 was 
monitored following emetine-induced protein synthesis inhibition. Consistent 
with emetine chase experiments using MEFs [356], the lack of SOCS3 in AS-
M.5 cells caused a significant reduction of the half-life of cavin-1 from >8 hours 
in WT cells to 3 hours in SOCS3-null AS-M.5 cells (Figure 4–4). Therefore, 
these data indicate that the presence of SOCS3 enhances cavin-1 stabilisation 
in AS-M.5 cells. Interestingly, these results contrast the well-established role of 
SOCS3 in substrate-destabilisation via ubiquitylation and proteasomal 
degradation [307].  
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Figure 4–1 SOCS3 deletion significantly reduces endogenous 
protein levels of cavin-1 and caveolin-1 in AS-M.5 cells. 
WT and SOCS3-/- AS-M.5 cells were grown to confluency in 6-well plates 
and harvested in RIPA lysis buffer. Soluble protein lysates were equalised 
for protein content before fractionation by SDS-PAGE on 10 % (w/v) 
polyacrylamide gels for immunoblotting with antibodies as indicated. 
Densitometry analysis of three independent experiments were performed 
using Image Studio Lite Software Version 5.2.5. Values are means ±SEM. 
The statistical significance was assessed using an unpaired, two-tail t-test 
(GraphPadPrism, *p < 0.05). 
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Figure 4–2 SOCS3 deletion significantly reduces endogenous 
protein levels of cavin-1 and caveolin-1 in MEFs. 
WT and SOCS3-/- MEFs were grown to confluency in 6-well plates and 
harvested in RIPA lysis buffer. Soluble protein lysates were equalised for 
protein content before fractionation by SDS-PAGE on 10 % (w/v) 
polyacrylamide gels for immunoblotting with antibodies as indicated. 
Densitometry analysis of the immunoreactive bands was performed using 
Image Studio Lite Software Version 5.2.5. Values are means ±SEM of 
three different experiments. The statistical significance was assessed 
using an unpaired, two-tail t-test (GraphPadPrism, *p < 0.05). 
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Figure 4–3 Real-time qPCR revealed that the mRNA expression level 
of cavin-1 is significantly increased in SOCS3−/− MEFs as compared 
to WT (SOCS3+/+) controls.  
Total RNA samples were obtained, and cavin-1 mRNA levels were 
quantified by reverse transcription followed by qPCR analysis. GAPDH 
mRNA was used as an endogenous control. Real-time qPCR was 
performed to measure cavin-1 mRNA levels using the primers as shown 
in Table 2-8. The data were analysed using the 2(−ΔΔCt) method. Results 
representative of n=3 experiments. Statistical analysis was performed 
with the Student t test and are presented as the mean ± SEM. Significant 
differences are marked by asterisk (* = p < 0.05). 
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Figure 4–4 Destabilisation of cavin-1 in SOCS3- deficient endothelial 
cells.  
WT and SOCS3-/- AS-M.5 cells were seeded into 6cm diameter dishes 
and grown until confluent. Cells were then treated with emetine, a protein 
synthesis inhibitor, at a concentration of 100µM for 1, 2, 3, 5 and 8 hours 
in serum-free medium. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with cavin-1 and GAPDH antibodies. Quantitative 
analysis of cavin-1 protein levels in WT and SOCS3-null AS-M.5 cells from 
three experiments is presented as mean values ± SEM (*p<0.05 versus 
cavin-1 levels in SOCS3+/+ AS-M.5 cells, # p<0.05 vs. t=0). 
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4.3 The effect of SOCS3 induction by cAMP elevation 
on cavin-1 
cAMP plays a major role in the regulation of multiple functions in the innate and 
adaptive immune response. Such regulatory function is clearly demonstrated 
when cAMP-elevating drugs enhance the production of anti-inflammatory 
mediators and reduce the pro-inflammatory factors produced by multiple 
immune cells [395]. cAMP homeostasis is maintained through the expression 
of adenylate cyclases (ACs), which catalyse its formation from ATP. 
Furthermore, phosphodiesterases (PDEs) comprise a family of more than 100 
enzyme variants that contribute to degradation of intracellular cyclic 
nucleotides. Indeed, these variants are allocated into 11 families [396] 
according to their structure and the interaction and specificity for cyclic 
nucleotides.  
cAMP triggers several downstream pathways in the cell via activation of protein 
kinase A (PKA) [397], which dissociates into its regulatory and catalytic subunits 
upon binding of cAMP. These catalytic units phosphorylate specific Ser and Thr 
residues on several target proteins [398]. Furthermore, multiple cAMP-
responsive transcription factors, including activating transcription factor-1 (ATF-
1), cAMP-response element binding protein (CREB), and distinct members of 
the cAMP-responsive element modulator (CREM) family [399], are also 
phosphorylated by PKA. Importantly, nuclear-localised PKA can phosphorylate 
CREB at serine-133[400] and this promotes translocation to the nucleus where 
it binds to target promotors and, following binding to CRE promoter sites and 
recruitment of transcriptional activators such as p300 and CBP, promotes gene 
transcription. Generally, the phosphorylated transcription factors bind to cAMP-
response elements (CREs) in the target genes with a significant interaction with 
CREB-binding protein (CBP) and p300, which coactivate the transcription 
process [401]. Phosphorylation of CREM, CREB, and ATF-1 could be also 
established by other kinases while distinct protein phosphatases can 
counterbalance PKA effects [398]. In addition to activation of PKA, cAMP can 
also act by modulation of cyclic nucleotide-gated channels (CNGs), the 
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exchange protein directly activated by cAMP (Epac) and guanine-nucleotide-
exchange factor (GEF) [402, 403]. 
 
4.3.1 SOCS3 induction by cAMP stabilises cavin-1 
Although proteasomal degradation maintains low SOCS3 levels in the cell, 
several routes are implicated in SOCS3 induction, including Toll-like receptors 
[344], the JAK/STAT pathway and cAMP elevation through activation of EPAC 
and PKA-independent ERK activation [304, 404]. As a result of the abundance 
of SOCS3-inducing routes, several ubiquitinated targets exist. Actually, the 
abundance of SOCS3-inducing routes renders a variable pool of ubiquitinated 
targets. SOCS3 has been recognised as one of two ubiquitin ligases induced 
by cAMP [405]. The latter has been identified as a potent inhibitor of the pro-
inflammatory signalling pathways [395]. Therefore, multiple anti-inflammatory 
therapeutic approaches could be elucidated by revealing novel cAMP/EPAC1 
targets. 
Williams et al. [356] attempted to identify novel ubiquitinated SOCS3 substrates 
following cAMP activation to further elucidate the involvement of cAMP in 
inflammation. The proteomic screening experiments have shown an interaction 
between cavin-1 and SOCS3 proteins. As presented in Section 4.2, SOCS3 
can contribute to cavin-1 stability. Thus, it is important to investigate the impact 
of cAMP-induced SOCS3 accumulation on the levels of cavin-1 and the 
resultant functional consequences. A time-dependent accumulation of SOCS3 
was observed following exposure to the cAMP-elevating agent forskolin (Fsk, 
50 µM). Such accumulating pattern, which peaked after 4 h, was associated 
with transient increase in SOCS-3 mRNA, which could be detectable at 1, 3 and 
5 h (data not shown). Following treatment of WT and SOCS3-/- MEFs with Fsk 
for 6 hours, cavin-1 expression was decreased in SOCS3-deficient MEFs at t=6 
hrs vs t=0, whereas SOCS3 accumulation in response to Fsk-stabilised cavin-
1 levels in the WT counterparts after 6 hrs of Fsk exposure (Figure 4–5). 
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cAMP causes CREB phosphorylation via protein kinase A induction. CREB 
then binds to the cAMP-regulated enhancer, which is located in many target 
genes. Of those genes, Nur77 is one of those genes and it can be induced by 
cAMP [356, 384]. Therefore, Nur77 expression was utilised in the present thesis 
to aid as a positive control to monitor cAMP elevation. 
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Figure 4–5 The effect of SOCS3 deletion on Fsk-mediated regulation 
of cavin-1 and Nur77 expression levels in MEFs.  
WT and SOCS3-/- MEFs were seeded in 6 well plates and grown until 
confluent. Cells were then treated with Fsk (50µM) for 1, 2, 4 and 6 hours. 
Following treatment, soluble cell extracts equalised for protein 
concentration prior to fractionation by SDS-PAGE for immunoblotting with 
indicated antibodies. Quantitative analysis of cavin-1 protein levels in WT 
and SOCS3-null MEFs is presented as mean values ± SEM (*p<0.05 
versus cavin-1 levels in SOCS3+/+ MEFs, # p<0.05 vs. t=0). One of seven 
experiments. 
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4.3.2 Examining cAMP-dependent regulation of cavin-1  
Previous studies suggested that cavin-1 migrates at a high molecular weight 
(10-15 kDa) upon separation by polyacrylamide gel electrophosresis, which is 
probably due to posttranslational modifications [114]. Cavin-1 acetylation takes 
place at the N-terminal methionine residue [406] and it can be also SUMOylated 
and ubiquitinated [307]. In addition, the involvement of cavin-1 in cell signalling 
is supported by its phosphorylation at multiple sites [118, 407]. Cavin-1 
fractionation into active and inactive forms for transcription is possible and such 
phosphorylation sites may potentially change the capacity of cavin-1 to 
dissociate ternary transcription complexes [408]. Aboulaich et al. [406] found 
that cavin-1 has four phosphorylation sites as demonstrated by immobilized-
metal afﬁnity chromatography. Ser-36 and Ser-40 are sites for phosphorylation 
by glycogen synthase kinase-3, whereas protein kinase A and casein kinase 2 
phosphorylate Ser-365 and Ser366 sites, respectively [406]. 
Hormone-stimulated lipolysis in the adipocytes is one of the important 
intracellular processes that has been linked to cavin-1 [409]. Glucagon and 
epinephrine cause activation of cAMP/PKA signalling after binding to their 
receptors (glucagon and ß-adrenergic receptors, respectively) [406]. Hormone-
sensitive lipase (HSL) is an intracellular lipase that regulates lipolysis. It 
contains PKA phosphorylation sites [410, 411] and it can co-immunoprecipitate 
with cavin-1 proteins. Interestingly, insulin can cause translocation of both HSL 
and cavin-1 from the plasma membrane to the cytosol [409]. 
The results of the present thesis indicated that cavin-1 was detected as an 
approximately 50-kDa band in the positive-control WT cells. However, cavin-1 
immunoreactivity was observed in preliminary time course experiments 
following Fsk treatment (data not shown). The involvement of immunoreactive 
cavin-1 proteins in cAMP/PKA signalling was investigated by conducting time 
course experiments in which WT MEFs were stimulated with Fsk in the 
presence or absence of a PKA inhibitor (H89). Although H89 treatment inhibited 
the ability of Fsk to induce cAMP-responsive gene Nur77, cavin-1 levels 
evidenced no change (Figure 4–7). Therefore, cavin-1 immunoreactivity is 
supposedly regulated independent of cAMP/PKA signalling. 
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To further attain a confirmatory evidence, molecular cAMP induction 
requirements were assessed. Given that such induction entails new protein 
synthesis (Nur77 is translation-dependent), the assumption of requiring new 
protein synthesis with the changes in cavin-1 immunoreactivity was 
investigated. Thus, WT MEFs were incubated with protein synthesis inhibitor 
emetine (100 μM) or a vehicle 30 min prior to treating with Fsk. Although this 
treatment was sufficient to inhibit Nur77 accumulation in response to Fsk 
treatment, emetine had no effect on cavin-1 immunoreactivity as compared to 
the vehicle control groups (Figure 4–7). Thus, a cavin-1 activity, which seems 
to be translation-independent, is not regulated via a cAMP/PKA Pathway. 
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Figure 4–6 Stabilisation of cavin-1 following cAMP elevation is PKA-
independent. 
WT MEFs were seeded in 6 well plates and grown until confluent. Cells 
were then treated with H89 (5µM) 30 min prior Fsk (50µM) stimulation for 
1, 3, and 5 hours as indicated. Following treatment, soluble cell extracts 
equalised for protein concentration and then separated by SDS-PAGE for 
immunoblotting with indicated antibodies. Quantitative analysis of cavin-1 
protein levels in WT MEFs is presented as mean values ± SEM. All 
samples were analysed in three independent experiments. n.s. indicates 
statistically non-significant difference between H89-treated and untreated 
groups. 
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Figure 4–7 Effect of protein synthesis inhibitor emetine on Fsk-
mediated changes in cavin-1 immunoreactivity. 
WT MEFs were grown to confluency in 6-well plates and then treated with 
Fsk (50µM) in the presence or absence of emetine (100µM) for 5 hours 
prior to harvesting. Protein extracts were prepared and equalised for 
protein content before fractionation by SDS-PAGE on 10 % (w/v) 
polyacrylamide gels for immunoblotting with the indicated antibodies. 
Results representative of n=3 experiments. 
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4.3.3 Examining phosphorylation status of cavin-1 following 
cAMP elevation 
Protein phosphorylation is one of the important regulatory processes in all cells. 
Two major classes of enzymes, protein kinases and protein phosphatases, can 
control such reversible events. The important biological processes of relevance 
that could be activated or inactivated by phosphorylation include protein 
synthesis, signal transduction and DNA transcription as well as other cellular 
actions, such as motility and division [412]. 
The experiments in the present section used treatment with a non-selective 
phosphatase to determine whether phosphorylation altered cavin-1 protein 
immunoreactivity [413]. To this end, WT MEFs were lysed in a lysis buffer 
without phosphatase inhibitors and divided into two aliquots; one received calf 
intestinal phosphatase (CIP) and the other received buffer alone. Following 
incubation for 2 hrs at 37oC, samples were resolved by SDS-PAGE and 
immunoblotted for cavin-1. Given that phosphorylation has been suggested to 
be the primary mechanism by which CREB was controlled [414], anti-Ser-133 
pCREB antibody was used as a positive control to assess CIP activity. 
As shown in Figure 4–8, CREB phosphorylation on Ser-133 was detected 2h 
following Fsk stimulation and this modification was abolished by phosphatase 
treatment. In contrast, no changes in cavin-1 immunoreactivity were detectable, 
suggesting that any cAMP-mediated phosphorylation of cavin1 had no effect 
on immunoreactivity. 
  
 
 
112 
 
Figure 4–8 Effect of phosphatase treatment on cavin-1 
immunoreactivity. 
WT MEFs were grown to confluency in 6cm diameter dishes after which 
the media was refreshed before treating with Fsk (50 µM) for 2h prior to 
harvesting. Cells were lysed in the absence of phosphatase inhibitors. 
Protein-equalised soluble cell extracts were divided into aliquots and then 
incubated at 37˚C for 2 h in the presence (+) or absence (−) of calf 
intestinal alkaline phosphatase (1 unit/1μg protein). Following 
phosphatase treatment, samples were resolved by 12% SDS-PAGE for 
immunoblotting with the indicated antibodies. Results representative of 
n=3 experiments. 
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4.4 Discussion 
4.4.1 Role of SOCS3 in stabilising cavin-1 
Cavin-1 is a novel SOCS3-interacting protein. Williams et al. [356] confirmed 
such interaction via co-immunoprecipitation experiments, showing a co-
expression of myc-tagged cavin-1 proteins exclusively with Flag-SOCS3, and 
also the interaction was confirmed between HA-SOCS3 and Flag-cavin-1 to 
exclude the effect of tag-mediated combination. An overexpression approach 
was exploited in the early experiments aimed to characterise cavin-1/SOCS3 
interaction. Here, I sought to define this interaction in cell systems expressing 
the endogenous protein. 
The results of this chapter have shown that SOCS3 knockout in the whole-cell 
extracts of AS-M.5 and MEFs resulted in a significant reduction of cavin-1 and 
CAV-1. Interestingly, this reduction was found in the absence of any changes 
in cavin-1 mRNA suggesting that the presence of SOCS3 stabilises cavin-1 
through an unknown mechanism. In addition, SOCS3 knockout in endothelial 
AS-M.5 cells caused a significant shortening of the half-life of cavin-1 as 
compared to WT MEFs. SOCS3 does not ubiquitinate cavin-1 but instead 
supports cavin-1. This indicates a potent SOCS3-mediated stabilisation of 
cavin-1, which contrasts the well-established destabilising effect of SOCS3 on 
its target proteins. So far, only Eps15 homology domain-containing protein 2 
(EHD2) has been shown to be a cavin-1 interacting protein despite the lack of 
a direct effect on cavin-1 turnover [168]. Therefore, it is possible that cavin-1 
becomes less susceptible to proteolysis when bound to SOCS3 which limits 
further proteolysis. Stabilising cavin-1 might potentially be critical for controlling 
inflammatory pathways involved in diabetes and cardiovascular disease. 
4.4.2 Role of cAMP elevation in cavin-1 stabilisation  
cAMP elevation has been linked with SOCS3 induction in multiple cell lines, 
including primary endothelial cells from multiple vascular beds [304], MEFs 
[404], and AS-M.5 cells [356]. Fsk-mediated cAMP elevation maintained cavin-
1 levels in SOCS3+/+ MEFs over a time period of 6 hrs and this effect was 
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diminished in SOCS3-/- MEFs (Figure 4–5), suggesting a role of SOCS3 
induction in cavin-1 stabilisation. 
Moreover, there is no evidence to suggest that cavin-1 is directly regulated by 
the cAMP/PKA pathway. Likewise, cAMP-mediated CREB ser-133 
phosphorylation may not be involved in cavin-1 phosphorylation. To the best of 
my knowledge, the role of caveolar proteins in cAMP/PKA pathway has only 
been recently reported by Kuo et al. [415] where loss of caveolae led to 
increased cAMP/PKA signalling in EC and CAV-1 was found negatively 
regulated cAMP/PKA signalling at the level or upstream of G proteins. In 
addition, the authors have revealed that CAV-1-deficient EC enhanced Fsk-
stimulated PKA CREB phosphorylation at Ser-133 and they suggested a unique 
mechanism of CAV-1-dependent regulation of cAMP/PKA signalling-mediated 
lipolysis in endothelium versus adipocytes [415]. This is consistent with the 
observed effect of cAMP elevation on CAV-1 upregulation in EC (data not 
shown). However, it seems that cavin-1 regulation is independent of the 
cAMP/PKA pathway. In sum, there may be a potential unidentified relationship 
of CAV-1 with cavin-1 following Fsk-induced cAMP/PKA signalling.  
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5  Functional investigation of cavin-1/SOCS3 
interaction 
5.1 Introduction 
The knowledge regarding the basic molecular components that contribute to 
caveolar generation is increasing remarkably. One of these components is a 
group of biomechanical integral membrane proteins, namely caveolins, that 
form distinct oligomers in the inner leaflet of the plasma membrane [114, 214, 
416]. In addition, cavin proteins that contain assembled trimeric coiled coils, 
show higher levels of solubility than caveolins [102, 145, 417]. The size and 
shape of caveolae are determined by a large 80S complex that comprises 
caveolins and cavins [122, 418], while both cavin-1 and CAV-1 are crucial for 
caveolae formation [121, 181]. Other caveolar components include Eps15 
Homology Domain (EHD) proteins, which functions at the caveolar neck [419-
421], and pacsin 2 (Syndapin 2), which is located less frequently at the neck of 
caveolae as compared to EHD [422].  
Both cavin-1 and CAV-1 have integral roles in a variety of diseases resulting 
from loss-of-function mutations as revealed in knockout mice and human 
patients. Indeed, this suggests caveolae-mediated effects on the maintenance 
and functionality of a number of cell types, including cells of the endothelium, 
muscles, and adipose tissue [112, 114, 214]. However, the mechanisms by 
which the resulting diseases take place remain fairly ununderstood. Moreover, 
caveolae are presumably involved in the modulation of a wide variety of 
signalling pathways, including signalling to regulate the activities of insulin 
receptors and eNOS [41, 423, 424]. 
Given the complicated functional aspects of caveolae in the cell (detailed in 
chapter 1 section 1.2.4), cellular response to the absence of such structures 
seems to be a plausible matter of further investigations. This would be of a 
particular importance for those cells that are mostly caveolae-dependent, such 
as endothelial cells. 
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5.1.1 Aims 
According to data presented in chapter 4, MEFs and AS-M.5 cells lacking 
SOCS3 had reduced protein expression of CAV-1 and cavin-1. As such, the 
first aim of this chapter was to investigate the potential effect of SOCS3 deletion 
on caveolae abundance in both cell lines. Moreover, to determine whether 
cavin-1 is a functionally significant SOCS3-interacting protein, we aimed to (1) 
assess subcellular localisation of SOCS3 in cavin-1-deficient MEFs and their 
wild counterparts using immunofluorescence microscopy and (2) to define the 
integrative role of cavin-1 in SOCS3 -dependent IL-6 inhibition. 
5.2 Results 
5.2.1 Effect of SOCS3 deletion on caveolae abundance 
In section 4-2, the regulatory role of SOCS3 on CAV-1 abundance was 
demonstrated via promoting cavin-1 stabilisation. SOCS3-deficient MEFs had 
reduced cavin-1 levels by 47 ± 4% and Cav-1 levels by 65 ± 7% in MEFs while 
cavin-1 and Cav-1 levels decreased by 25 ± 4% and 42 ± 7%, respectively, in 
SOCS3-null AS-M.5 cells (section 4-2). Therefore, the effect of reduced cavin-
1 and CAV-1 expression on the abundance of caveolae was investigated using 
transmission electron microscopy (TEM), which allows the assessment of 
caveolae morphology and dynamic biogenesis in SOCS3-deficient cells and 
their wild counterparts.  
TEM is utilised to directly visualise the organisation of different cellular 
components on a nanometre scale. The significant role of TEM is augmented 
when used in combination with molecular detection techniques given the 
enhanced resolution of TEM is sufficient to detect intracellular proteins in the 
respective compartments and small membrane proteins. This could be attained 
by electron-dense markers, including gold particles, which are conjugated to 
secondary antibodies. Therefore, labelling of the ultrastructural antigens in this 
technique is called immunogold EM [425]. Given that CAV-1 is a major 
structural protein (22 kDa) that can act as a biomechanical marker of caveolae 
[114] (Section 1.2.1.1), our preliminary experiments were designed to identify 
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caveolae via detection of the intracellular localisation of CAV-1 through 
immunogold staining in WT MEFs.  
As such, following their growth on 6 cm cell culture dishes, confluent cells were 
scraped off, centrifuged at 1,500g for 5 min and subsequently prepared for 
electron microscopy (section 2.2.7). The pellets were then incubated with 
polyclonal Rabbit antibodies designated to target multiple unique CAV-1 
peptides (BD Biosciences 610059) followed by incubation with gold-
nanoparticle-associated secondary antibodies directed against the primary 
antibodies. Results showed that CAV-1 proteins distributed on the cellular 
surface and other regions in WT MEFs (Figure 5–1). Despite the substantial 
visualisation of cellular content and biomolecules by immunogold EM, it may be 
regarded an extremely laborious technique that entails multiple technical 
challenges. As a result of these technical challenges, gold labelling was not 
pursued in the present work. Instead, caveolar morphology was directly 
detected on the cell surface. Morphologically, caveolae are identified as 
spherical or flask-shaped plasma membrane invaginations of notably consistent 
shape and size (∼70 nm average outer diameter). The unique omega-shaped 
Ω morphology of caveolae as well as their arrangement as single structures or 
in chains or grape-like clusters [426, 427] can be visualised under electron 
microscopy (Figure 5-1B). 
Immortalised SOCS3−/− and cavin-1−/− MEFs and the corresponding WT cell 
lines grown until confluency on Thermanox® coverslips were fixed and 
embedded in Epon (section 2.2.7). Ultrathin sections were viewed on a LEO 
912AB TEM and images were captured. The length of plasma membrane was 
calculated and the number of caveolae/µm was counted including caveolae that 
opened to the outside of the plasma membrane. Caveolae abundance was 
significantly increased in WT MEFs as compared to SOCS3-deficient cells 
(p<0.01). Interestingly, caveolae were not detectable in cavin-1 KO MEFs 
(Figure 5–2) and this was consistent with a previous evidence in the literature 
[121]. 
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Caveolae are well-known for their abundance in all cell types of the 
cardiovascular system, including cardiac myocytes, vascular smooth muscle 
cells, macrophages, and endothelial cells [428]. Therefore, the effects of 
SOCS3 deletion on caveolae abundance in the endothelial AS-M.5 cells were 
investigated in the present project. In addition, caveolae were morphologically-
characterised using TEM techniques. Results revealed that caveolae were 
detectable and abundant in WT AS-M.5 cells but, on the other hand, they were 
significantly reduced in SOCS3-deficient cells (Figure 5-3). As such, it can be 
concluded that the abundance of plasma membrane caveolae was markedly 
affected by CAV-1 and cavin-1 reduction in SOCS3-deficient cells. 
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Figure 5–1 Detection of caveolae 
(A) Immunogold labelling of caveolin-1-rich fraction examined by electron 
microscopy. WT MEFs were prepared for electron microscopy as 
described in section 2.2.7. Ultrathin sections were cut and incubated with 
anti-caveolin-1 antibody (BD Biosciences 610059) followed by incubation 
with gold-conjugated secondary antibody. Samples were imaged using a 
transmission electron microscope. (i-ii) Electron micrographs of WT MEFs 
depicting localisation of caveolin-1. The insets show the distribution of 
gold particles near the plasma membrane. Data shown were N=1. Scale 
bar =0.2µm  
(B) Caveolae are readily visualized via electron microscopy. Electron 
micrographs show typical membrane invaginations (single caveolae and 
clustered caveolae) found on the surface of (i) WT MEF and (ii) WT AS-
M.5 endothelial cell. Arrows indicate caveolae. Scale bars are (i) 0.2 µm 
and (ii) 0.5 µm.  
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Figure 5–2 Ultrastructural analysis of caveolae on the WT, SOCS3–/–
, and cavin-1–/– MEF surface. 
WT, SOCS3–/–, and cavin-1–/– MEFs grown on coverslips were fixed, 
dehydrated and embedded in Epon resin as described in Methods (2.2.7). 
Ultrathin sections were processed for TEM and imaged. (A) 
Representative electron micrographs of (i) WT, (ii) SOCS3–/– and (iii) 
Cavin-1–/– MEFs. Arrows indicate caveolae. Scale bar =0.2 μm. (B) 
Caveolae were quantitated along the plasma membrane to obtain the 
number of caveolae/µm. The length of the plasma membrane from each 
image was measured using image J. The total length measured was 550 
µm for each cell lines. Quantitation of the abundance of caveolae in MEFs 
revealed a significant reduction of caveolae in SOCS3–/– vs WT MEFs 
(**p<0.01) as well as in cavin-1–/– vs WT MEFs (****p<0.0001) using 
student’s t-test (2-tailed, un-paired). Error bars represent mean ± SEM. 
Data were from three independent experiments.   
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Figure 5–3 Ultrastructural analysis of caveolae on the WT and 
SOCS3-null AS-M.5 endothelial cell surface. 
Confluent immortalised SOCS3-null and WT AS-M.5 cells were fixed, 
dehydrated and Epon-embedded as described in Methods (2.2.7). 
Ultrathin sections were processed and then viewed under a LEO 912AB 
TEM at an accelerating voltage of 120kv. (A) Representative electron 
micrographs of WT AS-M.5 cells showing caveolae around the perimeter 
(i-iii). (B) A representative electron micrograph of caveolae on the 
SOCS3–/– AS-M.5 cell surface (i). Arrows: caveolae. Scale bar=0.5 µm. In 
the presence of SOCS3, 13 caveolae were identified on the surface of a 
single WT AS-M.5 cell, for a total length of 14µm (0.93 cav/µm) after the 
reconstruction of image stacks as depicted in (A). In contrast, only 2 
caveolae were identified from a similar length (0.14 cav/µm) on a SOCS3–
/– AS-M.5 cell surface as depicted in (B). (C) Quantitation of these 
invaginations from three independent experiments indicated that this 
phenomenon is significant (unpaired, one-tailed Student's t-test, **P < 
0.02). Data represent caveolae per µm ± SEM. 
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5.2.2 Using confocal microscopy to characterise SOCS3/cavin-
1 interaction 
Protein-protein interaction could be identified using multiple techniques yet the 
best methods are those which distil and refine such interactions. Of them, 
confocal microscopy has been established as an essential confirmatory 
technique to elucidate protein-protein interaction [429]. Hence, confocal 
microscopy was utilised to visualise SOCS3 and cavin-1 localisation in the cell 
as well as their potential co-existence.  
5.2.2.1 Optimisation of green ﬂuorescent protein (GFP)-tagged SOCS3 
To investigate protein-protein interactions using fluorescence microscopy, 
fluorophores can be utilised either directly (by using green fluorescent protein 
[GFP] or as a tag on a primary antibody) or as a tag on a secondary antibody 
(indirect) [429]. For SOCS3 localisation, three commercial anti-SOCS3 
antibodies were validated for use in a preliminary confocal-microscopy-
dependent experiment in the present thesis (data not shown). Nonetheless, the 
endogenous staining of SOCS3 in WT MEFs could not be detected over and 
above background staining in SOCS3-null MEFs. As such, a transfected 
SOCS3-GFP model was alternatively utilised. Furthermore, a titration assay 
was employed to identify the amount of SOCS3-GFP plasmid required for 
optimal expression (Figure 5–4). The Immunoblotting technique was able to 
detect SOCS3-GFP expression using anti-GFP antibodies. The amount of the 
plasmid sufficient to transiently transfect WT and cavin-1-deficient MEFs was 
estimated to be 2µg and thus SOCS3 distribution was examined by confocal 
microscopy accordingly.  
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Figure 5–4 Evaluation of the expression of GFP and SOCS3-GFP in 
WT MEFs.  
(A) WT MEFs grown on 6 cm dishes were transiently transfected with GFP 
or GFP-SOCS3 plasmids. These plasmids were titrated to detect and 
optimise GFP or GFP-SOCS3 expression for upcoming confocal 
microscopy experiments. Whole cell lysates were resolved via SDS -
PAGE and immunoblot analysis performed with anti-GFP and anti- 
GAPDH. The experiment was performed to N=1. (B) Densitometric 
intensity of GFP bands normalised to GAPDH were calculated. (C) 
Densitometric intensity of SOCS3-GFP bands normalised to GAPDH 
were calculated.  
WT MEFs plated at low density on coverslips were transiently transfected 
with 2µg GFP or SOCS3-GFP and then prepared for immunofluorescence 
(section 2.2.2). Representative confocal microscopy images show (D) a 
cell expressing GFP fluorescence (green) and (E) a cell expressing 
SOCS3-GFP (green). Scale bars: 10 µm. 
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5.2.2.2 SOCS3 localisation to plasma membrane is cavin-1-dependent  
Confocal microscopy was utilised to assess the subcellular localisation of 
endogenous cavin-1 as well as GFP and SOC3-GFP in transiently transfected 
cavin-1+/+ and cavin-1-/- MEFs. In cavin-1+/+ MEFs. Our data revealed that 
SOCS3-GFP was distributed in two subcellular pools, in the cytoplasm and in 
the plasma membrane (Figure 5–5A). Immunofluorescent staining with specific 
antibody for cavin-1 (Abcam ab48824) showed cavin-1 signal was 
predominantly localised at the rear or trailing edge of the cells as previously 
reported [430]. Interestingly, we observed co-localisation of cavin-1 and 
SOCS3-GFP exclusively at the plasma membrane and such co-localisation was 
found to be statistically significant on staining analysis by Pearson correlation 
coefficient (r2=>0.90). In contrast, in cavin-1-deficient cells, SOCS3-GFP was 
localised in an intracellular pool but not at the plasma membrane (Figure 5–5C). 
Expression of GFP solely showed a similar distribution in both WT and cavin-1-
/- MEFs while it was not co-localised with cavin-1 in WT cells (Figure 5–5D).  
Subsequently, to obtain a confirmatory evidence linking distinct localisation of 
SOCS3 at the plasma membrane to cavin-1, rescue experiments were 
performed using cavin-1-mCherry. On an immunoblot, as shown in (Figure 5-
6A), cavin-1 expression was restored in transiently transfected cavin-1–/– MEFs 
overexpressing cavin-1-mCherry cDNAs. In addition, confocal images of the 
transiently transfected cavin-1-deficient cells showed that the co-expression of 
cavin-1-mCherry and SOCS3-GFP was also restored at the plasma membrane 
(Figure 5-6B). Collectively, the results indicate that, in addition to the notable 
SOCS3/cavin-1 co-localisation, cavin-1 can be regarded a crucial determinant 
of SOCS3 localisation at the plasma membrane of intact cells. 
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Figure 5–5 Subcellular localisation of SOCS3-GFP and cavin-1 in WT 
and cavin-1-null MEFs. 
WT and cavin-1–/– MEFs differentiated on coverslips were transiently 
transfected with either SOCS3-GFP or GFP (2 µg). One day post-
transfection, cells were ﬁxed with paraformaldehyde, permeabilised, and 
labelled with anti-cavin-1 antibody (red) as described in Methods (2.2.8). 
Confocal images showing WT MEFs expressing (A) SOCS3-GFP, (B) 
GFP (green). Confocal images showing cavin-1–/– MEFs expressing (C) 
SOCS3-GFP, (D) GFP (green). The nucleus has been stained with DAPI 
(blue). Scale bar = 10 µm. (E) Pearson correlation coefficient (r2) were 
calculated from the intensity of expression of cavin-1/SOCS3-GFP at the 
plasma membrane in WT MEFs using Fiji/ImageJ software. 
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Figure 5–6 Distribution of GFP in WT and cavin-1-/- MEFs.   
(A) Lysates from cavin-1–/– MEFs transiently transfected with mCherry or 
cavin-1-mCherry (amounts are indicated) were separated by SDS-PAGE 
and subjected to immunoblot analysis using anti-cavin-1, anti-mCherry 
and GAPDH antibodies. Experiment was performed to N=1. (B) Cavin-1-
/- MEFs were transiently transfected with cavin-1-mCh for imaging by 
confocal microscopy. Data revealed colocalisation of SOCS3-GFP and 
cavin-1-mCh at the plasma membrane.  Scale bars =10 µm (Data 
presented in (B) were generated by Dr Jamie Williams, University of 
Glasgow). 
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5.2.3 Examining SOCS3 and cavin-1 in lipid rafts Isolated from 
WT and Cavin-1 KO MEFs  
To further examine whether SOCS3 recruitment to membrane fractions is 
dependent on the presence of cavin-1, a previously-utilised protocol was 
employed in the present work [115, 431]. It relies on the separation of caveolae-
containing fractions from bulk cellular proteins exploiting the low buoyant 
density and detergent resistance properties in of lipid rafts.  
cavin-1+/+ and cavin-1-/- MEFs were solubilised and centrifuged in 1% (v/v) 
Triton X-100 and a discontinuous sucrose gradient, respectively. Fsk was used 
to elevate SOCS3 levels in the cell lines. Results showed differences in the 
accumulation patterns of drug-resistant lipid rafts, including their marker flotillin-
1, where such accumulation was more apparent at the interface of the 5 and 
30% (w/v) sucrose layers than the 40% sucrose layer (Figure 5–7). In vehicle-
treated WT cell lines, higher densities showed low levels of immunoreactive 
reactions of SOCS3 and non-raft fractions were low in unstimulated cells. In 
both raft and non-raft fractions, SOCS3 levels were increased with the addition 
of Fsk (Figure 5–7A). For cavin-1, its distribution included both non-raft and raft 
fractions of low density sucrose and positive for flotillin-1 and caveolin-1. 
Notable, such distribution patterns were not affected by Fsk treatment (Figure 
5–7A). In cavin-1-deficient MEFs, Fsk treatment was also associated with 
increased SOCS3 accumulation yet, in contrast to WT cells, SOCS3 
localisation was greater in higher density fractions and rarely observed in lipid 
rafts (Figure 5–7B).  
Hence, these findings indicate SOCS3 accumulation in lipid rafts is mainly 
dependent on cavin-1 in agreement with the aforementioned confocal imaging 
results that revealed a remarkable SOCS3-GFP/cavin-1 co-localisation.  
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Figure 5–7 Localisation and expression of SOCS3 and cavin-1 in lipid 
rafts. 
(A) Fsk (50 μM) or vehicle (Veh) were added to WT MEFs for 4 hours 
followed by solubilisation in 1% (v/v) Triton X-100 for 30 mins and a 
subsequent centrifugation in a discontinuous gradient including the 
recommended (w/v) sucrose concentrations. SDS-PAGE was then used 
on equal fractions for immunoblotting with specific antibodies. P=pellet. 
(B) Fsk (50 μM, for 4 hrs) was added to cavin-1+/+ and cavin-1-/- MEFs 
followed by processing and analysis as described in (A). (Data generated 
by Dr Jamie Williams, University of Glasgow)  
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5.2.4 Characterisation the regions within SOCS3 that interact 
with cavin-1 
As previously reported (Figure 5–5), the full-length SOCS3 proteins (residues 
1-225) showed a significant interaction and co-localisation with cavin-1 at the 
plasma membrane. Subsequently, immunofluorescence imaging was used in 
this section to investigate the interactive regions in SOCS3 proteins with cavin-
1, including SH2 residues (residues 46-142) and SOCS box domains (residues 
177-225). As such, GFP-fused SOCS3 constructs, including ΔSH2 domains 
(ΔSH2) and ∆SOCS box domains (ΔSB), were utilised in this experiment. Either 
constructs were transiently transfected to WT MEFs and titrated with different 
amounts (0.5, 1, 2 and 4µg). Western blot analysis was used to quantify the 
expression of ΔSH2-GFP or ∆SB-GFP (Figure 5-8A). In transfected WT cells, 
fluorescent ΔSH2-GFP and ∆SB-GFP constructs were identified at the plasma 
membrane and intracellularly (Figure 5-8E). Furthermore, endogenous cavin-1 
was detectable at the plasma membrane of the trailing edge. Merged images 
showed a remarkable co-localisation of SOCS3ΔSH2-GFP and SOCS3∆SB-
GFP constructs with endogenous cavin-1 particularly at the plasma membrane. 
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Figure 5–8 Localisation of SOCS3 mutants in WT MEFs. 
(A) WT MEFs were transiently transfected with increasing amounts of 
SOCS3∆SH2-GFP or SOCS3∆SB-GFP cDNAs. Cell lysates were 
analysed for SOCS3 and GAPDH expression by SDS-PAGE and 
immunoblotting. Data shown were N=1. Densitometric intensity of bands 
normalised to GAPDH were calculated for (B) SOCS3∆SH2-GFP and (C) 
SOCS3∆SB-GFP. (D) A schematic diagram of SOCS3∆SH2-GFP and 
SOCS3∆SB-GFP constructs used in this experiment as well as full-length 
SOCS3-GFP. Different domains of SOCS3 were depicted, including a C-
terminal SOCS box (white), SH2 domain (dark gray), extended SH2 
subdomain (light gray), kinase inhibitory domain (black), small N-terminal 
domain (white). Residue 44-185 comprise the extended SH2 domain, 
which is interrupted by a 35 amino acid PEST motif (blue). Adapted with 
modifications from [311]. 
WT MEFs transiently transfected with either SOCS3∆SH2-GFP or 
SOCS3∆SB-GFP (2 µg) were ﬁxed with paraformaldehyde, 
permeabilised, and labelled with anti-cavin-1 antibody (red) as described 
in Methods (2.2.8). Confocal images showing WT MEFs expressing (E) 
SOCS3∆SH2-GFP, (F) SOCS3∆SB-GFP (green). The nucleus has been 
stained with DAPI (blue). Scale bar = 10 µm.   
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5.3 Investigating roles for cavin-1 in regulating pro-
inflammatory IL-6 signalling 
As previously detailed (sections 1.3, 1.4), the JAK/STAT and MAPK pathways 
are activated by most cytokines, including IL-6. Such cytokine family causes 
STAT3 activation predominantly and, to a less extent, STAT1 [432]. The 
pathways that aim to negatively regulate the JAK/STAT pathway, such as 
SOCS proteins, phosphatases, and protein inhibitors of activated STAT (PIAS), 
can thus prevent chronic inflammation [432].  
Several types of cells can secrete IL-6, including endothelial cells, keratocytes 
bone marrow cells, fibroblasts, and white blood cells [433]. This 22-28 kDa 
protein acts via a trans-signalling mechanism to regulate gp130 receptor-
mediated signalling. IL-6 and IL-6R have a high affinity to bind to gp130 
receptors via the IL-6R subunit. While gp130 is constantly expressed, IL-6R 
expression is limited to lymphocytes, hepatocytes, and leukocytes. Therefore, 
IL-R availability is crucial for IL-6 signalling. Shedding or alternate splicing could 
lead to the formation of of soluble IL-6R (sIL-6R) and subsequently mediate 
inflammatory signalling pathways (Borish and Steinke [433].   
Confocal imaging revealed a direct interaction between SOCS3 and 
endogenous cavin-1 and their co-localisation at the plasma membrane (Figure 
5–5), while in the absence of cavin-1, SOCS3 localisation was limited to the 
cytosol. Key Tyr residues are phosphorylated by cytokine-activated JAKs 
leading to the generation of a SOCS3 interaction motif and hence SOCS3 
recruitment to activated cytokine receptors takes place [323]. 
In the current experiment, the impact of cavin-1 deletion on STAT3 activation 
mediated by IL-6 was investigated in MEFs. This was performed by identifying 
Tyr705 phosphorylation which is crucial for the formation of transcriptionally-
active STAT3-derived complexes [434]. 
sIL-6Rα (25ng/ml), IL-6 (sIL-6Rα/IL-6, 5ng/ml), or a vehicle (25ng/ml) were 
added to the confluent MEFs cultures for 30 minutes and then the western blot 
showed a strong variation STAT3 phosphorylation on Tyr705 between WT and 
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cavin-1-/- MEFs (Figure 5–9A). The densitometric analysis revealed a ~3-fold 
increase of IL-6-mediated STAT3 phosphorylation on Tyr705 in cavin-1-
deficient cells as compared to WT MEFs (Figure 5–9B). 
So as to ascertain the typical role of cavin-1 in reducing such IL-6-mediated 
phosphorylation, cavin-1-/- cell lines that constitutively expressed GFP or cavin-
1-GFP were established by growing these MEFs in 6 cm dishes followed by 
transfection with a GFP plasmid or a cavin-1 plasmid tagged with GFP and then 
selected in G418. Microscopic techniques were used to visualise positive 
clones while isolation was performed by limiting dilution. Western blot was used 
to analyse the expression of cavin-1-GFP and GFP in cavin-1-/- MEFs (Figure 
5–10). The immunoblot showed that cavin-1 expression was restored in cavin-
1–/– MEFs constitutively expressing cavin-1-GFP. This cell line was successfully 
generated which could be utilised for functional investigation of the novel roles 
for cavin-1-SOCS3 interaction in regulating pro-inflammatory IL-6 signalling. To 
do this, WT and cavin-1–/– MEFs stably expressing GFP and cavin-1-GFP were 
treated with sIL-6R⍺/IL-6 trans-signalling complex. Results showed that STAT3 
phosphorylation on Tyr705 was significantly enhanced in cavin-1–/– MEFs 
expressing GFP (*** p < 0.001). Interestingly, this response was significantly 
reduced by rescuing cavin-1 expression in cavin-1–/– MEFs (*** p < 0.001) 
although it was not to the same level of WT (cavin-1+/+) MEFs (Figure 5-11).   
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Figure 5–9 Cavin-1 deletion enhances Tyr705 STAT3 
phosphorylation. 
WT (cavin-1+/+) and cavin-1−/− MEFs grown on 6 well plates were 
incubated with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for 30 min. Protein-
equalized cell lysates were then analysed by SDS-PAGE and 
immunoblotting with the indicated antibodies. Densitometric analysis for 
Tyr705 phospho-STAT3 normalized to respective total levels is presented 
as mean ±SEM for n=3 independent experiments. **P < 0.01 
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Figure 5–10 Cavin-1−/− MEFs stably expression GFP and cavin-1-
GFP. 
Cavin-1−/− MEFs seeded in 6 cm dishes were transfected with 4µg of 
either a cavin-1-GFP construct or a GFP control construct using PolyFect 
transfection reagent (Qiagen) as per manufacturer’s instructions. 
Following dilution and re-plating, cells stably expressing the constructs 
were selected by supplementing growth media with 0.5 mg/ml G418. (A) 
Detergent-soluble whole cell lysates from WT MEFs and cavin-1−/− MEF 
clones stably expressing GFP or cavin-1-GFP were separated by SDS-
PAGE and subjected to immunoblot analysis with the indicated 
antibodies. N=3. Representative images showing WT MEFs stably 
expressing (B) cavin-1-GFP or (C) GFP. Images on the left shows phase 
contrast of the same field. Scale bar = 200 µm.  
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Figure 5–11 Tyr705 phosphorylation of STAT3 is limited by cavin-1 
WT (cavin-1+/+) and cavin-1−/− MEFs stably expressing GFP or cavin-1-
GFP were treated with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for 30 min. 
Protein-equalized cell lysates were then fractionated by SDS-PAGE prior 
to immunoblotting with the indicated antibodies. Densitometric analysis for 
Tyr705 phospho-STAT3 normalized to a loading control (GAPDH). The 
mean data with SEM error bars were plotted and statistical significance 
tested using a Student’s t-test (2-tailed, un-paired) (GraphPadPrism, *** p 
< 0.001). N=3. 
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5.4 Discussion  
SOCS3 has been well-recognised for its great relevance in supressing 
downstream signalling mediated by cytokine receptors that employ the leptin 
receptor ObRb, the G-CSFR, and more importantly gp130 receptors [356]. 
However, the interaction of SOCS3 with other proteins within the cell might alter 
such inhibitory effect yet the relevant knowledge is scarce. The target proteins 
of SOCS3 for ubiquitination have been recently investigated in a study relying 
on a global proteomics approach [356]. Intriguingly, SOCS3 has been found to 
interact with cavin-1 and regulate its ubiquitination. In this chapter, the 
functional outcome of SOCS3-cavin-1 interaction was evaluated. In line with 
the significant role of direct and indirect immunofluorescence approaches in 
characterising protein-protein interactions, the microscopy techniques were 
utilised to define the mode of SOCS3/cavin-1 interaction. This chapter identified 
novel roles for SOCS3 in caveolae integrity as well as for cavin-1 in SOCS3 
recruitment to the plasma membrane. Additionally, a novel mechanism relying 
on SOCS3/cavin-1 interaction has been demonstrated to have a significant 
modulatory effect on IL-6-mediated proinflammatory signalling. Together, these 
data highlighted numerous important aspects of interaction between SOCS3 
and cavin-1 responsible for reciprocal regulation of their respective functions. 
The results in this chapter, as visualized by TEM, revealed that caveolae 
abundance has been significantly reduced in SOCS3-null MEFs and endothelial 
AS-M.5 as compared to WT cells. As such, a novel mechanism of SOCS3 
regulation has been identified in which SOCS3 can exert a regulatory role on 
cavin-1 function and stability and consequently maintain CAV-1 expression and 
caveolae. These findings were further confirmed by imaging and biochemical 
approaches. A similar caveolae-stabilising effect has been previously 
demonstrated by the Eps15 homology domain-containing protein 2 (EHD2) 
[168], which is known to function at the caveolar neck and being integrated in 
caveolae dynamics [419].  
Additionally, the present chapter showed that SOCS3/cavin-1 binding is directly 
exhibited and this plays a role in the efficient recruitment of SOCS3 to the 
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plasma membrane. In agreement with another study [430], results showed that 
cavin-1 localisation in the plasma membrane in WT MEFs was not uniformly-
distributed but rather cavin-1 is localised to the trailing edge of migrating cells 
and, notably, the same compartment of the plasma membrane was co-localised 
by a significant number of SOCS3-GFP. On the other hand, in the absence of 
cavin-1, confocal imaging showed that the distribution of SOCS3-GFP was 
chiefly intracellular while it was not detected in the plasma membrane. 
Nonetheless, SOCS3-GFP localisation at the plasma membrane was regained 
after transfection of cavin-1-deficient MEFs with cavin-1-mCherry and, again, 
both SOCS3-GFP and cavin-1-mCherry were co-localised consistently. 
Furthermore, given that cavin-1 localisation was essentially detected in 
membrane and cytoplasmic fractions as revealed by subcellular fractionation 
experiments [356], it is plausible that SOCS3 followed the same pattern of 
localisation in WT MEFs following induction by Fsk treatment for 5 h. 
Intriguingly, in the absence of cavin-1, SOCS3 distributed chiefly to the 
cytoplasm, indicating the importance of cavin-1 for the efficient localisation of 
endogenous SOCS3 to the membrane fraction. Moreover, SOCS3 deletion 
yielded a significant reduction of CAV-1 expression at the plasma membrane 
as shown by subcellular fractionation experiments. Indeed, the latter 
observation implies an indirect cavin-1-mediated role of SOCS3 in maintaining 
the expression of CAV-1. Such CAV-1 changes mediated by SOCS3 or cavin-
1 deletion were exclusive since flotillin levels were not affected by their deletion. 
Collectively, these data showed an intact co-localisation of cavin-1 and SOCS3 
at the plasma membrane, while cavin-1 is an important determinant of SOCS3 
at this site. 
SOCS3 contains a central SH2 domain flanked by a distinct N-terminal region 
and a C-terminal SOCS box. The SOCS box is a 40-residue-region that is 
involved in the degradation of target proteins [313]. The ability of the SOCS box 
region to bind elongin B and C (adaptor proteins) would subsequently lead to 
the formation of a ligase complex that involve Cul5 and Rbx2 and mediate the 
process of substrate ubiquitylation via the SH2 domain of SOCS3. Interestingly, 
SOCS3 could be associated with multiple membrane-bound receptors via the 
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SH2 domain and might have role in the regulation of their downstream signalling 
pathways [315] (detailed in section 1.4).  
In order to reveal the distinct regions in SOCS3 proteins that could be crucial 
for their interaction with cavin-1, a number of N- and C-terminal truncation 
mutants of SOCS3 has been investigated to get an insight into the important 
residues that have the ability to coimmunoprecipitate GFP-cavin-1 [356]. 
Importantly, all tested mutants showed a similar pattern of GFP-cavin-1 
coimmunoprecipitation to that of the full-length SOCS3 in WT cells. This 
indicates that SOCS3/cavin-1 binding is mediated by a specific region within 
the SH2 domain in these mutants. For further confirmation, confocal 
microscopy was used to investigate the important regions in SOCS3 proteins 
which are necessary for cavin-1/SOCS3 interaction. Results showed that the 
GFP-SOCS3∆SH2 and GFP-SOCS3 ∆SB mutants were localised within the 
cytoplasm and plasma membrane with a similar pattern of distribution to that of 
full-length SOCS3. 
It has been found that the SH2 domain of SOCS3 formed a complex with cavin-
1 at a non-pTyr location [356]. Structurally, residues 46-127 and residues 128-
142 comprise the main components of the SH2 domain of SOCS3 [311]. The 
PTyr-binding pocket located in all SH2 domains is formed partly of the β-sheet 
and α-helical regions within residues 46-127. On the other hand, residues 128–
142 comprise a part of an unstructured PEST motif which links the helix B of 
the SH2 domain with residues 166-185 (forming the BG loop and βG strand 
motifs) [311]. PEST motifs are involved in multiple functions, including protein 
turnover and protein-protein interactions [311]. To investigate the role of the 
PEST insert of the SOCS3 SH2 domain in cavin-1 interaction, 
coimmunoprecipitation experiments in transfected HEK293 cells using SOCS3 
ΔPEST mutants have been conducted, where (Gly-Ser)x4 peptides were used 
to replace the PEST motif (Pro129-Arg163). No coimmunoprecipitation could 
be observed, indicating a loss of the ability of SOCS3 ΔPEST to bind cavin-1 
[356]. Furthermore, in contrast to early overexpression experiments that tested 
the effect of the PEST sequence on SOCS3 functionality [311], the recent 
functional experiments which investigated endogenous SOCS3 signalling 
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revealed that the PEST motif of SOCS3 has an important role in cavin-1 
interaction via mediating a regulatory role on the JAK-STAT signalling pathway 
[356].    
Much data in the scientific literature demonstrate a fundamental involvement of 
caveolae in concentrating various signalling components, such as Ras, Src 
family kinases, β-arrestins, GPCRs, G proteins and downstream enzymes such 
as adenylyl cyclases (ACs) and eNOS, NOS3 [435]. Hence, caveolae are 
regarded as platforms that coordinate signalling transduction by 
compartmentalising receptors and their downstream effectors. This concept 
has been extensively validated in early experiments, in which the disruption of 
such domains via treatment of the plasma membrane with sphingomyelinases 
or changing membrane cholesterol levels could eventually lead to either 
enhancing or reducing distinct signalling events, including phospholipase D 
(PLD) activity and ERK activation, respectively [436]. 
Experiments relying on biochemical fractionation of cell extracts revealed that 
gp130 and JAK2 (specific JAK-STAT signalling components) were localised to 
lipid rafts. Nonetheless, the functional consequences seem to be dependent on 
the context given the varied effects of raft disruption (either inhibitory or 
activating) via treatment with β-cyclodextrin (a cholesterol-depleting agent) or 
homozygous deletion of caveolin-1 [356]. Other reports have exclusively tested 
the significance of caveolae for gp130 function, showing the ability of a large 
proportion of gp130 molecules, which are located in detergent-resistant lipid 
rafts, to coimmunoprecipitate with CAV-1 [437]. Additionally, gp130 could be 
redistributed to non-raft fraction on treatment with the cholesterol depleting 
agent β-cyclodextrin and this would also preclude STAT3 Tyr705 
phosphorylation by IL-6 [437]. Conversely, other reports have shown that both 
STAT3 and gp130 are localised to lipid rafts [252] and that both CAV-1 
expression and STAT3 activation are negatively correlated [438]. Hence, 
although membrane microdomains and the components of JAK-STAT 
signalling are weakly associated, the exact molecular mechanisms that drive 
such interaction still unclear.  
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The current study emphasises the significant role of cavin-1 in the SOCS3-
mediated inhibition of JAK-STAT signalling via direct binding to specific 
cytokine receptors, such as gp130 causing their inhibition. Additionally, loss of 
cavin-1 altered the inhibitory pathways that supress Tyr phosphorylation of 
STAT3 mediated by IL-6. The effect of cavin-1 deletion on the inhibitory role of 
cAMP, which has been shown to be dependent on SOCS3, was investigated in 
a recent report [356]. The authors found that treatment of WT MEFs with Fsk 
(a cAMP-elevating drug) led to a significant inhibition of IL-6-mediated STAT3 
Tyr705 phosphorylation. Moreover, cavin-1-deficient cells exhibited loss of such 
effect despite the production of equivalent SOCS3 levels in both cell lines by 
the effect of a combination of Fsk and IL-6. Therefore, it can be concluded that 
cavin-1 was indispensable for SOCS3-mediated inhibition of IL-6 signalling by 
cAMP. 
From another perspective, experimental studies in mice shown that CAV-1 
knockout resulted in a marked increase of the inflammatory cytokine (TNF-⍺, 
IL-6 and IL-12a) levels, elevation of superoxide dismutase in the lung, kidney, 
and liver, and a significant reduction of the phagocytic activity of macrophages 
[439]. In the same study, STAT3 was significantly activated. Importantly, 
despite the marked increase of SOCS3, which inversely correlates with STAT3, 
both STAT3 activation and its associated inflammatory response were not well-
controlled. Therefore, data in the present chapter provide an important 
explanatory evidence of the reasons of compromised SOCS3-mediated 
negative regulation on the inflammatory response in CAV-1 KO mice. Given the 
previously-demonstrated relevance of CAV-1 to mediating cavin-1 recruitment 
to the plasma membrane [102, 121], the present chapter showed a novel 
important mechanism by which SOCS3-mediated suppression of cytokine 
signalling is linked to plasma membrane localisation through the interaction with 
and stabilisation of cavin-1. 
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6. Final Discussion 
The pathophysiological outcomes of dysregulated gp130-mediated signalling 
on haematopoiesis, cell metabolism, inflammation and immune responses have 
been widely documented [440-442]. Thus, limiting the magnitude and duration 
of IL-6-dependent gp130/JAK/STAT signalling remains of paramount 
importance. In this regard, different mechanisms of negative regulation have 
evolved to restrict gp130-dependent intracellular signalling. Notably, SOCS3 
plays a prominent negative regulatory role by inhibiting JAK–STAT3 activation 
and targeting cytokine receptor complexes for proteasomal degradation via 
SOCS3 E3 ligase activity [443]. 
To date, several substrates, such as CD33, FAK1, Siglec7, IRS1/2, G-CSFR 
and JAK1, of the SOCS3 E3 ubiquitin ligase were identified (Section 1.4.5). Yet, 
the full spectrum of ubiquitin-regulated SOCS3 substrates remains unknown. 
Utilising an unbiased quantitative proteomics screen to identified SOCS3-
regulated proteins, Williams et al, 2018 revealed a novel and direct interaction 
between SOCS3 and the essential component of caveolae cavin-1 [356]. 
Consequently, we hypothesised that SOCS3-cavin-1 interaction is an important 
controlling element in caveolae stability and/or the pro-inflammatory signalling 
pathway mediated by IL-6 in the endothelial cells. In this study, one of the aims 
was to establish endothelial cell lines lacking SOCS3 expression via the 
CRISPR/Cas9 system. This system enabled us to investigate the effects of 
SOCS3 deletion on endogenous cavin-1 levels. The findings from this study 
demonstrated that the absence of SOCS3 increases cavin-1 turnover and 
significantly reduces both cellular levels of CAV-1 and cell surface caveolae in 
MEFs and endothelial AS-M.5 cells.  Consequently, via cavin-1 stabilisation, 
this study revealed a novel role for SOCS3 in regulating the assembly of 
caveolae. Additionally, results obtained using confocal microscopy highlighted 
the important role of cavin-1 in the recruitment of SOCS3 to the plasma 
membrane. Collectively, our data would uncover a novel mechanism by which 
the essential component of caveolae cavin-1 negatively regulates gp130-
medaited signalling through recruiting SOCS3 (Figure 6-1).  
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Figure 6–1 The proposed interaction between cavin-1 and SOCS3 to 
inhibit cytokine signalling.  
The complex of IL-6 and soluble IL-6 receptor (sIL-6R) can bind to gp130 
on endothelial cells, which subsequently induces pro-inflammatory 
cytokine trans-signalling. The signal is transmitted from the extracellular 
space into the cytoplasm. The gp130-associated JAKs are then activated, 
leading to phosphorylation of tyrosine motifs within the cytoplasmic 
domains of gp130, which recruit STAT3. Consequently, STAT proteins 
are phosphorylated, dimerised, and translocated to the nucleaus. This 
would eventually induce the expression of proinflammatory and 
prosurvival genes. Additionally, SOCS3 expression is induced as a 
negative feedback loop to suppress the signalling pathway. Intriguingly, 
SOCS3 is integrated as an essential component of the E3 ubiquitin ligase 
complex, which ubiquitinate JAK. Ultimately, the signalling cascade is 
terminated by proteasomal degradation [307]. The findings of the present 
thesis proposed a model of a direct SOCS3-cavin-1 interaction, which 
contributes to effective SOCS3 recruitment to the plasma membrane and 
its efficient binding to cytokine receptors, such as gp130 causing their 
inhibition. Reproduced with modifications from Williams et al 2018 [356].  
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6.1 Therapeutic possibilities 
6.1.1 Modulation of caveolae 
Body-fat distribution is a known risk factor for unfavourable cardiovascular 
consequences [444]. Studies have shown that the lack of cavin-1 expression in 
animal models led to loss of caveolae and the development of a lipodystrophic 
phenotype, which is characterised by glucose intolerance, hyperlipidaemia, and 
overall adiposity. Although the hyperlipidaemic phenotype was apparent in both 
cavin-1-null and CAV-1-null animals, the onset of dyslipidaemia was earlier and 
its severity was more pronounced in cavin-1-deficient models as they showed 
a complete absence of caveolae arguably in all tissues, including cardiac and 
skeletal muscles [445]. 
In human, alterations in cavin-1 protein, which result from distinct frameshift 
mutations within the exon 2 of the expressing gene, have been identified and 
were associated with muscular dystrophy, insulin resistance, and general 
lipodystrophy [44, 127, 130]. In these patients, all caveolin subtypes were 
downregulated in skeletal muscles, while surface caveolae were lacking in 
skeletal muscles [127] and patient-derived fibroblasts [44]. Since the interaction 
of cavin-1 and SOCS3 requires multiple functional regions on cavin-1 for 
optimal binding [356], it would be expected that patients with congenital 
generalised lipodystrophy, and subsequently cavin-1 mutations, would have 
impaired SOCS3-cavin-1 interactions and hence exaggerated IL-6 responses. 
In this context, cardiac-specific SOCS3 knockout in murine models has been 
associated with contractile dysfunctions along with ventricular arrhythmias 
[389]. Intriguingly, patients with dysfunctional cavin-1 proteins exhibit a wide 
variety of ventricular arrhythmias. Therefore, future investigations are needed 
to reveal the mechanism by which SOCS3 and/or cavin-1 mutations could 
contribute to specific defective regulatory pathways and hence to the incidence 
of these pathologies [356]. 
Furthermore, atherosclerosis is basically a condition that involves large conduit 
arteries and is instigated by a number of chemical, immunological, or 
mechanical risk factors which lead to endothelial activation [446]. Patients with 
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atherosclerosis usually experience a chronic damage to the endothelial lining 
associated with proliferation of smooth muscles in the vessel wall as well as 
lipid deposits formation [447]. Despite the major progress accomplished in 
understanding the pathogenesis of atherosclerosis and its relation to 
cardiovascular disease, the exact process by which an atherosclerotic plaque 
is initiated and developed remains relatively unclear [448]. For such a purpose, 
the associated risk factors have been investigated, revealing that patients with 
smoking, diabetes, obesity, hypertension, and increased plasma lipids are more 
likely to develop atherosclerosis [449]. Interestingly, the pathogenic changes 
during plaque formation are regulated by caveolae as evidenced from studies 
based on genetically-modified mice. For instance, when CAV-1-/- mice were 
cross bred with apoE-/- mice, loss of CAV-1 was associated with a significant 
downregulation of specific proatherogenic molecules and hence yielded a 
protective role against atherosclerosis [450]. The authors attributed the 
reduction in plaque formation to the significant reduction of oxidised lipids 
transcytosis, which is originally mediated by caveolae. Later on, these results 
were confirmed by Sessa’s group, where a specific endothelial re-expression 
model of CAV-1/caveolae was developed relying on the re-establishment of 
atherosclerotic lesions, validating the relevance of caveolae in atherosclerosis 
[451]. In a follow-up study, the authors evaluated CAV-1 overexpression in 
endothelial cells in transgenic mice and they found a profound atheroscelerotic 
formation and progression, supporting the role of CAV-1 in the regulation of 
atheroma development [452]. 
Based on these findings, it would be expected that the reduction of caveolae 
abundance would be of clinical potential. However, there is a remarkable 
challenging cut-off, where the plaque-limiting levels of caveolae should, on the 
other hand, maintain the normal physiologic functions of the endothelium. 
Importantly, reduction the levels of caveolae for therapeutic purposes might be 
considered based on the following observations. First, it has been shown 
previously that a 40–50% reduction of CAV-1 expression could be performed 
using HMG-CoA reductase inhibitors in endothelial cells [453], which signifies 
an additional atheroprotective role of statins rather than the well-established 
lipid-lowering actions. Second, it seems that caveolae position within the 
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endothelium and its relation to the prevailing hemodynamic patterns could be 
impactful. That is, exercise training in individuals with a high risk of 
atherosclerosis development would change flow profiles, alter caveolae levels, 
and ultimately lower the atherogenic liability in endothelial cells [446]. 
Therefore, several atherosclerosis-ameliorating approaches could be further 
uncovered and targeted accordingly. In this respect, novel drugs could be 
developed to target the newly-identified SOCS3-cavin-1 interaction to reduce 
the risk of cardiovascular disease in patients at risk as well as to maintain the 
vascular health in specific populations, such as diabetic patients. The current 
era of small-molecule immunomodulators provides promising targets for drug 
development in the future. Besides, targeted disruption of the cavin-1/SOCS3 
complex would not only refine our therapeutics, particularly with improved 
understanding of inflammation, but also would help discovering novel drugs. 
6.1.2 Regulation of JAK–STAT singnalling pathway 
Aberrant catalytic activities of JAK proteins can lead to either an increase or 
reduction of kinase activity and subsequently the development of hematological 
defects, inflammatory diseases, immunodeficiencies, autoimmune diseases, 
myeloproliferative disorders and increased susceptibility to infection. Therefore, 
in light of the plethora of studies concerning JAK-STAT signalling and its 
relevance to health and disease, it is expected that this pathway could be a 
promising drug target. Multiple mechanisms have been implicated in JAK 
dysregulation, such as somatic or inherited point mutations, gene 
translocations, receptor mutations, and changes in the activity of SOCS 
proteins or phosphatases, which are considered important JAK regulators 
[454].  
Multiple exon12 mutations in the JAK2 genes have been identified in patients 
with V617F-negative idiopathic erythrocytosis (IE) or polycythaemia vera (PV) 
[455]. The most prominent findings in these patients are low serum 
erythropoietin (EPO) levels, erythrocytosis and ligand-independent cell growth. 
In addition, the amino acids 542–543 (N542-E543del) of JAK2 are 
predominantly deleted. In the instance of JAK2V617F positivity, SOCS3-
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mediated downregulation of EPO signalling and proliferation of V617F-
expressing cells are not established.  
Furthermore, Suessmuth et al. (2009) reported a PV patient with a SOCS3F136L 
mutation (within the SH2 domain) and an additional heterozygous mutation in 
JAK2N542-E543del. In such a patient, EPO-induced proliferation was markedly 
elevated by SOCS3F136L-expressing cells, leading to a persistent 
phosphorylation of JAK2 mediated by EPO. Indeed, these results indicate that 
SOCS3 function is disrupted by the SOCS3F136L mutation, which has a robust 
clinical potential in PV [455]. Given that F136 is located within the cavin-1-
interacting domain, the PEST insert [356], such a mutation might change the 
patterns of SOC3-cavin-1 interaction and subsequently alter SOCS3-mediated 
inhibition of JAK-STAT signalling. As such, future studies are warranted to 
investigate the way by which SOCS3 and/or cavin-1 mutations can affect or 
dysregulate signalling pathways to trigger diseases. 
Moreover, SOCS3 inhibits JAK kinase activity by preventing both substrate and 
ATP binding and hence preclude IL-6-induced JAK/STAT activation [456]. The 
clinical potential of SOCS3 is increasingly appreciated given its induction by a 
number of routes as well as its direct involvement in cancer, diabetes, 
inflammation and both viral and bacterial infections [457]. In addition, it has 
been shown that the in vivo regulatory role of SOCS3 proteins is exerted on 
distinct subsets of cytokines, such as IL-6, IL-11, LIF and CNTF, as well as 
leptin, G-CSF, and IL-12 as revealed by the recently developed conditional 
deletion models and biochemical analyses methodologies (Fig. 6-2). Such 
selectivity is potentially attributable to the high affinity of SOCS3 for its 
receptors, including gp130, leptinR, IL-12Rβ, and G-CSFR [324]. Although 
several cytokines, including EPO, GM-CSF, or thrombopoietin (TPO) are able 
to utilise the JAK-STAT pathway and to induce SOCS3 expression, there is no 
evidence so far for their dysregulation in SOCS3 conditional knockout mice. 
Actually, this signifies the redundant nature of the SOCS family [324]. Thus, the 
discovery of novel proteins which have the ability to interact with SOCS3 would 
presumably reveal new biological implications of SOCS3. It is possible that 
additional proteins should be integrated as interactors to maximise the 
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regulatory roles of SOCS3. In this respect, the CUE domain-containing 2 
(CUEDC2) protein was found using a yeast two-hybrid screening to specifically 
interact with SOCS3 and this interaction is required for effective inhibition of 
JAK1/STAT3 signalling  [458]. In conclusion, SOCS3 has been implicated in 
the regulation of a variety of signalling pathways. Based on the previously-
established evidence over the past 20 years, SOCS3 regulation seems to be a 
promising therapeutic solution to treat pathogenic infections, diabetes, 
rheumatoid arthritis, and cancer. Therefore, SOCS3-cavin-1 interaction opens 
a new horizon to cytokine response and immune responses. 
 
Figure 6–2: The physiological functions of SOCS3 
SOCS3 role is mediated by direct binding to specific receptors, including 
gp130, G-CSFR, IL-12Rβ, and leptinR. The inhibitory effects of SOCS3 
on signalling pathways regulate several biological processes. Figure 
adapted from [324].  
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6.2 Limitations of the study 
The current study has some limitations worth noting. First, although SOCS3 
knockout clones were effectively produced in AS-M.5 cells as described 
(Section 2.2.9) and subsequently six knockout clones were confirmed by 
immunoblots (Figure 3-6), some variations between clones were observed 
following the induction of Nur77 in response to cAMP. Thus, PCR genotyping 
and Sanger sequencing are needed to verify efficient allelic knockout in clonal 
cell lines by identifying the CRISPR-induced alterations at the DNA level. 
Second, antibody-based detection of endogenous SOCS3 in our preliminary 
immunofluorescence experiments was challenging due to the lack of specificity 
and the immunoreactivity demonstrated in SOCS3-/- cells. Therefore, the 
expression of fluorescent protein fusions was used to investigate the subcellular 
distribution of SOCS3. 
Finally, cavin-1-/- MEFs stably expressing GFP-cavin-1 were established and 
characterised as described in (Figure 5-10). However, it is recommended to 
utilise a fluorescence-activated cell sorter (FACS) to enrich and sort the 
expressing cells in an accurate and quantitative manner for optimal clonal 
purity. 
6.3 Future work 
Targeting SOCS3-cavin-1 interaction may be exploited for desired functional 
outcomes in a diverse array of biological pathways, including IL-6, insulin, and 
eNOS. This could be approached using a combination of immunoblotting cell 
lysates with or without peptide inhibitors, which interfere with such interaction. 
In addition, experiments involving SOCS3 and cavin-1 null mice are likely to 
shed some light into pathophysiological significance of the present PhD study. 
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Appendices 
APPENDIX A: Interaction of suppressor of cytokine signalling 3 with cavin-1 
links SOCS3 function and cavin-1 stability 
 
A.1 CONTRIBUTION TO WORK 
 
The following appendix is a reprint of Williams et al. “Interaction of suppressor 
of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability”, 
published in Nature Communications volume 9, Article number: 168 (2018). 
Nasser Alotaiq is second author on this publication. His contribution to the work 
including (1) a novel tool: Establishing stable endothelial cell lines completely 
lacking SOCS3 expression via CRISPR/Cas system, (2) novel data generated 
by confocal microscopy and transmission electron microscopy. 
 
A.2 REPRINT OF “Interaction of suppressor of cytokine signalling 3 with cavin-
1 links SOCS3 function and cavin-1 stability”  
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Interaction of suppressor of cytokine signalling 3
with cavin-1 links SOCS3 function and cavin-1
stability
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Effective suppression of JAK–STAT signalling by the inducible inhibitor “suppressor of
cytokine signalling 3” (SOCS3) is essential for limiting signalling from cytokine receptors.
Here we show that cavin-1, a component of caveolae, is a functionally signiﬁcant SOCS3-
interacting protein. Biochemical and confocal imaging demonstrate that SOCS3 localisation to
the plasma membrane requires cavin-1. SOCS3 is also critical for cavin-1 stabilisation, such
that deletion of SOCS3 reduces the expression of cavin-1 and caveolin-1 proteins, thereby
reducing caveola abundance in endothelial cells. Moreover, the interaction of cavin-1 and
SOCS3 is essential for SOCS3 function, as loss of cavin-1 enhances cytokine-stimulated
STAT3 phosphorylation and abolishes SOCS3-dependent inhibition of IL-6 signalling by cyclic
AMP. Together, these ﬁndings reveal a new functionally important mechanism linking
SOCS3-mediated inhibition of cytokine signalling to localisation at the plasma membrane via
interaction with and stabilisation of cavin-1.
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Cytokines control many important biological responses,including haematopoiesis, T-cell differentiation andexpansion, and inﬂammatory status1,2. Multiple tempo-
rally distinct inhibitory mechanisms operate to ensure signalling
responses downstream of activated cytokine receptors are tran-
sient in nature. Therefore, sustained pathway activation perpe-
tuates chronic inﬂammatory conditions such as rheumatoid
arthritis and colitis, haematological malignancies such as poly-
cythemia vera, and also solid tumour development3–5.
Several cytokine receptors, including gp130 (the signal trans-
ducing component of the interleukin-6 (IL-6) signalling com-
plex), activate receptor-associated Janus kinases (JAKs) which
then trigger receptor engagement with proteins such as signal
transducer and activators of transcription (STATs), particularly
STAT3. Phosphorylated STATs can then dimerise and translocate
to the nucleus, where they function as transcription factors by
binding to speciﬁc promoter elements and recruiting transcrip-
tional co-activators1,2.
“Suppressors of cytokine signalling” (SOCS) proteins comprise
a family of eight related members (cytokine-inducible SH2-
containing protein (CIS), SOCS1–7) identiﬁed initially by their
role as cytokine-inducible negative feedback inhibitors of signal
propagation from speciﬁc cytokine receptors6. SOCS3 is recruited
to activated cytokine receptors following the formation of a
SOCS3 interaction motif upon phosphorylation of key Tyr resi-
dues by cytokine-activated JAKs. SOCS3 terminates signalling
from gp130 by binding via a central SH2 domain to PTyr759,
allowing it to interact with and inhibit adjacent receptor-bound
JAKs via its kinase inhibitory region (KIR) thereby preventing the
recruitment and tyrosine phosphorylation of STATs7. The C-
terminal SOCS box domain directs SH2 domain-bound inter-
acting proteins for ubiquitylation due to its ability to bind elongin
B and C, Cullin family member Cul5, and RING (Really Inter-
esting New Gene) ﬁnger protein Rbx27. Following SOCS3-
dependent ubiquitylation, targets such as FAK1 can be degraded
either by the proteasome8,9 or, in the case of the granulocyte
colony-stimulating factor receptor (G-CSFR), by trafﬁcking into
lysosomal compartments following internalisation10. However,
despite advances in our molecular understanding of how SOCS3
interacts with cytokine receptors and JAKs, the extent to which
other cellular proteins regulate SOCS3 function is unclear.
Recently, CUE domain-containing 2 (CUEDC2) was identiﬁed as
a novel SOCS3-interacting protein that could enhance its inter-
action with elongin C11. Such observations raise the possibility
that additional protein interactors may be required to maximise
the ability of SOCS3 to regulate signalling.
Cavin-1 (alternatively known as polymerase I and transcript
release factor (PTRF)) is an abundant component of caveolae,
which function as specialised lipid raft microdomains within the
plasma membrane. Caveolae were ﬁrst identiﬁed by electron
microscopy as 50–100 nm ﬂask-shaped plasma membrane inva-
ginations12 and are now known to play critical roles in controlling
endocytosis, sphingolipid metabolism, and compartmentalisation
of signalling pathways13. Cavin-1, which is one of a family of four
related proteins (cavins 1 to 4), is recruited by one or more
“caveolin” proteins (caveolins 1 to 3) to the plasma membrane
during the latter stages of caveola biogenesis, and is thought to be
essential for caveola formation by stabilising caveolin proteins at
the plasma membrane14.
While some studies have demonstrated localisation of cytokine
receptors and JAKs in lipid raft microdomains15–18, little is
known about the impact of caveolin expression/function on
JAK–STAT signalling and no studies have speciﬁcally examined a
role for cavins. In this study, we identify a novel interaction
between SOCS3 and cavin-1. This interaction is not only required
for optimal SOCS3-mediated inhibition of IL-6-mediated
JAK–STAT signalling but also for effective stabilisation of
cavin-1 and hence caveolin-1. Therefore, our ﬁndings deﬁne a
new relationship between SOCS3 and cavin-1 in which each
partner plays previously unappreciated roles in maintaining
effective inhibition of JAK–STAT signalling (cavin-1), cavin-1
expression, and caveola stability (SOCS3).
Results
Cavin-1 as a SOCS3-regulated ubiquitylated protein. As well as
inhibiting cytokine receptor signalling by inhibiting the Tyr
kinase activity of receptor-bound JAKs19, SOCS3 can also control
the stability of SH2 domain-bound proteins as part of an elongin/
cullin/SOCS3 (ECSSOCS3) E3 ubiquitin ligase complex6,7,20.
While several ubiquitinated substrates of SOCS3 are known, the
full spectrum has yet to be identiﬁed. Thus, we pursued an
experimental approach to elaborate on SOCS3 function by
investigating SOCS3-regulated proteins. Since there is no con-
sensus sequence for ubiquitylation, we used a stable isotopic
labelling of amino acids in cell culture (SILAC)/mass spectro-
metry approach to compare ubiquitinomes from wild-type SOCS3
+/+ (WT) and SOCS3−/− murine embryonic ﬁbroblast (MEF) cell
lines expressing equivalent levels of a tandem afﬁnity
puriﬁcation-compatible tagged ubiquitin transgene following
SOCS3 induction (Supplementary Fig. 1). Using this approach,
ubiquitylated proteins regulated by SOCS3 would be predicted to
be enriched in WT but not SOCS3−/− MEFs.
A ubiquitin transgene containing a tandem hexahistidine and
biotin tag (HB-Ub) was used to allow two-step tandem afﬁnity
puriﬁcation of the ubiquitinome via sequential Ni-NTA and
streptavidin afﬁnity chromatography under fully denaturing
conditions necessary to inactivate deubiquitinases and prevent
co-puriﬁcation of non-covalently interacting ubiquitin-binding
proteins21,22. Stable HB-Ub-expressing WT and SOCS3−/− MEFs
were generated via retrovirus-mediated gene transfer and assessed
by immunoblotting for equivalent expression levels of the HB-Ub
transgene. SOCS3 was induced by elevation of intracellular cyclic
adenosine monophosphate (cAMP) levels with forskolin (50 μM),
a direct activator of adenylyl cyclase. To increase the probability
of detecting proteins whose ubiquitylation was SOCS3 dependent,
protein tyrosine phosphatases were inhibited using a combination
of sodium orthovanadate and H2O2 to preserve the PTyr status of
potential substrates and maximise interaction with the SOCS3
SH2 domain23, while the ubiquitinome was preserved using
proteasome inhibitor MG132. Tandem afﬁnity-puriﬁed ubiquiti-
nomes from WT and SOCS3−/− MEFs were then analysed using
an Orbitrap Velos FTMS and data processed using the MaxQuant
computational platform24 (170). Under these conditions, Max-
Quant detected cavin-1 (O54724) with a log2(normalised H L−1)
= 1.37 (5 unique peptides, count ratio of 6). This suggested
that cavin-1 was a ubiquitylated protein speciﬁcally depleted in
SOCS3−/− MEFs.
SOCS3 enhances cavin-1 stability. Our proteomics screen sug-
gested that SOCS3 regulates cavin-1 stability. To examine this, we
compared the ability of increasing levels of SOCS3 to trigger the
proteasomal degradation of co-transfected cavin-1 and FAK1, a
previously characterised substrate of ECSSOCS38,9. Consistent
with previous work, increased SOCS3 expression triggered a
decrease in FAK1 levels that could be rescued by inclusion of
proteasome inhibitor MG132. In contrast, levels of cavin-1 were
not altered even at the highest level of SOCS3 expression and
were not increased by proteasome inhibitor MG132 (Fig. 1a). To
determine whether SOCS3 could regulate levels of endogenous
cavin-1, we assessed the effects of SOCS3 deletion on cavin-1
expression levels in MEFs. Immunoblotting of whole-cell extracts
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revealed that levels of cavin-1 protein were signiﬁcantly reduced
in SOCS3−/− MEFs versus WT cells. This reduction occurred
under conditions in which cavin-1 mRNA levels were sig-
niﬁcantly increased in SOCS3−/− MEFs versus WT cells (Fig. 1b,
c). The decrease in cavin-1 protein was paralleled by a similar
decrease in caveolin-1 expression levels (Fig. 1b), which is con-
sistent with previous studies showing that loss of cavin-1 triggers
reductions in all three caveolin isoforms14. We then measured the
half-lives of cavin-1 protein in WT and SOCS3−/− MEFs by
monitoring time-dependent changes in cavin-1 expression in
whole-cell extracts following inhibition of protein synthesis with
emetine25. For these experiments, cells were also pre-treated with
forskolin (Fsk) to elevate cAMP levels and increase SOCS3
expression in WT MEFs26,27 Direct comparison of cavin-1
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Fig. 1 Cavin-1 stability is enhanced in the presence of SOCS3. a HEK293 cells co-transfected with ﬁxed amounts of either myc-tagged FAK1 or GFP-cavin-1
expression constructs and increasing levels of Flag-SOCS3 were treated with or without proteasome inhibitor MG132 (6 μM) as indicated. Detergent-
soluble whole-cell lysates were analysed by SDS-PAGE and immunoblotting. b Detergent-soluble whole-cell lysates prepared from SOCS3+/+ (+/+) and
SOCS3−/− (−/−) MEFs equalised for protein content were analysed by SDS-PAGE and immunoblotting. c Quantitative real-time PCR of cavin-1 mRNA
levels in WT (SOCS3+/+) and SOCS3−/−MEFs. Data are presented as mean± standard error for N= 3 experiments. d Upper: Protein-equalised soluble cell
extracts from SOCS3+/+ and SOCS3−/−MEFs chased for the indicated times in serum-free medium with protein synthesis inhibitor emetine (100 μM) were
analysed by SDS-PAGE and immunoblotting with the indicated antibodies. Lower: Quantitation of cavin-1 levels in SOCS3+/+ and SOCS3−/− MEFs is also
shown. Results are presented as mean values± standard error for N= 3 experiments. *P< 0.05 vs. corresponding treatment in SOCS3+/+MEFs, ψP< 0.05
vs. t= 0
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human angiosarcoma-derived ECs treated with either vehicle or 50 μM Fsk for 5 h were equalised for protein content for SDS-PAGE for immunoblotting
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cells as indicated. Cell surface caveolae (indicated by the arrows) were readily detectable in WT cells (left panel). In contrast, plasma membranes from
SOCS3-null cells were ﬂat and caveolae density was signiﬁcantly reduced compared to WT cells (right panel). Scale bar= 0.5 μm. c Quantitation of caveola
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stability in WT versus SOCS3−/− MEFs demonstrated that the
absence of SOCS3 signiﬁcantly reduced the half-life from >8 h
(WT MEFs) to 2 h (SOCS3−/− MEFs: Fig. 1d). Thus, in contrast
to the well-deﬁned role of SOCS3 in destabilising target proteins
by targeting them for ubiquitylation and proteasomal degrada-
tion, the presence of SOCS3 stabilised cavin-1.
Effect of SOCS3 deletion on caveola abundance. Our data thus
far suggested that SOCS3 was an important regulator of caveolin-
1 abundance via stabilisation of cavin-1. Homozygous deletion of
the cavin-1 gene in mice results in marked reductions in the
expression of all caveolin isoforms and a lack of detectable
caveolae in multiple cell types, including endothelial cells (ECs) in
which caveolae are especially abundant14.
To examine the impact of SOCS3 on caveola abundance,
clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 technology was used to generate SOCS3-null
AS-M.5 human angiosarcoma-derived immortalised ECs28.
Treatment of WT AS-M.5 cells with cAMP-elevating agent Fsk
was able to promote SOCS3 induction similar to that observed in
MEFs and primary EC lines as previously reported26,27 However,
this effect was lost in SOCS3-null AS-M.5 cells, while Nur77, a
well-characterised cAMP-inducible gene product29, was detect-
able in both WT and SOCS3-null AS-M.5 cells following Fsk
treatment (Fig. 2a, Supplementary Fig. 2). Similar to MEFs
(Fig. 1b), SOCS3 deletion signiﬁcantly reduced cavin-1 and
caveolin-1 protein levels in AS-M.5 whole-cell extracts (Fig. 2a),
demonstrating that this effect is independent of the cell system
being investigated.
We then used transmission electron microscopy (TEM) to
assess any consequences of the observed changes in cavin-1 and
caveolin-1 expression on the abundance of cell surface caveolae.
Caveolae were readily detectable in WT AS-M.5 cells as plasma
membrane-localised ﬂask-shaped invaginations ranging from 50
to 100 nm in diameter (Fig. 2b). In contrast, these were barely
detectable in SOCS3-null cells (Fig. 2b, c). Therefore, signiﬁcant
reductions in cavin-1 and caveolin-1 protein levels triggered by
the loss of SOCS3 in endothelial cells are translated into
signiﬁcantly reduced numbers of cell surface caveolae.
Cavin-1 interacts with SOCS3 via a SH2 domain PEST
sequence. To assess whether SOCS3 could directly interact with
cavin-1, co-immunoprecipitation (co-IP) experiments were per-
formed in lysates isolated from transfected HEK293 cells tran-
siently expressing Flag-SOCS3 and myc-cavin-1. These
experiments demonstrated that myc-cavin-1 was present in anti-
Flag antibody immunoprecipitates only when co-expressed with
Flag-SOCS3, indicating the two proteins formed a complex
(Fig. 3a). Similar results were obtained using Flag-cavin-1 and
HA-SOCS3 (Supplementary Fig. 3), indicating that the effect was
independent of the combination of tags used. Analysis of lysates
and unbound samples from the experiments demonstrated that
under conditions in which SOCS3 could be fully precipitated
from lysates, a proportion of cavin-1 remained unbound, sug-
gesting that not all available cavin-1 could interact with SOCS3
under these condition (Supplementary Fig. 4). To assess the
interaction of endogenously expressed SOCS3 and cavin-1, WT
and SOCS3-null AS-M.5 cells were stimulated with Fsk prior to
IP of cavin-1 and analysis by immunoblotting. These experiments
demonstrated that immunoreactive SOCS3 was speciﬁcally enri-
ched in cavin-1 IPs from WT AS-M.5 cells (Fig. 3b), consistent
with the co-IP data from experiments using transfected cells
(Fig. 3a).
To identify the regions within SOCS3 that are important for
SOCS3/cavin-1 interaction, we initially utilised a panel of Flag-
tagged N- and C-terminal SOCS3 truncation mutants30,31 for
their ability to co-IP green ﬂuorescent protein (GFP)-tagged
cavin-132 as compared to WT SOCS3. Interestingly, all of the
truncation mutants tested were able to co-IP GFP-cavin-1 to the
same extent as full-length WT SOCS3 (Fig. 3c), suggesting that a
region within the SH2 domain present in each of the mutants was
necessary for SOCS3 binding to cavin-1. To test this, we
expressed full-length SOCS3 (residues 1–225) and the region of
the SOCS3 SH2 domain (residues 46–142, termed SOCS3 ΔSH2)
required for cavin-1 binding (Fig. 3d) as GFP-tagged fusion
proteins and compared their ability to co-IP myc-tagged cavin-1
in transfected HEK293 cells. As a negative control, we used a GFP
fusion protein containing residues 177–225 of the SOCS box that
we identiﬁed as dispensable for cavin-1 interaction (Fig. 3c).
Similar to WT SOCS3-GFP, SOCS3 ΔSH2-GFP was able to co-IP
myc-tagged cavin-1 above the non-speciﬁc levels observed with
the SOCS3 SOCS box-GFP fusion and cavin-1 alone, albeit not to
the same extent as WT SOCS3-GFP (Fig. 3d, lane 2 versus lane 8).
Therefore, these data showed that residues 46–142 within the
SOCS3 SH2 domain were both necessary and sufﬁcient for
SOCS3 interaction with cavin-1.
As many SOCS3 binding partners, including gp130, CD33 and
FAK1, must be Tyr phosphorylated in order to interact with
SOCS3, we pursued three experimental approaches to examine
whether or not the PTyr-binding pocket within the SOCS3 SH2
domain was required for interaction with cavin-1. First, we
treated transfected HEK293 cells with protein Tyr phosphatase
inhibitor sodium orthovanadate in the presence or absence of
hydrogen peroxide23. These experiments demonstrated that the
isolation of GFP-cavin-1 in anti-Flag (SOCS3) immunoprecipi-
tates was not altered by increases in global Tyr phosphorylation
levels (Fig. 4a), suggesting that cavin-1 formed a complex with
SOCS3 via a mechanism that did not require prior Tyr
phosphorylation. Secondly, we tested R71K-mutated SOCS3, in
which the conserved PTyr binding site within the SOCS3 SH2
domain is disrupted30,31, for its ability to form a complex with
cavin-1. Co-IP assays revealed that a R71K-mutated SOCS3
bound cavin-1 equivalently to WT SOCS3 (Fig. 4b), again
supporting the concept that cavin-1 interacted with the SOCS3
SH2 domain in a manner independent of its capacity to bind Tyr-
phosphorylated ligands. Finally, N-terminally biotinylated pep-
tides encompassing the Tyr759 motif of gp130 in phosphorylated
(PTyr759 peptide) and non-phosphorylated (Tyr759 peptide)
forms were used as bait to test the effect of cavin-1 co-expression
on the ability of SOCS3 to be precipitated in peptide pull-down
assays. As reported by others30, SOCS3 speciﬁcally associated
with the PTyr759 peptide under these conditions. Using a
maximally effective concentration of peptide (100 nM), co-
expression with cavin-1 did not reduce the ability of SOCS3 to
precipitate with PTyr759 peptide (Fig. 4c). Taken together, these
data demonstrated that cavin-1 interacted with the SOCS3 SH2
domain at a location distinct from the well-deﬁned PTyr-binding
pocket.
The region of the SOCS3 SH2 domain identiﬁed in the studies
above consists of two structurally distinct components. Firstly,
residues 46–127 comprise of β-sheet and α-helical regions that
form part of the PTyr-binding pocket common to all SH2
domains. Secondly, residues 128–142 form part of an unstruc-
tured PEST sequence insert that links the SH2 domain helix B
with BG loop and βG strand motifs (residues 166–185)33. PEST
motifs are unstructured hypermobile regions that have roles in
multiple cellular processes by controlling protein–protein inter-
actions and protein turnover34,35. We noted the presence of a
PEST sequence within the classic SH2 domain structure is also
displayed by CIS but none of the other SOCS family proteins33.
Having excluded the PTyr-binding functionality for SH2 domain
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interaction with cavin-1, we next examined whether the PEST
sequence insert was involved. To do this, we utilised a ΔPEST
SOCS3 deletion mutant in which the PEST motif (Pro129-
Arg163) was removed and replaced with (Gly-Ser)x436. ΔPEST
SOCS3 was expressed at comparable levels to WT SOCS3 in
transfected HEK293 cells and, consistent with previously
published work33, replacement of the PEST sequence did not
diminish speciﬁc interaction with PTyr759 peptide as determined
by in vitro peptide pull-down assays (Fig. 5a). In contrast, the
ability of ΔPEST SOCS3 to bind cavin-1 in co-IP experiments
was almost completely lost (Fig. 5b), thus demonstrating that the
SOCS3 SH2 domain PEST insert was speciﬁcally required for
cavin-1 interaction. Additional co-IP experiments using CIS,
which also has a PEST insert in its SH2 domain, revealed that it
was also able to form a complex with cavin-1 in co-transfected
cells (Fig. 5c). Next we sought to determine whether the SOCS3
a
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PEST sequence was sufﬁcient to confer interaction with cavin-1.
Bioinformatic analysis using ePESTﬁnd (http://emboss.
bioinformatics.nl/cgi-bin/emboss/epestﬁnd) identiﬁed human
Grap2 as a candidate SH2 domain-containing protein that lacked
a detectable PEST sequence. In addition, Grap2 was unable to
form a complex with cavin-1 upon co-expression in transfected
HEK293 cells (Fig. 5d). Therefore, Pro129-Arg163 from SOCS3
was transplanted onto the central Grap2 SH2 domain and the
resulting chimera (Grap2-S3PEST) assessed for its ability to form
a complex with co-expressed cavin-1 in transfected HEK293 cells.
These experiments demonstrated that insertion of SOCS3 PEST
sequence was sufﬁcient to confer an ability to bind cavin-1 on the
resulting Grap2-S3PEST chimera, albeit to a much weaker extent
than WT SOCS3 (Fig. 5d).
Multiple cavin-1 regions required for SOCS3 interaction. To
examine whether SOCS3 interacts directly with cavin-1, peptide
arrays of overlapping 25-mer peptides sequentially shifted by ﬁve
amino acids and spanning the full-length cavin-1 open reading
frame were overlaid with puriﬁed recombinant SOCS3 and
visualised by probing with anti-SOCS3 antibodies (Fig. 6a). Dark
spots represent positive areas of SOCS3 interaction. Using this
approach we found that SOCS3 could interact strongly with two
distinct regions spanning >70 amino acids within the cavin-1
open reading frame: an N-terminal region spanning residues
75–152 and a C-terminal region encompassing residues 200–295.
To validate the importance of these regions in controlling inter-
action with SOCS3 in intact cells, we generated a panel of myc
epitope-tagged N- and C-terminal truncation mutants of cavin-1
(Fig. 6b) and tested their ability to co-IP Flag-SOCS3 upon co-
expression in transfected HEK293 cells. All the truncated cavin-1
mutants expressed comparably to WT cavin-1 except for the C1
construct encoding residues 1–75 (Fig. 6c). These experiments
demonstrated that, compared with WT cavin-1, each of the N-
terminal and C-terminal truncation mutants was compromised in
its capacity to co-IP with SOCS3. In conjunction with data from
the peptide array experiments, our ﬁndings demonstrate that
multiple SOCS3 binding interfaces within cavin-1 were required
for optimal interaction with SOCS3.
Cavin-1 promotes SOCS3 localisation to the plasma mem-
brane. Cavin-1 is required for stabilisation and maturation of
caveolae at the plasma membrane, although it is also present with
caveolin-1 in non-lipid raft fractions37. SOCS3 is thought to be
a
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recruited to activated cytokine receptors at the plasma membrane
following the formation of a SOCS3 interaction motif upon
phosphorylation of key Tyr residues by cytokine-activated
JAKs19. Therefore, to examine a role for cavin-1 in controlling
SOCS3 localisation, we used confocal microscopy to assess the
effect of cavin-1 deletion on the subcellular distribution of a
SOCS3-GFP fusion protein expressed in transfected cells plated at
low density. A transfected SOCS3-GFP construct was used for
these experiments as we failed to speciﬁcally detect endogenous
SOCS3 staining in WT MEFs over and above background
staining in SOCS3−/− MEFs in confocal imaging experiments
using three separate commercially available antibodies. In trans-
fected WT MEFs, two populations of SOCS3-GFP-derived
ﬂuorescence were detectable: a punctate intracellular pool and a
plasma membrane-localised pool (Fig. 7a). Endogenous cavin-1
was localised predominantly at the plasma membrane of the
trailing edge of the cells as described by others38. Merging of the
images revealed co-localisation of SOCS3-GFP and cavin-1 spe-
ciﬁcally at the plasma membrane (Fig. 7a). Analysis of SOCS3-
GFP/cavin-1 staining produced Pearson's correlation coefﬁcient
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values of >0.90 at the plasma membrane, indicative of a high
degree of co-localisation (Fig. 7b). Conversely, in cavin-1−/−
MEFs SOCS3-GFP was undetectable at the plasma membrane
and only present within a punctate intracellular pool (Fig. 7a).
Importantly, transient co-expression of SOCS3-GFP with co-
transfected cavin-1-mCherry into cavin-1−/− MEFs was able to
restore their co-localisation at the plasma membrane (Fig. 7c).
Expression of GFP alone in WT MEFs did not produce any
detectable co-localisation with cavin-1, and its distribution was
similar in both WT and cavin-1−/− MEFs (Supplementary
Fig. 5A, B).
Additionally, subcellular fractionation experiments demon-
strated that cavin-1 was mainly present in membrane and
cytoplasmic fractions. This mirrored the subcellular distribution
of SOCS3 in WT MEFs following induction by Fsk treatment for
5 h. Interestingly, cavin-1 deletion shifted the distribution of
SOCS3 predominantly to the cytoplasm (Fig. 7d). Thus, the
presence of cavin-1 was important for localising endogenous
SOCS3 to the membrane fraction, consistent with our confocal
imaging experiments using SOCS3-GFP (Fig. 7a–c). Subcellular
fractionation experiments also demonstrated that SOCS3 deletion
produced a comparable reduction in caveolin-1 expression at the
membrane as deletion of cavin-1, indicative of an indirect role for
SOCS3 in maintaining caveolin-1 expression via stabilisation of
cavin-1 (Fig. 7d). This change was speciﬁc for caveolin-1 as levels
of the membrane marker ﬂotillin were unaffected by deletion of
either SOCS3 or cavin-1 (Fig. 7d). Therefore, together these data
indicate that cavin-1 co-localised with a plasma membrane pool
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of SOCS3 in intact cells and was an important determinant of
SOCS3 localisation to the plasma membrane.
Cavin-1 limits IL-6-stimulated Tyr705 STAT3 phosphoryla-
tion. While some studies have demonstrated localisation of
cytokine receptors and JAKs in lipid raft microdomains15–18,
relatively little is known about the impact of caveolin expression/
function on JAK–STAT signalling and no studies have speciﬁcally
examined a role for cavins. Our data suggested that cavin-1 and
SOCS3 interacted directly and co-localised at the plasma mem-
brane, while SOCS3 was mainly cytosolic in the absence of cavin-
1. To examine any functional impact of cavin-1 on cytokine
signalling, we examined the effects of cavin-1 deletion in MEFs on
IL-6-mediated activation of STAT3, as determined by phos-
phorylation at Tyr705 which is required for STAT3 to form
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transcriptionally active complexes39. While stimulation of both
WT and cavin-1−/− MEFs with a sIL-6Rα/IL-6 trans-signalling
complex triggered a transient increase in STAT3 phosphorylation
on Tyr705, the response was greater and more sustained in cavin-
1−/− MEFs, being detectable at the 60 and 120 min time points in
cavin-1−/− but less pronounced in WT cells (Fig. 8a). Interest-
ingly, Tyr705 phosphorylation was speciﬁcally enhanced as
STAT3 phosphorylation on Ser727 (which is mediated by several
candidate Ser/Thr kinases40) was unaffected by cavin-1 deletion.
Moreover, the increase in IL-6 signalling occurred despite
reduced levels of JAK1 in cavin-1−/− MEFs, although this
reduction did not reach statistical signiﬁcance (Fig. 8a). Other
cytokine receptor complexes that utilise gp130 include those for
leukaemia inhibitory factor (LIF) and oncostatin M (OSM): LIF
signals via gp130/LIF receptor (LIFR) heterodimers, while OSM
signals downstream using either LIFR/gp130 or OSM receptor/
gp130 complexes41. As observed with sIL-6Rα/IL-6, Tyr705
phosphorylation of STAT3 in response to either LIF or OSM was
greater in cavin-1−/− versus WT MEFs at 60 min (Fig. 8b). Taken
together, these data suggested that loss of cavin-1 compromised
one or more inhibitory mechanisms responsible for suppressing
gp130- and JAK-mediated Tyr phosphorylation of STAT3.
Previous studies have demonstrated that depletion or loss of
SOCS3 results in prolonged activation of STAT3 in response to
speciﬁc cytokines42–44, similar to the effect observed upon cavin-1
deletion. We have shown previously that the ability of cAMP to
inhibit IL-6 signalling in vascular ECs, MEFs, and COS cells has
an absolute requirement for Epac1-dependent induction of
SOCS326,27,45. Given the importance of cavin-1 in localising
SOCS3 to the plasma membrane and the sustained phosphoryla-
tion of STAT3 on Tyr705 observed following sIL-6Rα/IL-
6 stimulation of cavin-1−/− MEFs, we examined the impact of
cavin-1 deletion on the inhibitory effect of cAMP which has
previously been shown to be SOCS3 dependent26,45. These
experiments demonstrated that while pre-treatment of WT MEFs
with cAMP-elevating drug Fsk (50 μM) signiﬁcantly inhibited
sIL-6Rα/IL-6-stimulated Tyr705 phosphorylation of STAT3, this
effect was lost in cavin-1−/− MEFs even though Fsk in
combination with sIL-6Rα/IL-6 produced equivalent levels of
SOCS3 in WT and cavin-1−/− MEFs (Fig. 8c). These results also
did not reﬂect a non-speciﬁc reduction in cAMP responsiveness
following loss of cavin-1 as Fsk could trigger the accumulation of
cAMP target gene Nur77 equivalently in both WT and cavin-1−/−
MEFs (Supplementary Fig. 6). Therefore, the presence of cavin-1
was necessary for SOCS3-mediated inhibition of IL-6 signalling
by cAMP.
Discussion
The importance of SOCS3 in limiting downstream signalling
from cytokine receptor complexes that utilise gp130, as well as the
leptin receptor ObRb and the G-CSFR, is well established6,7
However, relatively little is known about how SOCS3 interaction
with other intracellular proteins can impact on its ability to
inhibit signalling. As part of a study to identify SOCS3-regulated
substrates, we performed “stable isotopic labelling of amino acids
in cell culture” (SILAC) analysis of ubiquitinome proﬁles in WT
and SOCS3−/− MEFs stably expressing a tandem afﬁnity pur-
iﬁcation (TAP)-tagged ubiquitin transgene46. Using this
approach, the caveola scaffolding protein cavin-1 was identiﬁed as
a ubiquitinated protein whose levels were stabilised in WT cells.
We have demonstrated that cavin-1 can interact with SOCS3 and
that the absence of SOCS3 results in increased turnover of cavin-1
and a parallel reduction in cellular levels of caveolin-1 and cell
surface caveloae. We have also demonstrated that cavin-1 is
important for effective SOCS3-mediated suppression of
JAK–STAT signalling in response to sIL-6Rα/IL-6 trans-signal-
ling complexes.
The importance of caveolae and other lipid raft microdomains
for maintaining signalling from the plasma membrane has been
demonstrated for a variety of systems, including endothelial nitric
oxide synthase and Src47,48. In comparison, relatively little
information is available on how they regulate JAK–STAT path-
way activation. Localisation of JAK–STAT signalling components,
including gp130, receptors for growth hormone, ciliary neuro-
trophic factor and LIF, and JAK2 to lipid rafts has been deter-
mined by biochemical fractionation of cell extracts15–18,49–52.
However, the functional consequences appear to be context
dependent, such that raft disruption by treatment with
cholesterol-depleting agents like β-cyclodextrin or homozygous
deletion of caveolin-1 can either inhibit15,16,49 or enhance52,53
downstream signalling. Thus, Lisanti and colleagues52 have
examined the effects of manipulating caveolin-1, and demon-
strated that caveolin-1 can suppress prolactin receptor-mediated
JAK2-dependent phosphorylation and activation of STAT5a in
murine mammary epithelial cells in vitro, consistent with
observations that caveolin-1 deletion in vivo enhances prolactin
receptor signalling53. The mechanism proposed was via a direct
interaction between caveolin-1 and JAK2, although no evidence
of a direct effect of caveolin-1 on JAK2 Tyr kinase activity was
presented52. Other studies have speciﬁcally examined the
importance of caveolae for gp130 function, demonstrating that a
signiﬁcant proportion of cellular gp130 resides in detergent-
resistant lipid rafts and can co-IP with caveolin-1. In addition,
cholesterol depletion with β-cyclodextrin has been shown to
trigger the re-distribution of gp130 to non-raft factions and
attenuate the ability of IL-6 to stimulate STAT3 phosphorylation
on Tyr70516. In contrast, others have found that both gp130 and
STAT3 are localised to lipid rafts15 and demonstrated an inverse
relationship between caveolin-1 expression and STAT3 activa-
tion54. Therefore, while a weak association between membrane
microdomains and JAK–STAT signalling modules has been
made, the molecular mechanisms responsible for this interaction
remain unclear.
Our data would suggest a novel route through which caveola
accessory protein cavin-1 can modulate cytokine receptor sig-
nalling via interaction with the inhibitory regulator SOCS3. While
SOCS3 expression is induced in response to many stimuli, con-
ditional gene targeting strategies have revealed that sensitivity to
SOCS3 is restricted to a panel of plasma membrane-localised
cytokine receptors6,7,41. Consistent with another study38, we
found that while cavin-1 was localised to the plasma membrane
in WT MEFs, it was not distributed uniformly, instead localising
to the trailing edge of migrating cells. Importantly, a signiﬁcant
proportion of SOCS3-GFP co-localised to the same plasma
membrane compartment in WT but not cavin-1−/− MEFs.
Together with data showing that cavin-1 could co-IP with SOCS3
and that puriﬁed SOCS3 could interact with multiple cavin-1-
derived peptides in vitro, we propose that cavin-1 binds SOCS3
directly and that this contributes to efﬁcient SOCS3 recruitment
to the plasma membrane where it can effectively bind and inhibit
cytokine receptors such as gp130. A key aspect of this model
(Fig. 9) is that SOCS3 can still bind Tyr phosphorylated peptide
in vitro in the presence of cavin-1. Interestingly, the SOCS3 SH2
domain appeared to fulﬁl both PTyr and cavin-1 binding func-
tions as cavin-1 interaction required the PEST motif present
within the SOCS3 SH2 domain, which we and others have shown
to be dispensable for PTyr binding33,36. In some respects, this is
similar to the recently described interaction between SOCS3 and
CUEDC2, which also binds the SH2 domain and enhances
SOCS3-mediated inhibition of JAK1–STAT3 activation by IL-611.
Since CUEDC2 potentiates SOCS3 function it would be
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anticipated that, like cavin-1, its interaction with the SH2 domain
must be independent of PTyr binding, suggesting it may also
involve the PEST sequence. However, in contrast to cavin-1,
CUEDC2 localises to the cytoplasm and nucleus55. Nevertheless,
our observations and those of Zhang et al.11 raise the possibility
that multiple proteins may bind within the SOCS3 SH2 domain
to facilitate localisation with Tyr phosphorylated binding partners
in distinct subcellular compartments. In this regard, it should be
noted that confocal imaging and subcellular fraction experiments
detected SOCS3 in the cytoplasm as well as the plasma mem-
brane, and that cavin-1 deletion resulted in the speciﬁc loss of the
plasma membrane pool.
To date, we are only aware of one other study which has
examined the impact of the PEST sequence on SOCS3 function36.
However, these experiments were performed in HEK293 cells co-
transfected to express a STAT3-responsive reporter gene and
increasing amounts of either WT or ΔPEST SOCS3. The authors
noted that at maximal levels of WT and ΔPEST SOCS3 expres-
sion, both constructs abolished LIF-stimulated activation of
STAT3. However, upon normalising SOCS3 function with the
expression levels of WT and ΔPEST SOCS3, they also noted that
at submaximal expression levels the functionality of ΔPEST
SOCS3 was less than that of WT SOCS3. Thus, they concluded
that WT SOCS3 is slightly more efﬁcient at inhibiting STAT3
activation36. Others have shown that low expression levels of
SOCS3 inhibit signalling via interaction with g130 followed by
inhibition of JAK activity, whereas overexpression SOCS3 can
inhibit gp130 signalling independently of interaction with the
SOCS3 binding site and works instead via direct inhibition of
JAK119,56 These data would also suggest that any functional
deﬁcits in ΔPEST SOCS3 in localising to gp130 would be over-
come by its overexpression. In contrast, our functional experi-
ments examining signalling from endogenous proteins suggest an
important aspect of SOCS3 PEST motif function is an interaction
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with cavin-1 that is critical for effective regulation of JAK–STAT
signalling. The effects on signalling of reconstituting cavin-1−/−
MEFs with mutated cavin-1 that fails to interact with SOCS3 but
retains the ability to stabilise caveolin-1 would be very informa-
tive in dissecting whether cavin-1 is essential for SOCS3 function
or simply enhances it through facilitating recruitment to the
plasma membrane. It would also be important to assess any
functional consequences of SOCS3 on gp130 ubiquitylation57 and
receptor trafﬁcking10 in order to fully assess the impact of cavin-1
on SOCS3 function.
While this adds an extra layer of regulation for SOCS3, our
study has also identiﬁed a previously unknown mechanism by
which SOCS3 can regulate cavin-1 function by enhancing its
stability and, as a consequence, maintaining expression levels of
caveolin-1 and cell surface caveolae. Similar observations have
recently been reported for Eps15 homology domain-containing
protein 2 (EHD2) which, to our knowledge, is the only other
example of a cavin-1-interacting protein that regulates caveola
stability, although a direct effect on cavin-1 turnover has not been
examined58. More generally, our ﬁndings also raise the possibility
that cavins constitute a new class of SOCS3-interacting proteins.
While the presence of cavin-1 and caveolin-1 is sufﬁcient to
generate caveolae in many cell types59, MEFs also express cavin-2
and cavin-3. Elegant biochemical and biophysical studies have
demonstrated that cavins assemble into oligomeric complexes
both in cells and in vitro60,61. While each of the cavins is
detectable on individual caveolae59, cavin-2 and cavin-3 appear to
form distinct hetero-oligomeric complexes with cavin-1 rather
than with each other60. Thus, it would be anticipated that
SOCS3 should interact with both cavin-1/cavin-2 and cavin-1/
cavin-3 oligomers and therefore distribute itself uniformly around
caveolar bulbs similarly to cavin-161. As the SOCS3 PEST
sequence was necessary for cavin-1 interaction, it would also be
informative to assess what extent this property is shared among
similar sequences present in other SOCS family members. Ana-
lysis of the SOCS family revealed that CIS, which like SOCS3 can
also interact with cavin-1, contains a PEST motif located in its
SH2 domain, while SOCS1, SOCS5, and SOCS7 each have one or
more PEST sequences located within their N-terminal domains.
In contrast, no PEST motifs are found in SOCS2, SOCS4, and
SOCS6. Given the distinct roles of different SOCS family mem-
bers in regulating signalling62, the functional signiﬁcance of the
identiﬁed PEST motifs and their roles in determining the
localisation of individual SOCS proteins via distinct protein
interactions warrant further investigation.
Finally, our ﬁndings may have implications in the context of
how cavin-1 and SOCS3 dysfunction can trigger disease. Several
inactivating frameshift mutations within exon 2 of the cavin-1
gene that result in the production of altered cavin-1 proteins have
been identiﬁed in patients with general lipodystrophy, muscular
dystrophy, and insulin resistance63–66. In each case, a lack of
functional cavin-1 is associated with the downregulation and/or
mislocalisation of all three caveolin subtypes in skeletal muscle
and an absence of cell surface caveolae in patient-derived ﬁbro-
blasts64 and skeletal muscle63. As multiple regions within cavin-1
are required for optimal binding of SOCS3, the mutated cavin-1
proteins identiﬁed in patients with congenital generalised lipo-
dystrophy would be predicted to be compromised in their ability
to interact with SOCS3, thereby resulting in enhanced IL-6
responses. In this regard, cardiac-speciﬁc homozygous deletion of
murine SOCS3 results in contractile dysfunction and the occur-
rence of a variety of ventricular arrhythmias67, the latter of which
is also observed in patients with inactivating cavin-1 mutations64.
Finally, a F136L germline SOCS3 mutation found in a subset of
polycythemia vera patients has been shown to display an
impaired capacity to inhibit erythropoietin receptor-JAK2 sig-
nalling68. As F136 is located within the PEST insert we have
identiﬁed as critical for cavin-1 interaction, this mutation may
alter cavin-1 binding to SOCS3 to block its inhibitory effects on
JAK–STAT signalling. Based on our ﬁndings, future studies will
therefore need to examine how cavin-1 and/or SOCS3 mutations
identiﬁed in patients interact to trigger defective regulation of
signalling in these pathologies.
Methods
Cell culture and transfection. HEK293 cells were obtained from the European
Collection of Authenticated Cell Cultures (ECACC) through Sigma. Immortalised
SOCS3−/− and cavin-1−/− MEFs and the corresponding WT cell lines have been
described previously59,69. HEK293 cells and MEFs were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal bovine
serum (FBS), 1 mM L-glutamine, 100 Uml−1 penicillin and 100 μM streptomycin.
AS-M.5 human angiosarcoma-derived ECs generously provided by Dr Vera
Krump-Konvalinkova and Professor Charles Kirkpatrick (Johannes Gutenberg
University of Mainz, Germany)28 were cultured in endothelial growth medium-2
supplemented with 2% (w/v) FBS, hydrocortisone, ascorbate, and recombinant
growth factors as recommended by the supplier (Lonza). HEK293 cells at 80%
conﬂuence on poly-D-lysine-coated dishes were transfected with 2–8 μg of com-
plementary DNA (cDNA) per 100 mm dish using PolyFect transfection reagent
(Qiagen) as per THE manufacturer’s instructions.
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For SILAC experiments, MEFs were grown in either heavy SILAC DMEM
(13C6-arginine, 13C6-lysine; R6K6) or control SILAC DMEM (12C6-arginine, 12C6-
lysine; R0K0) (Dundee Cell Products, UK) supplemented with 10% (v/v) dialysed
calf serum, 100 Uml−1 penicillin, 100 μM streptomycin, 4 μg ml−1 puromycin, 200
mg l−1 L-proline and 1 μM D-biotin. Arginine can be metabolised from 13C6-
arginine to an isotope of the non-essential amino acid 13C5-proline via the arginase
pathway thus complicating data analysis70. As such, media were supplemented
with L-proline (200 mg l−1) to prevent arginine conversion. Furthermore, as
overexpression of the HB-Ub-tag reduces the availability of cellular D-biotin21,
growth medium was supplemented with D-biotin (1 μM) to prevent saturation of
in vivo biotinylation by excessive HB-Ub-tag expression. Plat-E retroviral
packaging cells were maintained in DMEM supplemented with 10% (v/v) FBS,
100Uml−1 penicillin, 100 μM streptomycin, 1 μg ml−1 puromycin, 10 μg ml−1
blasticidin, and 1 mM glutamine.
Constructs. Murine Grap2 (cat no. MR204666) and murine CIS (cat no.
MR203328) in pCMV6-Entry were from Origene. Human SOCS3 CRISPR/Cas9
knockout (KO) and human SOCS3 HDR plasmids (cat. no. sc-400455) were from
Santa Cruz Biotechnology. Expression constructs for Flag-tagged WT murine
SOCS3 (hereafter termed pcDNA3/Flag-SOCS3), the truncation mutants ΔN20,
ΔN36, ΔC40, and ΔC84, R71K-mutated SOCS3, and the ΔPEST mutant SOCS3
(generously provided by Dr Jeff Babon, Walter and Eliza Hall Institute of Medical
Research, Australia) have all been described previously30,31,33,71. N-terminally
GFP-tagged murine cavin-1 has been described previously32 while a cavin-1-
mCherry expression construct was generously provided by Dr Ben Nichols (MRC
Laboratory of Molecular Biology, Cambridge, UK).
Full-length murine WT SOCS3, ΔSH2 SOCS3 (amino acids 46–142), and SOCS
box domain-only (amino acids 177–225) GFP fusion proteins were generated by
PCR ampliﬁcation and sub-cloning in-frame with the GFP open reading frame in
pEGFP-N1 (Clontech). The following primers were used to generate PCR products
using pcDNA3/Flag-SOCS3 as the template prior to digestion with the indicated
restriction enzymes for sub-cloning:-
Forward primers: WT (GAA GAA GAA TTC GCC ACC ATG GTC ACC CAC
AGC AAG), SOCS box only (GAA GAA GAA TTC GCC ACC ATG GTA CTG
AGC CGA CCT CTC), SH2 domain only (GAA GAA GAA TTC GCC ACC ATG
TTC TAC TGG AGC GCC GTG). EcoRI sites for sub-cloning underlined,
initiating Met codon in italics. Reverse primers: WT and SOCS box only (TT CTC
GGG ATC CGC AAG TGG AGC ATC ATA CTG ATC CAG G). ΔSH2 SOCS3
(TTC TCG GGA TCC GCT TCC GTG GGT GGC AAA G). BamHI sites for sub-
cloning underlined.
Myc-tagged WT murine cavin-1 and the truncation mutants N1 (amino acids
74–392), N2 (amino acids 168–392), N3 (amino acids 193–392), N4 (amino acids
250–392), C1 (amino acids 1–76), C2 (amino acids 1–167), C3 (amino acids
1–192), and C4 (amino acids 1–249) were generated by PCR ampliﬁcation and sub-
cloning in-frame with the C-terminal myc epitope (EQKLISEEDL) in pcDNA3.1/
mycHis A(-) (Invitrogen). The following primers were used to generate PCR
products using pEGFP-C1/cavin-1 as the template prior to digestion with the
indicated restriction enzymes and sub-cloning:-
Forward primers: WT, C1, C3, C3 and C4 constructs (GGA GAA CCT CTA
GAC GCC ACC ATG GAG GAT GTC ACG CTC), N1 (GGA GAA CCT CTA
GAC GCC ACC ATG CAA GCC CAG CTG GAG), N2 (GGA GAA CCT CTA
GAC GCC ACC ATG CTG AGC GTC AGC AAG TCG), N3 (GGA GAA CCT
CTA GAC GCC ACC ATG CGG CCC GAG GAT GAC ACC), N4 (GGA GAA
CCT CTA GAC GCC ACC ATG ACG CGT GAG AAC CTG GAG). XbaI sites for
sub-cloning underlined, initiating Met codon in italics. Reverse primers: C1 (TTC
TCG GAT CCA CTG GGC TTG GGT CAG CTG), C2 (TTC TCG GAT CCA TTT
GGC CGG CAG CTT GAC), C3 (TTC TCG GAT CCA CTC GCC CTC GCC
CAG CTC), C4 (TTC TCG GAT CCA GCG CAC CTT GGT CTT CTC). WT, N1,
N2, N3, and N4 constructs (TTC TCG GAT CCA GTC GCT GTC GCT CTT
GTC). BamHI sites for sub-cloning underlined.
A mutated Grap2(SOCS3-PEST) in which residues 129–163 encompassing the
SOCS3 PEST sequence were inserted between amino acids 149–150 within the
Grap2 ORF in pCMV6-Entry was synthesised by GeneArtTM. All constructs were
veriﬁed by sequencing to ensure the absence of additional unanticipated mutations.
Retroviral delivery of a His6+biotin Ub (HB-Ub) transgene. Using Lipofecta-
mine2000 (Invitrogen), Plat-E retroviral packaging cells in 10 cm dishes at
approximately 80% conﬂuence were transfected with a HB-Ub-expressing plasmid
kindly donated by Professor Peter Kaiser (University of California at Irvine, USA)
22. Following incubation in media without antibiotic selection, retrovirus-
containing media were collected following two sequential incubation periods, one
of 24 h at 37 °C and a second of 24 h at 32 °C.
Retroviral-mediated generation of cell lines. MEFs in 10 cm dishes at
approximately 40% conﬂuence were transduced with 2 ml of retrovirus containing
media in a ﬁnal volume of 4 ml DMEM supplemented with 10% (v/v) FBS, 1 mM
glutamine, and 10 μg ml−1 polybrene. After 12 h, the media were replaced with
DMEM supplemented with 10% (v/v) FBS, 1 mM L-glutamine and 100Uml−1
penicillin, 100 μM streptomycin and 1 μg ml−1 puromycin to select for positive
clones. Following dilution and re-plating, positive clones were expanded and HB-
Ub-expressing clones identiﬁed by immunoblotting whole-cell extracts with a
polyHis antibody.
Tandem afﬁnity puriﬁcation. SOCS3+/+ and SOCS3−/− MEFs were harvested in
lysis buffer (8M urea, 300 mM NaCl, 50 mM NaH2PO4, 0.5% (v/v) NP-40, pH 8.0)
supplemented with 1 mM phenylmethylsulfonyl ﬂuoride (PMSF). Following
sonication (3 × 10 s pulses, with a 10 s rest phase, at 40% amplitude), supernatants
were isolated by centrifugation at 21,000×g for 30 min at room temperature (RT)
and equalised for protein content. Lysates from SOCS3+/+ and SOCS3−/− MEFs
were mixed in a 1:1 ratio before incubation with 30 μl of 50% (v/v) Ni2+-NTA-
Sepharose beads per milligram of protein and rotated overnight at RT. Beads were
isolated by centrifugation at 100×g for 1 min and then washed sequentially, once
with 20 bead volumes of buffer A (8M urea, 300 mM NaCl, 50 mM NaH2PO4,
0.5% (v/v) NP-40, pH 8.0) supplemented with 1 mM PMSF and 10 mM imidazole
and twice with 20 bead volumes of buffer B (8 M urea, 300 mM NaCl, 50 mM
NaH2PO4, 0.5% (v/v) NP-40, pH 6.3) supplemented with 10 mM imidazole and 1
mM PMSF. Beads were isolated by centrifugation at 100×g for 1 min and bound
proteins eluted twice with 5 bead volumes of elution buffer (8 M urea, 200 mM
NaCl, 50 mM NaH2PO4, 2% (w/v) SDS, 10 mM EDTA,100 mM Tris, 500 mM
imidazole, pH 8.0) supplemented with 1 mM PMSF.
Eluate from the Ni afﬁnity chromatography step was directly added to 10 μl of
50% (v/v) streptavidin-Sepharose beads per milligram of initial protein lysate and
rotated overnight at RT. Beads isolated by centrifugation at 100×g for 1 min at RT
were washed sequentially, twice with 25 bead volumes of buffer C (8 M urea, 200
mM NaCl, 2% (w/v) SDS, 100 mM Tris, pH 8.0) and twice with 25 bead volumes of
buffer D (8 M urea, 1.2 M NaCl, 0.2% (w/v) SDS, 100 mM Tris, 10% (v/v) ethanol,
10% (v/v) isopropanol, pH 8.0). Bound proteins were eluted with one bead volume
of aqueous biotin (50 mM) at 95 °C for 5 min. Following isolation by centrifugation
at 100×g for 1 min at RT, eluate was concentrated using Amicon 10K Ultra-2
Centrifugal Filter Devices (Millipore) as per the manufacturer’s instructions.
In-gel trypsin digestion. Sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis (SDS-PAGE)-fractionated TAP eluate was stained with InstantBlue
(Expedion) prior to manual sectioning into several manageable gel slices. Indivi-
dual gel slices were washed sequentially with 500 μl, 100 mM ammonium bicar-
bonate and then 500 μl, 50% (v/v) acetonitrile/ammonium bicarbonate (100 mM)
for 30 min with shaking. The samples were reduced with the addition of 150 μl 100
mM ammonium bicarbonate and 10 μl 45 mM dithiothreitol for 30 min at 60 °C.
Samples were cooled to RT before alkylation using 10 μl 100 mM iodoacetamide in
the dark for 30 min at RT. Gel pieces were then washed in 500 μl 50% (v/v)
acetonitrile/ammonium bicarbonate (100 mM) for 1 h with shaking at RT. Fol-
lowing treatment with 50 μl acetonitrile for 10 min, the solvent was discarded and
the gel pieces dried using a vacuum centrifuge for 1 h. Gel slices were fully rehy-
drated in trypsin suspended in 1 ml 25 mM ammonium bicarbonate and incubated
overnight at 37 °C after which the supernatant was transferred to a fresh 96-well
plate without disturbing the gel pieces. Residual digested protein was extracted by
using 20 μl 5% (v/v) formic acid for 20 min at RT with shaking followed by the
addition of 40 μl acetonitrile for a further 20 min with shaking at RT. Pooled
extracts were dried using a SpeedVac centrifugal evaporator before resuspension in
10 μl dH20 prior to mass spectrometry.
Liquid chromatography and mass spectrometry. Samples were analysed on a
Dionex Ultimate 3000 RSLS Nano ﬂow system (Dionex). The samples (5 μl) were
loaded onto a Dionex 100 μm× 2 cm 5 μm C18 Nano trap column at a ﬂow rate of
5 μl min−1 by the Ultimate 3000 RS autosampler (Dionex). The composition of the
loading solution was 0.1% formic acid and acetonitrile (98:2). Once loaded onto the
column, the sample was then washed off into an Acclaim PepMap 75 μm× 15 cm,
2 μm 100 Å C18 Nano column at a ﬂow rate of 0.3 μmmin−1. The trap and nano
ﬂow column were maintained at 35 °C in an UltiMate 3000 Rapid Separation LC
system (Thermo Fisher). The samples were eluted with a gradient of solvent A:
0.1% formic acid (solvent A) versus acetonitrile (solvent B) starting at 1% B rising
to 15% then to 45% B over 50 and then 90 min. The column was washed using 90%
B before being equilibrated prior to the next sample being loaded.
Column eluate was directed to a Proxeon Nano spray electrospray ionisation
(ESI) source (Thermo Fisher) operating in positive ion mode and then into an
Orbitrap Velos FTMS. The ionisation voltage was 2.5 kV and the capillary
temperature was 230 °C. The mass spectrometer was operated in tandem mass
spectrometry (MS/MS) mode scanning from 300 to 2000 amu. The top 20 multiply
charged ions were selected from each full scan for MS/MS analysis, the
fragmentation method was CID at 35% collision energy. The ions were selected for
MS2 using a data-dependent method with a repeat count of 1 s and repeat and
exclusion time of 15 s. Precursor ions with a charge state of 1 were rejected. The
resolution of ions in the ﬁrst stage (MS1) was 60,000 and 7500 for the second
stage (CID MS2). Data were acquired using Xcalibur v.2.1 (Thermo Fisher).
Analysis of LC-MS/MS. Post-LC-MS/MS analysis was performed using Max-
Quant v.1.1.1.3672 and searched with Andromeda search engine73 against the IPI
mouse.v3.80 Fasta formatted database (release February 2011). Phosphorylation (S,
T, Y), ubiquitination (GlyGly), and oxidation (Met) were set as variable
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modiﬁcations, whereas carbamidomethylation (Cys) was set as ﬁxed modiﬁcation.
The peptides used for protein quantiﬁcation were set to unique and razor and
minimum ratio count set to 1. Requantify was set to “TRUE” for deep searching of
paired SILAC peaks. “Labelled amino acid ﬁltering” was set to “FALSE” to improve
analysis using R6K6 SILAC labelling. All other options were set to default.
CRISPR/Cas9 generation of SOCS3-null AS-M.5 EC lines. Using SuperFect
transfection reagent (Qiagen), AS-M.5 cells in 6 cm dishes at approximately 80%
conﬂuence were co-transfected with human SOCS3 CRISPR/Cas9 KO and human
SOCS3 HDR plasmids. Following dilution and re-plating, positive clones were
isolated by selection in medium supplemented with puromycin (2 μg ml−1).
SOCS3-null clones were identiﬁed by immunoblotting whole-cell extracts with
SOCS3 antibody following cellular treatment with Fsk (50 μM, 5 h) to induce
SOCS3 gene expression26,45.
Antibodies. The following antibodies were obtained from the indicated suppliers:
anti-Flag M2 antibody (Sigma F3165, 1 in 1000), anti-HA HA-7 antibody (Sigma
H9658, 1 in 1000), PTRF/cavin-1 (Abcam ab48824, 1 in 1000), caveolin-1 (BD
Biosciences 610059, 1 in 1000) and anti-phosphotyrosine monoclonal antibody
4G10 (Millipore 05–321, 1 in 1000), GAPDH (Abcam, ab8245, 1 in 20,000), anti-
myc 9E10 (ascites generated by ProSci, 1 in 2000), anti-α-tubulin 12G10 (DSHB
12G10, 1 in 10,000), SOCS3 (M20; Santa Cruz sc-7009, 1 in 500), STAT3
(EPR787Y: Abcam ab68153, 1 in 1000), phospho-STAT3 (Tyr705) (3E2: Cell
Signaling 9138L, 1 in 1000), phospho-STAT3 (Ser727) (6E4: Cell Signaling 9136, 1
in 1000), JAK1 (BD Transduction Laboratories 610232, 1 in 1000), JAK2 (D2E12:
Cell Signaling 3230, 1 in 1000), and ﬂotillin-1 (BD Transduction Laboratories
610821, 1 in 500). Sheep polyclonal anti-GFP serum was generously provided by
Professor Graeme Milligan (University of Glasgow, UK) and was used in a 1 in
2000 dilution.
Immunoblotting. Cell lysates were prepared as described previously74. Cells were
washed twice with ice-cold phosphate-buffered saline (PBS) and lysed by scraping
into lysis buffer (50 mM HEPES pH 7.4, 150 mM sodium chloride, 1% (v/v) Triton
X-100, 0.5% (v/v) sodium deoxycholate, 0.1% (w/v) SDS, 10 mM sodium ﬂuoride,
5 mM EDTA, 10 mM sodium phosphate, 0.1 mM PMSF, 10 μg ml−1 benzamidine,
10 μg ml−1 soybean trypsin inhibitor, 2% (w/v) EDTA-free complete protease
inhibitor cocktail (Sigma)). After 30 min on ice, lysates were vortexed and cleared
by centrifugation. Equivalent amounts of protein, as determined by bicinchoninic
acid protein assay, were resolved by SDS-PAGE, transferred to a nitrocellulose
membrane, and analysed by immunoblotting as previously described26,74,75.
Uncropped immunoblots used to generate Figs. 1b and 5b are shown in Supple-
mentary Figure 7.
RNA analysis. Total RNA extraction from MEFs grown in 60 mm dishes was
carried out using a miRNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. The cDNA was generated from 1 μg total RNA using 200 U Super-
Script™ II Reverse Transcriptase (Invitrogen) following the manufacturer’s
instructions with 100 ng random hexamers, 2.5 mM of each dNTP and 40 U
RNaseOUT (Invitrogen) in a ﬁnal volume of 20 μl. Real-time quantitative PCRs
were performed on a MX3000 system (Stratagene) using Power SYBR® Green PCR
Master Mix (Applied Biosystems) in a ﬁnal volume of 10 μl containing 1 μl cDNA,
0.5 mM of each primer, and 1x Power SYBR® Green PCR Master Mix. The murine
cavin-1 primers used were GCAAGGTCAGCGTCAAC (forward primer) and
CCGGCAGCTTGACTTCA (reverse primer). GAPDH primers used for normal-
isation were GGCTGGCATTGCTCTCAA (forward primer) and
GCTGTAGCCGTATTCATTGTC (reverse primer). Primers were purchased from
Dharmacon.
Co-immunoprecipitation and peptide pull-down assays. For co-IP assays, either
transfected cells or WT and SOCS3-null AS-M.5 cells were harvested in ice-cold
PBS, pelleted by centrifugation at 1000×g for 5 min at 4 °C, and lysed in co-IP
buffer (50 mM HEPES, pH 7.4, 120 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol,
1% (v/v) Triton X-100, 5 mM NaF, 1 mM sodium orthovanadate, 10 μg ml−1
benzamidine, 0.1 mM PMSF, 10 μg ml−1 soybean trypsin inhibitor, 2% (w/v)
EDTA-free complete protease inhibitor cocktail). Following solubilisation by
incubation for 1 h at 4 °C with rotation, lysates were centrifuged at 21,000×g for 15
min at 4 °C and the supernatant equalised for protein content and volume. Non-
speciﬁcally binding proteins were removed from soluble fractions by a 1 h pre-
clearing step using 40 μl of 50% (v/v) slurry of protein G-Sepharose 4B FF beads
(Sigma) re-suspended in 100 μl 2% (w/v) IgG-free bovine serum albumin (BSA).
Following sedimentation of protein G-Sepharose beads by brief centrifugation, pre-
cleared lysates were incubated overnight at 4 °C with rotation with either 40 μl
fresh protein G-Sepharose beads pre-equilibrated with 2% (w/v) IgG-free BSA and
anti-cavin-1 antibody or 40 μl pre-conjugated anti-Flag M2-agarose beads (Sigma).
Immune complexes were then isolated by brief centrifugation and washed three
times with 1 ml of co-IP buffer. Following removal of the ﬁnal wash, protein
complexes were eluted for analysis by SDS-PAGE by the addition of 40 μl of
electrophoresis sample buffer containing 12% (w/v) SDS and incubation for 30 min
at 65 oC followed by a further 5 min at 95 °C.
For peptide pull-down assays, protein-equalised soluble extracts from
transfected HEK293 cells were incubated with 100 nM N-terminally biotinylated
peptides (Severn Biotech, UK) and streptavidin-agarose prior to isolation of
complexes by brief centrifugation and washing as described above. The peptides
used had the following amino acid sequences: Tyr759 (Y), biotin-
TSSTVQYSTVVHSG; and PTyr759 (pY), biotin-TSSTVQpYSTVVHSG). Samples
were then eluted for analysis by SDS-PAGE and immunoblotting as described
above.
Peptide array overlays. Arrays were produced by automatic SPOT synthesis and
synthesised on continuous cellulose membrane supports on Whatman 50 cellulose
membranes using Fmoc-chemistry with the AutoSpot-Robot ASS 222 (Intavis
Bioanalytical Instruments AG) as we have previously described76. Following
blocking of non-speciﬁc protein binding sites by incubation in tris-buffered saline
with Tween-20 (TBST; 50 mM Tris pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween 20)
containing 5% (w/v) BSA, membranes were overlaid with 10 μg ml−1 puriﬁed
recombinant Trx-polyHis-tagged SOCS3 (Sino Biological Inc.) diluted in TBST-5%
(w/v) BSA. After washing in TBST, bound SOCS3 was detected by probing overlays
with anti-SOCS3 antibody followed by IRDye-conjugated secondary antibody prior
to visualisation using a LI-COR Odyssey Sa imaging system. As a negative control,
identical arrays were identically treated in parallel minus recombinant SOCS3.
Subcellular fractionation. Conﬂuent 10 cm dishes of WT, cavin-1−/−, and SOCS3
−/− MEFs were used to prepare subcellular fractions using a Subcellular Protein
Fractionation Kit (Thermo Scientiﬁc) in accordance with the the manufacturer’s
instructions.
Confocal microscopy. For analysis of endogenous cavin-1 and transfected SOCS3-
GFP, WT, and cavin-1−/− MEFs in 10 cm dishes were transiently transfected with
or without SOCS3-GFP expression constructs. The following day, cells were split
onto glass coverslips and left for a further 24 h. Cells were then washed with PBS
and ﬁxed with 3% (w/v) paraformaldehyde (PFA) in PBS for 25 min. After washing
with PBS and quenching residual PFA with 20 mM glycine in PBS, cells were
permeabilised with 0.1% (v/v) Triton X-100 and non-speciﬁc binding sites blocked
by a 30 min of incubation at RT in PBS containing 3% (w/v) BSA and 10% (v/v)
donkey serum. Cells were then incubated with rabbit anti-cavin-1 antibody
(Abcam ab48824, 1 in 100 dilution) for 90 min at RT. Cells were washed with PBS
containing 0.1% (v/v) Triton X-100, 1% (w/v) BSA, and 10% (v/v) donkey serum
prior to incubation with Alexa Fluor 594-conjugated donkey anti-rabbit IgG (Life
Technologies A21207, 1 in 200 dilution) for 1 h at RT. Finally, the cells were
washed with PBS, mounted in ProLong® Gold anti-fade reagent containing nuclear
stain 4’,6-diamidino-2-phenylindole (DAPI), and visualised using a LSM510 laser
scanning confocal imaging system (Carl Zeiss). Images were analysed by Meta-
morph software to generate Pearson’s correlation coefﬁcients.
For experiments involving co-expression of SOCS3-GFP and cavin-1-mCherry
in cavin-1−/− MEFs, cells at 80–90% conﬂuence on 6 cm dishes were transfected
with 1 µg of each construct using PolyFect transfection reagent as per the
manufacturer’s instructions. The following day, cells were seeded into ×16 Lab-Tek
chamber slides (Fisher Scientiﬁc) at a density of 5 × 104 cells per chamber and
cultured for a further 24 h. Cells were then washed twice with Hanks' balanced salt
solution with Ca2+/Mg2+ and 0.2% (w/v) sucrose to preserve morphology before
ﬁxing by incubation with 4% (w/v) PFA at RT for 20 min in the dark. After
removal of ﬁxative and two washes with PBS, nuclei were stained with 10 µg ml−1
Hoechst 33342 (Life Technologies) prior to imaging using a VivaTome spinning
disk confocal microscope (Carl Zeiss). Images were analysed using Fiji ImageJ and
the Coloc 2 plugin.
Transmission electron microscopy. WT and SOCS3-null AS-M.5 cells were
seeded at a density of 1 × 106 cells per ml into 6-well plates and onto Thermanox
coverslips (13 mm diameter) for culturing to conﬂuency. The cells were then ﬁxed
in 1.5% (w/v) glutaraldehyde in 0.1 M sodium cacodylate buffer at 4 °C for 1 h.
Following three washes in 0.1 M sodium cacodylate buffer in 2% (w/v) sucrose, the
cells were incubated with 1% (w/v) osmium tetroxide/0.1 M sodium cacodylate for
1 h, washed three times in distilled water, and incubated in 0.5% (w/v) uranyl
acetate in the dark for 1 h. Following two rinses in distilled water, cells were
dehydrated in stepwise alcohol increments (30–100% (v/v)) and incubated over-
night in a 1:1 mix of propylene oxide/TAAB araldite Epon 812 resin. The pro-
pylene oxide was then allowed to evaporate to leave pure resin, which was changed
twice before the sample was embedded in fresh resin which was allowed to poly-
merise at 60 °C for 48 h. Ultrathin sections were cut using a Leica Ultracut UCT
and a Diatome diamond knife, contrast stained with aqueous 2% (w/v) methanolic
uranyl acetate and Reynolds lead citrate, and viewed using a LEO 912AB TEM
(Carl Zeiss) at an accelerating voltage of 120 kV. TIF images were captured using
an Olympus Soft Imaging System and image contrast modiﬁed using Adobe
Photoshop CS.
Statistics. Statistical signiﬁcance was assessed either by one-way analysis of var-
iance or unpaired t-tests with an α probability of 0.05. At least three separate
experiments were used for analysis.
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